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Most renal diseases have a common end inflammatory pathway,
which is associated with a leukocytic infiltrate. Chemokines are
small proteins that are responsible for the chemoattraction of
leukocytes into areas of injury or insult. CX3CL1, also known as
fractalkine, exists as a transmembrane protein as well as a soluble
protein. It acts as a cell adhesion molecule in addition to its
chemoattractant properties.
This thesis firstly examines the distribution of CX3CL1 in renal
tubular epithelial cells (RTEC) and in the second part of the thesis the
regulation of CX3CL1 by stimulation of the thromboxane prostanoid
(TP) receptor is examined.
The localisation of CX3CL1 was initially demonstrated primarily on
the apical surface of tubular epithelial cells in human renal biopsy
specimens with histological diagnoses of acute tubular necrosis and
acute allograft rejection. A cell model was then developed in MDCK
cells to examine the distribution more closely.
There are a limited number of mechanisms potentially responsible
for the trafficking of CX3CL1 to the apical membrane and it was
established that N-glycosylation of CX3CL1 is required for its
presence on the apical membrane of RTEC.
The mobility of CX3CL1 within the cell membrane was next assessed
and it was shown to be relatively immobile. We hypothesized that
this would promote cell adhesion and indeed further experiments
confirmed that CX3CL1 in RTEC does promote adhesion of cells
bearing the cognate receptor.
Given that CX3CL1 and thromboxane A2 are both found in similar
inflammatory conditions, are both present early in the inflammatory
process and that stimulation of the TP receptor has been shown to
regulate other chemokines, we next evaluated the effect of
stimulation of TP on CX3CL1. We found that both total and surface
cellular levels of CX3CL1 were reduced following stimulation of TP.
A maximal nadir was present after 30-60 minutes and the levels
returned to baseline by 4 hours.
The mechanism for the loss of CX3CL1 was then assessed. CX3CL1 is
known to recycle between the cell surface and an internal
compartment. No effect of TP stimulation was seen on the
endocytosis or exocytosis of CX3CL1. Stimulation of TP was
however, shown to stimulate tumour necrosis factor-a converting
enzyme (TACE) via ERK phosphorylation. TACE inducibly cleaves
CX3CLI, releasing the soluble chemokine. TACE siRNA was used to
knock down TACE gene expression and this prevented the loss of
cellular CX3CL1, confirming that TP stimulation induces TACE
cleavage of CX3CL1. T he results of further experiments are discussed
in the discussion chapter.
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Chronic renal impairment is a significant health burden and the
Western world, in particular but by no means exclusively, is
experiencing an exponential increase in patients requiring renal
replacement therapy. While a large number of aetiologies contribute to
injury, many of these converge on common immune and non-immune
pathways of inflammation and scarring, which are discussed in greater
depth below. We are particularly interested in the chemokine CX3CL1
and its receptor CX3CR1 as mediators of injury and as potential targets
for therapeutic intervention. The role of chemokines, especially
CX3CL1, as recruiters of macrophages and other leukocytes in renal
disease is outlined and we then discuss the regulation of this
chemokine, it's mode of action and the effects of inhibition of the
chemokine-receptor pair. We also review the thromboxane pathway as
a potential initiator and site for intervention in inflammation and
examine the cross-talk between this pathway and chemokines.
Mechanisms ofRenal Disease Progression
The renal response to injury is outlined briefly below and will be
expanded on in the following pages. The initial injury to the kidney
may be the result of toxins, immune complexes, hypoxia, infection,
protein overload, vasoactive agents such as angiotensin II, or
mechanical stress, amongst others. These insults promote the secretion
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of pro-inflammatory mediators such as cytokines and chemokines from
the renal cells, with subsequent leukocytic infiltration. This initiation
process is followed by an amplification process, whereby the leukocytes
themselves secrete more proinflammatory mediators, thus exaggerating
the response. Infiltrating neutrophils and macrophages generate radical
oxygen species and lipid mediators adding to the local tissue damage.
Macrophages also secrete various growth factors, which stimulate
mesangial cell proliferation and matrix synthesis. Although the
initiation response is usually compartmentalised, i.e. an insult to the
glomerulus results in an inflammatory response within the glomerulus,
the amplification response may extend into other areas such that
glomerular growth factors, for example, may spill over into the tubules
and stimulate the tubulointerstitial cells. Similarly circulating factors
may have effects away from the initial insult. The amplification phase is
followed either by progression to chronic inflammation and fibrosis or
repair and resolution depending on the cytokine profile of the local
environment and the macrophage phenotype activated. It is proposed
that fibrosis is a maladaptation of a normal healthy response to injury
but it is not clear what promotes fibrosis over repair.
At the cellular and molecular levels, the pathophysiology of renal
fibrosis is complex with involvement of both resident and infiltrating
cells. It is a dynamic process that is regulated at multiple levels, but
critical to the process is the ability to accumulate extracellular matrix.
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Depending on the site and nature of the initial injury, the major renal
fibrogenic cells are glomerular mesangial cells, interstitial fibroblasts
and tubular epithelial cells. Bone marrow derived cells may also play a
role (1).
Hypotheses of Renal Fibrosis
To explain the effect of the initial insult on the final outcome, two, not
necessarily mutally exclusive, hypotheses, have been put forward to
explain progressive renal damage and interstitial fibrosis. The first
theory suggests that the proximal tubule is the site of primary insult.
This insult then exposes the tubular epithelial cells to increased amounts
of protein, which results in more protein reabsorption by the tubules.
This 'protein overload' then stimulates an inflammatory response with
subsequent increased interstitial matrix formation. The second theory
has a glomerular origin and suggests that any loss of renal functioning
mass results in glomerular hyperfiltration and intraglomerular
hypertension. This triggers glomerular hypertrophy and proliferation
and is associated with crescent formation. This glomerular expansion
encroaches on the glomerular-tubular junction causing obstruction, with
eventual tubular destruction and interstitial fibrosis (2, 3). Furthermore,
endothelial damage leads to podocyte loss and denudment of the
basement membrane, allowing the ultrafiltrate to reach the
tubulointerstitial space, where it triggers an inflammatory response.
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There may be different mechanisms at play in glomerular versus
interstitial fibrosis.
In the first of the models, that of increased protein reabsorption by
tubular epithelial cells, the reabsorbed proteins cause damage to
lysosomal pathways, increase secretion of growth factors, such as
Transforming Growth Factor-(3 (TGF-(3), Fibroblast Growth Factor
(FGF), Endothelial Growth Factor (EGF), Tumour Necrosis Factor-a
(TNF-a) and Platelet Derived Growth Factor (PDGF) and increase
oxidative stress responses in the tubular epithelial cells (4-6).
Furthermore, stressed tubular cells release various chemokines
including CCL2, CCL5 and CX3CL1 (7-9). These proteins are
chemotactic for leukocytes and facilitate the infiltration of leukocytes
into the damaged area. The injured tubular cells also release other
factors such as connective tissue growth factor (CTGF), endothelin-1
(ET-1) and fibronectin that contribute to the fibrotic process. There is a
positive feedback loop formed in which infiltrating macrophages release
more chemokines and growth factors. Infiltrating T cells release
gamma-interferon and other cytokines that activate chemokines and
other inflammatory cells. In addition, the renal tubular epithelial cells
also add to the autocrine and paracrine regulation of cytokine and
chemokine production.
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In the glomerular origin of fibrosis model, there is loss of nephron mass
with increased single nephron function and increased intraglomerular
pressure. There is also endothelial damage, which results in exposure of
the endothelium to profibrotic factors such as angiotensin II (Ang II),
endothelin-1 (ET-1), connective tissue growth factor (CTGF) and
plasminogen activator inhibitor-1 (PAI-1).
Angiotensin II and Renal Injury
Angiotensin II has both haemodynamic effects, contributing to the
increased intraglomerular pressure, and non-haemodynamic effects. It
stimulates the glomerular and tubular secretion of growth factors such
as TGF-(3, PDGF and basic Fibroblastic Growth Factor (bFGF), cytokines
such as TNF-a, cell adhesion molecules such as Vascular Cell Adhesion
Molecule-1 (VCAM-1) and it also stimulates smooth muscle cell
proliferation, stimulates mesangial cell hypertrophy and induces PAI-1
(10-13). The relationship between Angll and TGF-|3 pathways is
complex. Angll stimulates TGF-|3 secretion via protein kinase C (PKC)
and it also stimulates the production of the TGF-p receptor.
Furthermore, Angll can activate Smad 2 and 3 independently of TGF-|3,
via an extracellular signal-regulated kinase 1/2 (ERK1 / 2) pathway (14).
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Plasminogen activator inhibitor-1 and Renal Injury
PAI-1 is the primary inhibitor of tissue-type plasminogen activator (t-
PA) and urokinase-type plasminogen activator (u-PA). These two
proteins activate plasminogen, forming plasmin, which degrades fibrin.
Not only do t-PA, u-PA and plasmin degrade extracellular proteins,
they also activate latent matrix metalloproteinases, such as MMP-1 and
MMP-3, which also promote matrix breakdown. However, the pro-
fibrotic effects of PAI-1 are not all associated with its ability to decrease
proteolysis. It can also modulate cell migration and may play a role in
epithelial to mesenchymal transformation (EMT) (15). PAI-1 expression
is induced by Angll and aldosterone, both dependently and
independently of TGF-p (16).
Transforming Groivth Factor-/! and Renal Injury
Although factors, including cytokines, hormones and haemodynamic
factors are important for the resolution of inflammation, with or without
scarring, the most crucial factor seems to be Transforming Growth
Factor-p (TGF-p). Furthermore, TGF-P appears to act as a common link
between many of the other profibrogenic pathways, such as angiotensin
II, which is upstream of TGF-p, and connective tissue growth factor,
which is downstream of TGF-p.
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In most cells TGF-p is a growth inhibitor however in mesenchymal cells
it has biphasic properties and both stimulates and inhibits growth (17).
In the fibrotic kidney increased TGF-p signalling is achieved by many
mechanisms such as increased TGF-p gene expression, enhanced post-
translational activation of the protein, release of TGF-p from latent
complexes and increased receptor expression. In addition, there is
demonstrable loss of Smad transcriptional co-repressor protein function
allowing unconstrained TGF-p signalling (18).
TGF-p is produced by various renal cells, including endothelial cells,
renal tubular epithelial cells and macrophages. Its release is brought
about by numerous stimuli, including renin/angiotensin II, complement
activation, Toll-like receptor-2 (TLR-2) activation and protein overload.
Activation of TGF-p results in many downstream effects. In the kidney,
it contributes to the inflammatory infiltration and the promotion of
apoptosis of podocytes (19). It stimulates the transcription of
extracellular matrix genes in mesangial, endothelial and renal tubular
cells (20). It stimulates PAI-1 in a positive feedback loop and most of the
pro-fibrogenic actions of PAI-1 are exerted via TGF-p (21). It inhibits
proteinases such as Tissue Inhibititory Matrix Proteinases (TIMPs) and
collagenases, which prevent matrix breakdown and degradation. It
induces CTGF with the subsequent increased proliferation of renal
fibroblasts and extracellular matrix production (22). Finally, TGF-p is a
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major trigger for epithelial to mesenchymal transformation, which has
been shown to be significant in the fibrosis pathway, particularly in the
later stages. Iwano et al showed that up to 36% of fibroblast specific
protein-1 (FSP-1) positive fibroblasts were derived from renal proximal
tubules in a model of unilateral obstruction (23). More recently the
transformation of endothelial cells to mesenchymal cells has also been
recognised (24). TGF-|3 also has immunomodulatory effects and
deficient mice die of overwhelming inflammation. Moreover,
transgenic mice with overexpression of TGF-(3 are protected from renal
fibrosis, establishing an anti-inflammatory role for this growth factor
(25). These profibrogenic factors and pathways are not unique to kidney
injury but are involved in any injury repair throughout the body.
Repair versus Fibrosis
Following a glomerular injury, macrophages may stimulate mesangial
cells to secrete type IV collagen, laminin and fibronectin, which
contribute to glomerulosclerosis and fibrosis. In addition, mesangial
expansion causes narrowing or complete obliteration of glomerular
capillaries, resulting in damage to podocytes in the glomeruli and a
downstream effect on the peritubular capillaries causing ischaemia to
the tubules. The infiltrating leukocytes continue to secrete
proinflammatory mediators and activated renal tubular cells also
produce cytokines and chemokines, propagating the inflammatory
effect. The resultant fibrosis is from both the proliferation of resident
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fibroblasts and from epithelial to mesenchymal transformation of
tubular epithelial cells. Finally in the terminal phase of the
inflammatory process, there is cessation of the leukocytic infiltrate but
continued synthesis of the extracellular matrix by the fibroblasts.
Myofibroblasts contribute to the contraction of the fibrous tissue leading
to a shrunken kidney, as is often found in end stage renal failure.
Monocytes/Macrophages in Inflammation
The leukocytic infiltrate is paramount to the inflammatory response and
monocytes and macrophages make up an important component of this
infiltrate. Traditionally monocytes have been described as the
circulating mononuclear leukocytes, which then mature into
macrophages upon infiltration into tissues. It is now recognised that
there is also a reservoir of monocytes in the spleen that has the potential
to be rapidly deployed to sites of injury, prior to the increase in bone
marrow derived monocytes (26). Monocytes transdifferentiate into
macrophages, dendritic cells or osteoclasts, dependent on the local
environment. Fluman monocyte subsets are distinguished by the
expression patterns of CD14 and CD16, (CD14++CD16~ classical,
CD14 CD16++ nonclassical and CD14++CD16+ intermediate). Mouse
monocyte subsets have also been described, distinguished largely by the
markers Ly6C (or Grl), CCR2 and CX3CR1 (27). Approximately 40% of
murine monocytes are Ly6CloCX3CRlhlCCR2 and 60% are
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Ly6ChlCX3CRlloCCR27 These distinct populations have different
functions, many of which are not fully elucidated.
Monocytes are derived from macrophage/dendritic cell progenitors
(MDPs) in the bone marrow and egress from the bone marrow in a
CCR2 dependent manner (27, 28). They have a short half-life in the
circulation of 1 day in mice and about 3 days in humans with longer
half-lives being noted for CX3CRlhlLy6Cl0 monocytes compared to the
CX3CR1 loLy6CW subgroup (27, 29). Generally CX3CRlloLy6Chl
monocytes are termed inflammatory whereas CX3CRlhlLy6C'°
monocytes are thought to be non-inflammatory but this is a gross over¬
simplification. In adoptive transfer studies of CX3CRlloLy6Chl
monocytes into a non-inflammatory environment there was movement
back into the bone marrow and these same monocytes switched to the
CX3CRlh,Ly6Cl0 phenotype within 3 days and were again found in the
circulation (30). It therefore seems likely that the differentiation of MDPs
is not a terminal event.
Many studies have demonstrated an early increase in CX3CRlIoLy6Chi
monocytes in the first few days following a tissue injury, for example
following myocardial infarction (31), skeletal muscle injury (32) and in
liver injury (33). This is followed by an increase in CX3CRlhiLy6C'°
monocytes during the recovery phase. However, a further study
provides evidence for very early recruitment of CX3CRlhlGrll0
monocytes in the first hour post-injury (34). This pivotal study
demonstrated that CX^Rl^Grl10 monocytes crawl along the
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endothelium in a lymphocyte function-associated antigen-1 (LFA-1)
dependent manner, in a surveillance mode. Furthermore there was a
sixfold decrease in this patrolling in CX3CR1 deficient mice suggesting
that CX3CRI, via LFA-1, has an important role in the rapid immune
response to injury and infection. This study also showed that the
extravasated CX3CRlhiGrl'° monocytes promoted the differentiation into
classical macrophages, as discussed below, whereas CX3CRlloGrlhl
monocytes, which arrive in the damaged tissue later in the process,
promoted dendritic cell differentiation.
Macrophage subsets
Macrophage terminology has also evolved over the past decade.
Macrophages are now classified into the subgroups Ml (classically
activated) and M2 (alternatively activated), with M2 being further
subdivided into M2a, M2b and M2c. Differentiation into a particular
macrophage phenotype is dependent on the local cytokine milieu and
each different phenotype produces a distinct profile of inflammatory
agents and has unique surface markers (Table 1).
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Table 1
Macrophage activation states and functions
Macrophage Activation state Stimuli Phenotypic function Cytokine and Unique surface
phenotype inflammatory profile markers
Ml Classical activation IFN-r ♦ LPS. Proinflammatory IL-1. IL-12. IL-15. IL-18. IL-23. CD86. CD80
TNF. GM-CSF Thl response TNF-<«. IL-6. MCP-1. CCL2. MHC class IP*. IL-1R.
TLR/IL-1R ligand CCL3. CCL4. CCL20/MIP-3a
ROS. NO. iNOS. NOS2
IL-12**. IL-23"*.
IL-10*
M2 Alternate activation IL-4 orIL-13 Th2 responses. Fibronectin. BIG-H3. Mannose receptor.




class IP*, decoy IL-1R11.
FIZZI/Ym-1
Type II activation Immune complex Immunoregulation. IL-10. TNF-«. IL-1. IL-6. CD86. MHC class IP".
(M2b polarization) ♦ TLR/1L-1R ligands Th2 activation IL-12. SPHK1. CCL1 IL-10"\ IL-12to
Deactivated IL-10, TGF-fV Immunosuppression. IL-10. IL-10. IL-6. TGF-ft. SLAM (CD150). mannost




receptor. MHC class II10
BIG-H3. fascrctiri domain 4 protein. Ml P. macrophage inflammatory proletn: SLAM. s»gr*alir>g tymphocylic activation molecule: SPHKt. sphingosme kinase 1
Note that FiZZt and Ym r gene expression is characteristic of the alternative pathway of macrophage activation.
From Macrophage diversity in renal injury and repair. Ricardo SD, van
Goor H, Eddy AA. Journal of Clinical Investigation, 2008 118(11) 3522-
3530.
Chemokines: regulators of injury
A leukocytic infiltrate is crucial to any inflammatory process and this
requires signals to direct the extravasation of leukocytes to the site of
injury. This signal is achieved by chemokines, which are a subgroup of
the cytokine family and currently number approximately fifty. Most
chemokines are small, secreted proteins (approximately 8-13 kDa),
though two chemokines are larger transmembrane proteins (35, 36).
The chemokines are classified into 4 groups; C, CC, CXC and CX3C,
based on the number of conserved cysteine residues and any amino
acids between them, in the N-terminus. The major known role of
chemokines is that of chemoattraction for leukocytes bearing the
appropriate receptor but they are also involved in other processes such
as cell migration in organogenesis, cell survival during inflammation,
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leukocyte degranulation and anti-tumour immunity. The two known
transmembrane chemokines, CX3CL1 and CXCL16 also act as cell
adhesion molecules (37-39). Tables 2 and 3 demonstrate the major
chemokines with their known receptors and predominant functions.
Abbreviations used in tables 2 and 3:
MIP - macrophage inflammatory protein, MCP- macrophage
chemoattractant protein, RANTES- regulated on activation, normal T
expressed and secreted, HCC- haemofiltrate chemokine, TARC- thymus
and activation-regulated chemokine, MDC- macrophage derived
chemokine, SLC- secondary lymphoid-tissue chemokine, TECK-
thymus-expressed chemokine, PF4- Platelet factor 4, BRAK- Breast and
kidney expressed chemokine, ELC- Epstein Barr ligand chemokine,
MEC- mammary-enriched chemokine, GCP- granulocyte chemotactic
protein, COPD - chronic obstructive pulmonary disease, GRO- growth-
regulated oncogene, ENA- epithelial cell derived neutrophil activating
peptide, MIG- monokine induced by interferon-^ IP- interferon-
inducible protein, I-TAC- interferon-inducible T-cell alpha
chemoattractant, BCA-1- Bcell chemoattractant 1, SR-PSOX- scavenger
receptor for phosphatidylserine-containing oxidized lipids, RA-
rheumatoid arthritis, MS- multiple sclerosis, AS- atherosclerosis, IBD-
inflammatory bowel disease.
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Ligand Receptor(s) Associated Disease(s) or Functional Pathway
CCL1 CCR8 Granuloma formation, dendritic cell migration to
lymph nodes, type 2 cellular immunity
CCL2 (MCP-1) CCR2 Atherosclerosis, RA, MS, type 2 diabetes mellitus
CCL3 (MlP-la) CCR1 Rheumatoid arthritis, multiple sclerosis
CCL4 (MIP-ip) CCR1,
CCR5
RA, MS, HIV-1 co-receptor, transplant rejection
CCL5 (RANTES) CCR5 HIV-1 co-receptor, transplant rejection,
atherosclerosis
CCL6 (MRP-2) CCR1 Allergy

























CCL17 (TARC) CCR4 Parasitic infections, graft rejection, T-cell homing to
skin
CCL18 (MIP-4)
CCL19 (ELC) CCR7 Transport of T cells and dendritic cells to lymph
24
nodes, antigen presentation, cellular immunity
CCL20 CCR6 Allergic asthma, mucosal humoral immunity,
intestinal T-cell homing
CCL21 (SLC) CCR7
CCL22 (MDC) CCR4 Graft rejection, parasitic infection
CCL23 (MIP-3) CCR1
CCL24 (eotaxin-2) CCR3
CCL25 (TECK) CCR9 Inflammatory bowel disease, homing of T cell and
IgA+ plasma cells to gut
CCL26 (eotaxin-3) ccr3
CCL27 (PESKY) CCR10 T cell homing to intestine and skin
CCL28 (MEC) CCR3,
CCRIO
T cell homing to intestine and skin
Table 2. The CC Family of Chemokines and Chemokine Receptors
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Ligand Receptor(s) Associated disease or Pathway
CXCL1 (GRO-1) CXCR2 Inflammatory lung disease, COPD,
angiogenic for tumour growth
CXCL2 (GRO-2, MIP2a) CXCR2
CXCL3 (GRO-3, MIP2p) CXCR2
CXCL4 (PF4) CXCR4B
CXCL5 (ENA-78) CXCR2
CXCL6 (GCP-2) CXCR1, CXCR2 Inflammatory lung disease, COPD
CXCL7
CXCL8 (IL-8) CXCR1, CXCR2
CXCL9 (MIG) CXCR3(A&B) Inflammatory skin disease, transplant
rejection, MS
CXCL10 (IP-10) CXCR3(A&B) Transplant rejection
CXCL11 (I-TAC) CXCR3(A&B)
CXCL12 CXCR4 HIV-1 co-receptor, tumour metastasis,
haematopoiesis




CXCL16 (SR-PSOX) CXCR6 Inflammatory liver disease, AS
CXCL17
XCL1 (lymphotactin a) XCR1 RA, IgA nephropathy, tumour
responses
XCL2 (lymphotactin (3) XCR1
CX3CL1 (fractalkine) CX3CRI Atherosclerosis, renal inflammatory
disease, RA, IBD
Table 3. The CXC, XC and CX3C Families of Chemokines and Chemokine Receptors
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Chemokine and Receptor Binding
The chemokine repertoire produced by a particular cell and the local
environmental conditions influencing this production, will determine
the type(s) of leukocytes that will be recruited. CXC chemokines with a
glutamic acid-leucine-arginine (ELR) residue preceding the CXC
sequence are chemoattractant for neutrophils and promote
degranulation, whereas non-ELR CXC chemokines are attractant for
lymphocytes. Other chemokines such as many of the CC chemokines
attract largely T cells and dendritic cells. The CX3C chemokine attracts
monocytes and natural killer cells in addition to some T cells.
Chemokines bind to 7 transmembrane domain G protein-coupled
receptors. Ligand binding results in a conformational change in the
receptor and allows guanosine diphosphate (GDP) to be exchanged for
guanosine triphosphate (GTP) in the Ga subunit. This subunit then
dissociates from the G(3y subunit and both subunits stimulate various
distinct intracellular signalling pathways. There are more than 20
chemokine receptors and there is often more than one receptor for any
one ligand and conversely, often more than one ligand for any given
receptor. There is thought to be significant functional redundancy as a
specific function may be initiated by more than one receptor/ligand
pair. Adding to the complexity of chemokine system is the fact that
many of the chemokine receptors form homo- and hetero-oligomers
(40). This can have the effect of amplifying or inhibiting a particular
response. Chemokine receptors may even cross talk, directly or
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indirectly, with other signalling pathways further extending the number
of possible permutations resulting in a particular signal. In view of this,
there may be less functional redundancy than was originally suggested
and the formation of oligomers may contribute to the specificity of a
response. Adding to the broad spectrum of chemokine mediated
responses are the presence of splice variants and extensive
posttranslational modifications of the proteins.
At sites of inflammation chemokines are secreted by; injured tissues,
resident and recruited leukocytes and cytokine activated endothelial
cells. Soluble chemokine retention in the inflamed environment is
achieved by binding to local cell surface or matrix glycosaminoglycans,
thus creating a chemokine gradient. In this way, endothelial cells attract
and bind leukocytes with the cognate chemokine receptor, rolling over
the endothelial surface. Activation of this receptor induces integrin
receptor expression on the leukocyte, which then interacts with integrin
receptor ligands on the endothelial cell, such as intercellular cell
adhesion molecule 1 (ICAM-1), resulting in firm adhesion of the
leukocyte with subsequent diapedesis into the injured tissue. The two
transmembrane chemokines, CXCL16 and CX3CL1, are able to effect
leukocyte adhesion directly by the association of the chemokine domain
with its receptor. In addition, these chemokine cell adhesion molecules
also stimulate integrin expression, promoting leukocyte adhesion in the
same manner as the soluble chemokines (41). Resident leukocytes are
activated by the local secretion of cytokines and chemokines, with
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binding of leukocytes to chemokines bound to matrix
glycosaminoglycans.
Circulating chemokines can also bind to "silent" or "decoy" chemokine
receptors such as Duffy Antigen Receptor for Chemokines (DARC), D6
and CCXCKR (42). These receptors are not G protein coupled, despite
having a 7 transmembrane domain phenotype. They are apparently
non-signalling and are thought to be important for the transcytosis of
chemokines. Chemokine binding to decoy receptors may also act as a
chemokine reservoir although this function has not been conclusively
proven.
Some chemokines, rather than being inflammatory, have a more
homeostatic role. Production of these chemokines, for example by high
endothelial venules (HEV), does not require activation of the source cell.
These chemokines are often referred to as lymphoid chemokines as they
are primarily involved in lymphoid tissue interactions such as homing
of naive T cells or the follicular localisation of B cells (43). Chemokines
are important for both T and B cell activation and function. They play a
role in all aspects of the immune response including emigration of cells
from the bone marrow, homing of cells to the lymph nodes and spleen,
the chemoattraction of naive T cells to dendritic cells and the




CX3CLI (fractalkine), or neurotactin as it was originally termed in the
mouse, is the only known member of the CX3C subgroup of chemokines
and was first described in 1997 (35, 44). The full-length protein is
transmembrane and has a total of 373 amino acids. It consists of a 76
amino acid extracellular chemokine domain attached to a long mucin
stalk, a 19 amino acid transmembrane domain and a 37 amino acid





Figure 1. The structure of CX3CL1.
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CX3CL1 in renal diseases
Despite numerous aetiologies, most renal diseases culminate in a
common pathway of fibrosis often associated with a leukocyte,
particularly a macrophage infiltration. Given that CX3CL1 is
chemotactic for macrophages, it is reasonable to assume that
CX3CLI/CX3CRI would play a role in both acute and chronic renal
inflammation and fibrosis. Indeed this has been found to be the case in
many differing renal pathologies. In 1998 Chen et al published the first
experimental data showing that inhibition of CX3CL1 with the viral
protein vMIPII, a chemokine analogue encoded by the human herpes
virus 8, attenuated the leukocytic infiltration and subsequent
proteinuria in a rat model of anti-glomerular basement membrane (anti-
GBM) glomerulonephritis (45). The same group also showed that an
antibody to CX3CR1 was even more effective at reducing the
inflammatory response in the same model of anti-GBM disease (46).
Since then a body of work has been published demonstrating the
involvement of CX3CL1 / CX3CR1 in numerous models of renal diseases
and renal pathophysiology as highlighted below.
CX3CL1 in the embryonic kidney
In the developing kidney Grone et al found CX3CL1 in the nephrogenic
blastema, around the S shaped structure, in the mesangium of the
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developing glomerulus, in the venous and arterial endothelium, in the
medial smooth muscle cells and in the distal tubule and collecting ducts
(47). They also found CXCL10 and CXCL12 in the developing human
kidney and suggested that chemokines may be involved in the fine-
tuning of nephrogenesis and further hypothesised that the same
chemokines may be important in the adult kidney, playing a role in
tissue regeneration. Segerer et al looked more specifically at CX3CR1
distribution and found that it was present in human fetal kidneys,
between 8 and 17 weeks gestation, but with no clear pattern for specific
areas of the developing nephron or different stages of development (48).
CX3CL1 in renal inflammatory conditions
The expression of CX3CL1 mRNA and CX3CL1 protein secretion was
investigated by Cockwell et al, in human biopsy specimens with
vasculitic glomerulonephritis (predominantly glomerular
inflammation), acute renal allograft rejection (predominantly
tubulointerstitial inflammation), non-inflammatory glomerulonephritis
(minimal change nephrotic syndrome) and normal renal tissue (49).
They found that in the inflammatory conditions, CX3CL1 localised to the
inflamed compartment and correlated strongly with macrophage
infiltration. Several studies have used the anti-thyl.l antibody model of
mesangial proliferative glomerulonephritis in rats to assess the role of
CX3CL1 in renal disease (50, 51). The first of these set out to examine
why uni-nephrectomy prior to injection of the anti-thyl.l antibody
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results in more prolonged renal alterations. They found that uni-
nephrectomised animals had no difference in complement deposition,
mesangiolysis or expression of CCL2, CCL5, CCL17 or lymphotactin but
there was a significant increase in CX3CL1 production on day 14 when
compared to sham operated rats. This was accompanied by an increase
in CX3CR1 mRNA expression. A further experiment using two
injections of anti-thyl.l antibody in non-nephrectomized rats also
resulted in increased CX3CL1 expression and worse renal injury
suggesting that CX3CL1 has a role in chronic injury. The second study
using this model showed that activated mesangial cells were the major
source of CX3CL1 production and although increased mRNA was
detected as early as 2 hours post injection, there was no significant
increase in protein until 3 days later, whereas CCL2 production
increased earlier and waned earlier, suggesting that CCR2+ and
CX3CR1 + leukocytes are recruited at different time points in this disease
(51).
Despite several studies suggesting a pro-inflammatory role for
CX3CL1 / CX3CR1 in renal diseases in rats and humans, Haskell et al
found no difference in the degree of proteinuria or renal injury in
CX3CRI-/- mice compared to wild type mice, following nephrotoxic
serum induced glomerulonephritis (52). This could be due to a species-
specific effect or because of differences in the experimental protocols.
In human biopsy specimens of class III and IV lupus nephritis, but not
in the less severe class I or II nephritis, there was increased glomerular
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production of CX3CL1 with associated increased numbers of CD16+
monocytes, which characteristically have moderate to high CX3CR1
expression (53). Furthermore the CX3CL1 expression significantly
correlated with the histopathologic activity index, a measure of the
activity and chronicity of the inflammation and the CD16+ monocyte
count correlated with the clinical disease severity. Inoue et al had earlier
used a mouse model of lupus nephritis to show that glomerular CX3CL1
was significantly increased and the use of a CX3CL1 truncated analogue
before or during the early stages of the renal inflammation reduced the
glomerular hypercellularity, glomerulosclerosis, crescent formation and
vasculitis when compared to control animals, by reducing the
macrophage infiltration (54).
In 23 human biopsy samples of crescentic glomerulonephritis Furuichi
et al found interstitial but not glomerular CX3CL1, whereas CD16+ cells
were found in both areas of the kidney (55). Interestingly, steroid
treatment reduced the amount of CX3CL1 but had no effect on the
number of CD16+ cells, suggesting a more acute role for CX3CL1 in
crescent formation.
CX3CL1 in haemolytic uraemic syndrome.
More recently CX3CL1 / CX3CR1 has been implicated in the
pathophysiology of haemolytic uraemic syndrome (HUS). Ramos et al
noted a more than 50% decrease in circulating mononuclear leukocytes
(monocytes, natural killer (NK) cells and NK Tcells) expressing CX3CR1
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in children with HUS and the lowest levels of circulating CX3CR1+
leukocytes correlated with the most severe renal failure (56). The
authors postulated that CX3CL1 on activated endothelial cells interacts
with CX3CR1+ cells, removing them from the circulation and
contributing to renal injury in this disease. A further study has
expanded on this and found that one of the toxins responsible for HUS,
Shiga toxin-2, does indeed stimulate endothelial cell CX3CL1 expression
and additionally the toxin triggers CX3CL1 mediated leukocyte
adhesion (57).
CX3CL1 in transplantation.
The first studies to suggest a role for CX3CL1 in transplant rejection
were done in murine cardiac allograft models. CX3CL1 was increased,
particularly in vascular tissues and endothelium during rejection and
treatment with an anti-CX3CRl antibody brought about a 7-fold increase
in allograft survival (58). A further study found no difference in the
graft survival times between CX^jCRT7* and CX3CRlh/+ mice receiving
heterotopic heart transplants with no immunosuppression, but in the
presence of subtherapeutic levels of cyclosporin there was a significant
improvement in graft survival in the knockout mice, which was
associated with a decrease in infiltrating macrophages, natural killer
cells and other leukocytes (52). Several studies have examined the role
of CX3CL1/CX3CR1 in renal allograft rejection. The initial papers
described CX3CL1 detected by immunohistochemistry, on a proportion
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of tubules in human acute rejection, compared to negligible staining in
control kidneys (49, 59). CX3CL1 was detected on both the basolateral
and the apical membranes of these tubular epithelial cells (59). Segerer
et al investigated the presence of CX3CR1 in acute renal allograft
rejection, again in humans, and found that CX3CR1 staining correlated
with a subset of infiltrating cells (48). Another study examined the gene
expression of CX3CL1 in 12 biopsies from laser dissected renal allografts
with histological evidence of acute rejection and 10 control biopsies.
They found a marked increase in both the tubular and glomerular
expression of CX3CL1 mRNA in rejection, as quantified by real-time
PCR but there was a large variation between samples (60). More
recently Peng et al have used enzyme-linked immunosorbent assays
(ELISA) to measure urinary CX3CL1, CXCL9, CXCL10, CCL23,
granzyme B and perforin levels in 215 renal allograft recipients and 80
healthy controls (61). They found that all the chemokines were
increased in acute rejection but CX3CL1 was the only good discriminator
between acute rejection and acute tubular necrosis. Furthermore
CX3CL1 levels were the best predictors of steroid resistant rejection and
graft loss. One final study examined CX3CL1 staining by
immunohistochemistry in hyperacute, acute and chronic renal allograft
rejection and found markedly increased levels of CX3CL1 in the
tubulointersitium in chronic rejection in comparison to the other 2
groups. Moreover they found CX3CL1 in more than 80% of tubules in
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chronic rejection compared to less than 50% of acutely rejecting tubules
(62).
A couple of studies have tried to identify possible genetic
polymorphisms in CX3CR1 that are associated with allograft rejection,
one in cardiac transplantation and the other in renal transplantation, but
both studies had negative results (63, 64).
CX3CL1 in renal ischaemia-reperfusion injury.
Various groups have examined the role of CX3CL1 / CX3CR1 in ischemia-
reperfusion injury. Furuichi et al used CX3CR1 knockout mice to show
that there was no difference in the initial area of acute tubular necrosis,
the number of infiltrating neutrophils or the number of infiltrating
lymphocytes between these mice and the wild type mice following 60
minutes of ischemia with subsequent reperfusion (65). They did
however find 40% fewer infiltrating macrophages on day 7 post
ischemia, an effect that was lost by day 14. They found no difference in
the expression of other chemokines, TGF-|3 levels or platelet
accumulation between the two groups but found significantly lower
levels of PDGF-(3 in the CX3CR1 knockout mice at both 24 and 48 hours
post-injury. PDGF is a recognised stimulant of fibroblast proliferation
and extracellular matrix production. They also found that the
deterioration in renal function at day 14 was 25% less in the knockout
mice. Given that there were no significant early findings the authors
concluded that CX3CR1 was important for renal fibrosis but not for
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acute tubular necrosis. These results are in contrast to those of Oh et al
who demonstrated mainly endothelial localised CX3CL1 following acute
renal ischemia from as early as 8 hours post reperfusion (66). They also
found decreased infiltrating macrophages at 24 hours in mice pre-
treated with anti-CX3CRl antibody, though this effect was modest in
comparison to the use of clodronate to inhibit macrophage infiltration.
There was no effect of the anti-CX3CRl antibody on tubular cell
apoptosis and the conclusion was therefore that CX3CR1 was protective
by inhibition of tubular necrosis. This group did not look beyond a 24
hour time-point.
In a more recent article, Li et al used CX3CR1+/GFP mice and
demonstrated that renal dendritic cells, positive for CDllb, CDllc and
MHC II, comprised 85% of the GFP+ cells (67). They induced ischemia
and at 3 and 24 hours after reperfusion found an increase in
inflammatory renal macrophages, (F4/8010, Ly-6Chl, Gr-lmt and
CX3CRll0). At 3 hours the F4/8010 macrophages were Ly6Chlgh,
representing immature monocytes recently emigrated from the bone
marrow. By 24 hours there was down-regulated Ly6C expression. To
further investigate the role of chemokines and chemokine receptors in
ischemia reperfusion they used CCR2 knockout mice and in addition
created chimeras using CCR2' and CCR2f/+ cells transfused into
CCR2+/+ mice previously treated with bone marrow ablation. This
technique confirmed that CCR2 promoted the macrophage infiltration
and renal damage following ischemia reperfusion injury and this was
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due to both CCR2 dependent monocyte emigration from bone marrow
and to CCR2 dependent monocyte infiltration into injured kidney.
Added to this finding was the fact that CX3CR1 deficient mice also
developed less tubular necrosis and mice were shown to require
CX3CRI in addition to CCR2 for monocyte recruitment to the re-
perfused kidney following ischemic damage. This finding was in
keeping with the previous observations that CCR2 is essential for the
emigration of monocytes from the bone marrow (28) and that CCR2,
CCR5 and CX3CR1 mediate the differential infiltration of monocyte
subsets into atherosclerotic plaques (68, 69).
Chronic hypoxia has been postulated as a final common pathway to
renal failure and is supported by a substantial literature (70). Hypoxia
leads to tubular cell apoptosis and EMT, which in turn promote fibrosis
and further ischemia. Hypoxia also results in the generation of reactive
oxygen species in the tubulointerstitium and this has been shown to be
the mechanism of increased CX3CR1 expression in human renal
fibroblasts (71). Koziolek et al examined human renal biopsy specimens
and found markedly increased levels of CX3CR1 in fibrotic kidneys
compared to normal controls. Furthermore, they demonstrated over 4
times more CX3CR1 positive cells than co-labelled infiltrating
lymphocytes (CD3) or macrophages (CD68). They found that CX3CR1
was also produced by renal tubular cells, dendritic cells and
myofibroblasts. CX3CR1 expression was not increased by pro¬
inflammatory or pro-fibrotic cytokines such as IL-1 (3, TNF-a, PDGF,
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EGF, FGF-2 or TGF-|3, but it was increased by hydrogen peroxide. The
group went on to show that CX3CF1 induced cell motility in renal
fibroblasts, in much the same way as it induces vascular smooth muscle
cell motility in atherosclerosis (72).
Regulation of CX3CL1
The CX3CLI gene is found on chromosome 16 (35, 73). It is under the
control of proinflammatory stress-responsive transcription factors such
as Nuclear Factor-kb (NF-kB), Signal Transducer of Activated
Transcription-1 (STAT-1) and Activating Protein-1 (AP-1) (74-77).
CX3CLI is activated by inflammatory agents such as Tumour Necrosis
Factor-alpha (TNF-a), Interleukin-1 (IL-1), lipopolysaccharide (TPS) and
Interferon-gamma (IFN-y) (35, 78, 79). Stimulation with TNF-a and IFN-
y is synergistic in several cell types including astrocytes and smooth
muscle cells (80, 81).
NFkB and MAPK signalling pathways in CX3CL1 activation.
In the resting state NFkB is found in the cytoplasm, bound to the
inhibitory protein, inhibitor-kappa B-alpha (FcBa). Upon activation in
response to various signals from cytokines and other molecules, IkB is
phosphorylated, ubiquitinated and subsequently broken down in a
proteosome-dependent manner. The unbound NFkB is then able to
translocate to the nucleus, where it binds to specific promoter regions
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and induces gene transcription. This mechanism has been studied in
various cell types with regard to stimulation of CX3CL1 gene
transcription. Garcia et al used a dominant negative form of IkBcc and
various inhibitors of NFkB to demonstrate the role of NFkB induced
transcription of CX3CL1 in rat aortic endothelial cells (74). Chen et al
specifically examined the intracellular signalling involved in TNF-a
induced production of CX3CL1 in rat mesangial cells and again found
that NFkB induced transcription was one of the responsible mechanisms
for CX3CL1 production (76). Further stimulation of CX3CL1 production,
in various cell types, is achieved via Mitogen Activated Protein Kinases
(MAPK) such as the extracellular signal-regulated kinases (ERK1 / 2), c-
Jun N-terminal kinases and p38, which respond to extracellular stimuli,
including TNF-a, ILl-(3 and LPS (76, 82, 83). MAPK intracellular
signalling is involved in the regulation of various cell functions such as
gene expression, cell proliferation, chemokine production, secretion of
growth factors and cell survival. Chen et al, in addition to showing
NFkB induced transcription of CX3CL1 following TNF-a stimulation,
also found that inhibitors of protein kinase C (PKC) and p42/44
mitogen activated protein kinase (MAPK) attenuated expression of
CX3CL1 mRNA and protein in mesangial cells and they demonstrated
that AP-1 is also involved. More recently Wu et al discovered that
connective tissue growth factor (CTGF) stimulates CX3CL1 production
in cultured human mesangial cells via the ERK1/2, phosphoinositol-3-
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kinase (PI3K) / protein kinase B and NFkB pathways and another group
demonstrated that IL-1(3 stimulation of astrocytes activated p38 and
ERK1/2 to induce CX3CL1 production (83, 84).
IFN-y pathways in CX3CL1 activation.
Interferon-gamma induced CX3CL1 production is not mediated by
NFkB but instead uses STAT-1 (85, 86). In some cells IL-1 (3 is synergistic
with IFN-y to promote CX3CL1 production (86). Interferon-y is
produced primarily by activated T lymphocytes, but is also secreted by
natural killer cells, dendritic cells and natural killer T cells. It is the
characteristic type 1 T helper cell cytokine. It binds to a heterodimeric
receptor made up of interferon gamma receptors 1 and 2. (INF-y
additionally binds to cell surface heparan sulphate proteoglycans, which
inhibit its biological activity.) Engagement of the cytokine activates the
receptor associated Janus Activated Kinase-1 (JAK1), which acts as a
tyrosine kinase and results in the phosphorylation of the cytoplasmic
domain. This allows the recruitment of a STAT molecule, which is then
tyrosine phosphorylated. The stimulated STAT molecules are released
into the cytoplasm where they form dimers and translocate to the
nucleus. STATs bind to specific Ges sites on the enhancer or promoter
regions of genes and induce transcription. Although there are 4 JAK
proteins and 7 STATs, to date only STAT-1 and JAK-1 are associated
with IFN-y induced activation of CX3CL1 transcription (77, 87).
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Signalling pathways repressing CX3CL1 expression.
Several factors are known to negatively regulate CX3CL1 production.
Interferon- y induced CX3CL1 production in human umbilical vascular
endothelial cells (HUVECs) is reversibly inhibited by hypoxia and this is
associated with a concomitant increase in vascular endothelial growth
factor (88).
The interleukin-6 receptor has a cytokine binding a subunit (IL-6Ra)
and a transmembrane signalling gpl30 subunit. IL-6Ra, is produced by
leukocytes. In activated neutrophils the soluble form of IL-6Ra (sIL-
6Ra) is shed from the transmembrane form. In HUVECs sIL-6Ra
inhibits IL-1 or IFN-y induced CX3CL1 expression, whereas it augments
the expression of other chemokines and adhesion molecules such as
CXCL8, E-selectin and VCAM-1 (89, 90).
A metabolite of prostaglandin D2, 15-Deoxy-A12,14-prostaglandin J2 (15d-
PGJ2), is an agonist for peroxisome proliferator-activated receptor-y
(PPAR-y). It inhibits endothelial CX3CL1 expression, however this effect
is likely to be independent of PPAR-y, as other agonists did not have the
same effect (91). The down-regulation of CX3CL1 may be due to an
inhibitory effect on NF-kB, AP-1 and STAT-1 (82).
Heparin inhibits IFN-y induced CX3CL1 expression but not IL-1 (3
induced expression. This is due to heparin binding directly to IFN-y
and preventing binding to its receptor (77).
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Cleavage ofCX3CLl
Garton et al in 2001 performed a pulse-chase experiment with CX3CL1
and found that it was synthesised as a 50-75kDa protein that matured,
most likely by glycosylation, to a lOOkDa protein in the membrane.
From this full-length protein, a soluble protein of approximately 85kDa
was released and a 15-20kDa portion remained in the cell (92). Both this
group and Tsou et al went on to show that CX3CL1 is cleaved just
proximal to the transmembrane domain inducibly by a disintegrin and
metalloprotease-17 (ADAM-17), also known as tumour necrosis factor-a
converting enzyme (TACE) (92, 93). This shedding of CX3CL1 is
stimulated by phorbol-12-myristate-13-acetate (PMA), which is a protein
kinase C agonist. TACE cleaves numerous other proteins such as TNF-
a, transforming growth factor-a (TGF-a), L-selectin and IL-6. CX3CL1 is
also constitutively cleaved by another metalloprotease ADAM-10 (94).
There are thought to be numerous cleavage sites close to the proximal
transmembrane domain and it is not clear if these have any
physiological relevance. There are also other pathways involved in the
cleavage of CX3CL1 to lesser degrees, as inhibiting metalloproteases
does not completely abrogate the ectodermal shedding of the chemokine
(94, 95). More recently Dean and Overall have shown that CX3CL1 is a
substrate for the matrix metalloproteinase -2 (MMP2) (96). MMPs were
initially thought to simply degrade extracellular matrix, however they
are now known to contribute to the homeostatic regulation of the
44
extracellular environment and influence cell signalling pathways.
MMP-2 cleaves CX3CL1 in at least 4 regions and interestingly this
cleavage is mainly in the chemokine domain, as shown in figure 2.
Furthermore, a N-terminal truncation of the chemokine domain resulted
in loss of chemotactic function and in fact acted as a potent antagonist of
the CX3CLI receptor (96). The lysosomal cysteine protease cathepsin S
has also been shown to cleave CX3CL1 in neurological cells (97).
Subsequent work has provided evidence for the recycling of CX3CL1
between the cell membrane and an intracellular compartment (98). This
has been shown to protect CX3CL1 from rapid cleavage at the
membrane and provides a quickly accessible reservoir of full-length
chemokine when required (99).
Figure 2. Cleavage of CX3CL1.
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A schematic of CX3CL1 showing the various cleavage sites (arrows), by MMP-2 (1-4) or
ADAM 10 and ADAM 17. (Taken from RA Dean and CM Overall. Molecular and
Cellular Proteomics 6.3 (2007) 611-623.
CX3CR1 - the receptor for CX3CL1
CX3CR1 is the only known chemokine receptor for CX3CL1, although
US28, the promiscuous cytomegaloviral receptor also binds to CX3CL1,
as it does to many other chemokines (100, 101). The gene for CX3CR1 is
on chromosome 3, in common with many other chemokine receptor
genes. CX3CR1 is expressed on natural killer cells, monocytes and
subsets of CD3+ T cells, which are largely CD8+, as well as several types
of intrinsic cells such as synovial cells, vascular smooth muscle cells and
bowel epithelial cells (37, 81, 102-106). More recently, CX3CR1 was
found to be expressed on endothelial cells (107, 108). CX3CR1 is also a
co-receptor for the human immunodeficiency virus-1 (HIV-1), albeit a
weaker co-receptor than CCR5 (103), although receptor isoforms, with
extended N-terminal regions have been identified that are more potent
HIV co-receptors than the standard CX3CR1 isoform (109).
CX3CL1 chemotaxis and cell adhesion.
CX3CL1 chemotaxis involves signalling of receptor-coupled pertussis
toxin sensitive G proteins (37). The cell adhesion properties of CX3CL1
are somewhat more complex and are both G protein dependent and
46
independent (37, 108). CX3CL1 promotes cell adhesion both directly by
interaction with cells bearing CX3CR1 and indirectly by up-regulating
expression of integrins such as Intercellular Adhesion Molecule-1
(ICAM-1) (37-39, 41). The integrin independent mechanism does not
follow the model of cell rolling, activation and subsequent capture and
diapedesis, as shown in figure 3A, but rather involves the capture of
circulating activated leukocytes bearing the CX3CR1 receptor and the
firm binding of these directly to CX3CL1 (figure 3B) (38). Furthermore,
CX3CLl-dependent, integrin-independent cell adhesion does not require
calcium or an opposing cell membrane, is G-protein independent and
occurs under conditions of physiological flow with a slower off-rate
than is seen with most chemokine and receptor interactions (37-39, 41,
110). The exact mechanism is not fully understood but cell adhesion
critically requires the chemokine domain and it is proposed that the role
of the mucin-like stalk is to provide a way of distancing the chemokine
domain from the endothelial wall, promoting its contact with circulating
leukocytes (111). However other authors have suggested that the
unique structure of CX3CL1 alone, with prominent exposure of the
chemokine domain is not sufficient to explain its robust cell adhesion
properties and that perhaps the mucin-like stalk may play a role that
has still to be fully elucidated (37, 110). CX3CL1 also increases
expression of integrins such as ICAM-1 and Yang et al demonstrated
that this effect in endothelial cells is mediated via pertussis toxin
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sensitive CX3CR1, which results in activation of the Jak2/Stat 5 pathway
(112).
Finally, CX3CR1 plays a pivotal role in the crawling of CX3CRlhlGrl'°
monocytes along the endothelium lining in a surveillance role, with
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Figure 3. Mechanisms of leukocyte adhesion to the endothelial wall. A) The
conventional method with leukocyte cell rolling followed by activation and
subsequent interactions between selectins and integrins. After firmly adhering to the
endothelium, the leukocyte diapedeses into the injured tissue. B) Circulating
leukocytes expressing CX3CR1 are stimulated by soluble CX3CL1. These leukocytes
then bind directly to transmembrane CX3CL1 expressed by the endothelium before
diapedesis into the tissues. Leukocytes may also bind to other adhesion molecules on
the endothelial surface. Chemokine-R denotes chemokine receptor, E-selectin
Endothelial-selectin, P-selectin platelet-selectin, LFA-1 lymphocyte function associated
antigen-1, Mac-1 macrophage antigen-1, VCAM-1 vascular cell adhesion molecule-1,
ICAM 1,2 intercellular adhesion molecule 1,2, PECAM-1 platelet cell adhesion
molecule-1, CD99 cluster of differentiation 99.
CX3CL1 in non-renal disease.
CX3CL1 is expressed on both endothelial and epithelial cells, in addition
to certain other cell types eg. mesangial cells, macrophages and
dendritic cells (35, 113-116). It is found throughout the body and is
particularly prominent in the nervous system where it is constitutively
expressed in the olfactory bulb, cerebral cortex and hippocampal areas.
It plays a role in neuronal migration and is implicated in the
pathogenesis of neurodegenerative diseases, for example in a model of
Parkinson's disease, CX3CR1 deficient mice developed worse
neurotoxicity (117-120). CX3CL1 is up-regulated in a wide variety of
inflammatory conditions including asthma, psoriasis, Crohn's disease,
rheumatoid arthritis, atherosclerosis and transplant rejection (52, 58,
104, 105, 121-124). CX3CL1 plays a prominent role in atherosclerosis,
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along with CCL2. Studies using mice genetically modified to be
deficient in either CX3CL1 or CX3CR1 revealed significantly less
atherosclerosis compared to control animals under similar conditions
(125-127). Furthermore, the knockout of both CX3CR1 and CCR2 has an
additive effect, supporting the concept of independent roles for each
chemokine (125, 128). Tacke et al took this work further demonstrating
that although both CX3CRlhi and CX3CRll0 monocyte subsets enter
atherosclerotic plaques only CCR2CX3CRlIoLy6Chl monocyes required
CX3CR1 for their entry into the plaques whereas CCR2 CX3CRlhlLy6Cl0
monocytes were partially dependent on CCR5 for their entry (68).
Smooth muscle cell proliferation is another component of
atherosclerosis and the CX3CL1 / CX3CR1 axis is involved at several
levels. CX3CL1 is produced by aortic smooth muscle cells and promotes
the adhesion of monocytes (81). Lucas et al showed that human aortic
smooth muscle cells also produce CX3CR1 and these cells are capable of
migrating towards CX3CL1 along a chemokine gradient, facilitating
their accumulation within the atheroma (72). In addition to the
association between atherosclerotic monocytes, smooth muscle cells and
CX3CL1, Schafer et al showed that CX3CL1 contributes to in vitro platelet
activation and adhesion, by increasing P-selectin expression, via a
pertussis toxin sensitive pathway (129). This effect is blocked by aspirin,
nitric oxide and sodium nitroprusside. Adenosine diphosphate (ADP)
is also known to stimulate platelets and P-selectin production. Although
blocking ADP with apyrase decreased the effect of CX3CL1 stimulation
51
on P-selectin expression and platelet degranulation, it did not affect
platelet adhesion, suggesting that co-stimulation of ADP and CX3CL1
induces P-selectin expression. The same group went on to demonstrate
that both soluble and membrane bound CX3CL1 stimulate platelet
degranulation and P-selectin expression and that platelets are critical for
the CX3CL1 induced adhesion of leukocytes to endothelial cells under
high shear conditions (130) thus providing further weight to the
argument for the importance of this chemokine in inflammation.
Protective effects of CX3CL1/CX3CR1.
CX3CR1-mediated signals are essential for intraperitoneal bacterial
clearance in a model of septic peritonitis induced by cecal ligation and
puncture, in mice (131). In this model there was a similar degree of
peritoneal leukocytic infiltration comparing wild type and CX3CR1
knockout mice but there was a more than doubling of the mortality rate
(75% v 33%) in the deficient mice. CX3CL1 was found to stimulate the
gene expression of IL-1|3, TNF-a, IFN-y and IL-12, which are pro¬
inflammatory cytokines. There was attenuated bactericidal phagocytosis
by neutrophils and macrophages in the CX3CR1 deficient mice
associated with reduced intraperitoneal inducible nitric oxide synthase
activity. This study provides evidence for the role of CX3CL1 / CX3CR1
in the optimisation of bactericidal host defence. CX3CL1 plays a
significant role in wound healing and importantly, CX3CR1 seems to
have a substantial role in anti-tumour responses in mice, a function
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which may well extrapolate into humans (132, 133). Ishida et al
examined the role of CX3CL1/CX3CR1 in skin wound healing in mice
(133). They found that both were increased following a skin injury and
that CX3CR1 knockout mice had delayed wound healing. This was due
to a decreased macrophage infiltration in the knockout mice with
subsequent decreased macrophage products such as TGF-|3 and vascular
endothelial growth factor (VEGF). Furthermore there was also reduced
neo-revascularisation. The reparative role of CX3CL1 / CX3CR1 is not
fully understood and there is obviously a close association between the
processes involved in inflammation and those involved in subsequent
repair or fibrosis.
Localisation of CX3CL1 in renal injury
Using immunohistochemistry and in situ hybridisation Cockwell et al
showed that CX3CL1 is expressed in human renal biopsy specimens (49).
Furthermore they demonstrated expression of CX3CL1 within the renal
glomerulus in glomerular pathology and in the renal tubules in acute
allograft rejection, which is predominantly a tubular pathology.
Chakravorty et al continued this work and again using
immunohistochemistry showed that CX3CL1 is expressed on both the
basolateral and luminal surfaces of renal tubular epithelial cells in acute
allograft rejection (figure 4) (59).
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Figure 4. Immunohistochemical localisation of CX3CL1. Normal kidney (a) and acute
allograft rejection (b). Magnification x400. Taken from Chakravorty et al. Fractalkine
expression on human renal tubular epithelial cells: potential role in mononuclear cell
adhesion. J Exp Immunol 2002; 129: 150-159
It is widely acknowledged that although immunohistochemistry is a
good technique for assessing the presence or absence of a particular
protein in a specimen, it is not the optimal tool for assessing the precise
subcellular localisation of the protein. Since the location of CX3CL1 in
renal tubular epithelial cells will have implications for its function, we
sought to examine the exact intracellular location of CX3CL1 in these
cells, with a view to establishing the function of CX3CL1 in renal
tubules. Furthermore we made the assumption that CX3CL1 would
preferentially target a particular membrane in polarised renal tubular
cells and investigated the mechanism(s) responsible for this.
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Cell polarity and protein targeting
Epithelial cells form a barrier to the external environment but they also
have important roles in the transfer of proteins in and out of cells. They
are typically cuboidal or columnar in morphology with clearly defined
apical and basal membranes, separated by tight junctions and this
polarisation permits distinct functions to be carried out by the different
membranes. Cell polarisation is widespread in biology and despite the
extensive number of cell types exhibiting this phenomenon there are
relatively few mechanisms responsible for its achievement. The three
major contributory factors to cell polarity are i) protein sorting to a
particular membrane, ii) cell signalling complexes and infrastructure
associations with the cytosolic face of the particular membrane and iii)
cell orientation in 3-dimensional space by stimuli from adjacent cells
and extracellular matrix via adhesion receptors (134).
Cell polarity is essential for many cellular functions and a loss of
polarity can be seen in many disease states such as cancer, where cells
attain a mesenchymal phenotype allowing migration to other parts of
the body before integrating into the new organ. Within the kidney
tubules cell polarity is crucial to the maintenance of homeostasis as
solutes are exchanged at both the apical and basal membranes in a
finely regulated manner. Many renal diseases are due to protein mis-
sorting or exchanger malfunction within the tubular cells, resulting in
excessive or inadequate solute losses. Specific drugs target the receptors
found on a particular tubular membrane for example amiloride targets
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the epithelial sodium channel on the apical membrane, to increase
urinary sodium losses.
Proteins are constructed in the endoplasmic reticulum (ER) and are then
transported to the membrane via various organelles and vesicular
intermediates as shown in figure 5. In addition, there is usually some
degree of post-translational modification of the protein during the
transport from the ER to the membrane. Vesicular intermediates are
formed by three classes of proteins; coatomer protein complex-II sorts
the newly formed protein into vesicles and mediates transport from the
ER to the Golgi, coatomer protein complex-I mediates Golgi to ER
transport and intra-Golgi transport and the adaptor protein (AP)-
clathrin complex is responsible for transport between the Golgi,
endosomes and the plasma membrane. Movement of vesicles between
compartments is mediated by the actin and microtubule cytoskeleton.
The fusion of vesicles with the plasma membrane is regulated by Rab
GTPases, vesicle-tethering complexes and soluble N-ethyl-maleimide-
sensitive fusion protein attachement-protein receptors (SNAREs). These
mechanisms are generic to protein transport within the cell and are
modified to sort proteins specifically to a particular membrane in
polarised cells (fig 5).
One further possible route for protein transport is the transcytosis
pathway whereby a protein is transported to one membrane initially,
usually the basolateral membrane, and is then moved to the opposite




















Figure 5. A generic post-translational pathway for protein trafficking to the plasma
membrane.
F.R - endoplasmic reticulum, COP- coatamer protein complex, SNARE-soluble N-
ethyl-maleimide-sensitive fusion protein attachment-protein receptor, TGN- trans-
Golgi network.
Coordinated protein sorting, targeting and distribution in polarized cells. Mellman I
and Nelson WJ. Nature Reviews Molecular Cell Biology 2008, 9(11) 833-845.
The regulating mechanisms that direct a particular protein to a specific
membrane appear to be limited despite the vast array of proteins
synthesised by a cell. Essentially signalling codes are due to cytosolic
domains, glycosylation of the protein, transmembrane domains or to an
association with lipid rafts or caveolae. In general, apical sorting motifs
are transmembrane or extracellular whereas basolateral sorting motifs
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are more likely to be found in the cytoplasmic domain of the protein
though there are exceptions to this for example rhodopsin and
podocalyxin/Gpl35 are apical proteins that use a cytosolic domain for
membrane targeting (135,136).
Protein targeting via a cytosolic domain.
Various cytosolic domains have been established as basolateral
targeting motifs. Proteins such as the low density lipoprotein receptor
(LDLR) and the H+K+ATPase transporter use tyrosine based motifs.
The LDLR has two tyrosine motifs, one of which is important for
endocytosis and the other directs traffic to the basolateral membrane
(137). Other proteins have leucine or dileucine motifs that signal for
basolateral transport. Just how these motifs direct protein transport is
not understood. An association with AP-clathrin complexes is
suggested however knockdown of clathrin with small interfering RNA
(siRNA) affects the traffic of some proteins but not others and clearly
other pathways are involved (138).
Protein targeting via a transmembrane domain.
Transmembrane signalling motifs commonly are due to an association
with a glycosyl phosphoinositol (GPI) lipid anchor, such as those used
by THY-1 or by direct association with lipid rafts in the plasma
membrane. Lipid rafts are rich in glycosphingolipids, sphingomyelin
and cholesterol. After sorting of GPI-anchored proteins in the Golgi
complex, there is oligomerisation in the lipid rafts. GPI-anchored
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proteins are preferentially sorted to the apical membrane. There is still
only rudimentary information on just how apical clustering of proteins
within lipid rafts results in delivery of the protein to this membrane.
Protein targeting via glycosylation of the protein.
The final trafficking pathway relies on glycosylation of the protein and
this includes both N-linked and O-linked glycosylation. Numerous
proteins use this mechanism and it is generally used to direct the
protein to the apical membrane. In intestinal epithelial cells inhibition
of O-glycosylation prevents the apical targeting of mucins and brush
border glycoproteins (139, 140). Chemical inhibition of N-glycosylation
and mutation or deletion of glycosylation residues has been used to
show that this mechanism is also used for protein trafficking. The role
of N-glycosylation in apical protein trafficking was further supported by
a study by Scheiffele et al, in which they compared the secretion of
growth hormone in MDCK cells. Growth hormone is a non-
glycosylated protein, which is secreted to both the apical and basolateral
membranes in MDCK cells in an approximate 1:2 ratio. When it is
genetically modified to incorporate one N-glycosylation site it is
preferentially targeted to the apical membrane and the addition of 2
glycosylation sites directs over 90% to the apical membrane (141).
Chemical inhibition of N-glycosylation or mutagenesis of the
glycosylation site(s) has implicated this process in the apical targeting of
proteins such as erythropoietin, enteropeptidase, glycine transporter 2
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(GLYT2), sialomucin endolyn and membrane dipeptidase (142-146). It
seems that some proteins have just one crucial N-glycosylation site for
example, erythropoietin, whereas others, such as GLYT2, have multiple
sites and the loss of apical targeting is directly related to the number of
disrupted glycosylation sites. Interestingly, the addition of N-glycans to
proteins such as a truncated occludin and a chimeric ERGIC-53, which
both normally reside in the Golgi, results in increased apical distribution
(147). The exact mechanism involved in N-glycosylation directed apical
targeting is not yet elucidated and glycosylation is also known to have
effects on protein folding, regulation of intracellular transport and
protein stability. It is possible that disruption of glycosylation causes
protein mis-folding which then masks an apical signalling code.
The regulation of CX3CL1 by other inflammatory pathways.
The role of CX3CL1/CX3CR1 in renal diseases is gradually emerging but
clearly there is still much to learn. To date the well recognised
stimulators of CX3CL1, such as TNF-a and IFN-y, have been
investigated but there is little or no work studying other potential
pathways for the activation of CX3CL1 in the kidney. There are
numerous inflammatory pathways at play in the pathogenesis of renal
inflammation, with many points of interaction and cross-talk. Given the
highly vascular nature of the kidney and its high blood flow, we
questioned whether a common mediator of endothelial inflammation,
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namely thromboxane A2 (TXA2) would have an effect on renal
inflammation with particular reference its effect on CX3CL1. Both TXA2
and CX3CLI are present very early in the inflammatory process but no
direct link between the two pathways has previously been shown in
renal disease. We therefore chose to investigate this potential link more
closely.
Thromboxane A2 and the Thromboxane Prostanoid Receptor
Thromboxane A2 (TXA2), is a prostanoid formed from the
cyclooxygenase (COX) pathway metabolism of arachidonic acid, which
is itself, derived from cell membrane lipids (figure 6). TXA2 is a potent
vasoconstrictor, induces platelet aggregation and is a smooth muscle
cell mitogen (148). It is produced mainly by platelets but can also be
synthesised by monocyte/macrophages, vascular smooth muscle cells,
and endothelial cells. TXA2 mediates its effects by binding to the
thromboxane prostanoid receptor (TP), a G protein-coupled receptor
expressed in diverse hematopoietic cell types involved in inflammation,
including platelets, monocytes, T lymphocytes, and neutrophils, as well
as in endothelial cells, fibroblasts and smooth muscle cells. The highest
levels of TP mRNA are found in thymus, followed by spleen, lung and
kidney.
Despite its very short half-life, of about 20-30 seconds, TXA2 is extremely
potent and acts on cells in close proximity to the TXA2-synthesising cells
as an autocoid in autocrine or paracrine systems. In aqueous solutions it
61
is rapidly hydrolysed to thromboxane B2 (TXB2), which is inactive. TXA2
is released early in inflammation and has long been implicated in the
pathogenesis of atherosclerosis, as well as many other inflammatory
conditions.
Phosphatidylcholine Phosphatidylinositol














Prostaglandin 62 Prostaglandin F2
Prostaglandin E2
Figure 6. The Metabolism ofArachidonic Acid
62
Thromboxane AjThromboxane Prostanoid Receptor Signalling
The thromboxane prostanoid receptor (TP) is a 7 transmembrane G
protein coupled receptor. TP communicates with various families of G
proteins but the major interactions are between TP and Gq and G13.
Platelets deficient in both these G proteins are completely unresponsive
to TP stimulation. It is known that Gq is required for platelet
aggregation whereas G13 is needed for the conformational change of
platelets (149). The G proteins communicating with TP are tissue and
cell type dependent. There are two alternatively spliced variants of TP,
TPa and TP(3 (150, 151). TPa was originally cloned from placenta
whereas TP(3 was cloned from umbilical vein endothelial cells. These
two isoforms are thought to have identical ligand binding sites and
differ only in their C-terminal tail regions. Although mRNAs for both
splicing variants have been detected in most cells, the translated protein
is not always expressed, for example, platelets only express TPa (152).
In cells that express both isoforms differences in function have been
noted, for example TPa activates adenylyl cyclase in CHO cells whereas
TP(5 inhibits this enzyme, and this may be explained by coupling of the
two isoforms with different G proteins (153-155). Figure 7 demonstrates
the downstream signalling induced by the coupling of TP with different
G proteins.
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Cytoskeletal alterations, cell adhesion, motility, nuclear
transcription factors, cell survival and apoptosis
Figure 7. G protein coupling with the thromboxane prostanoid receptor and signal
transduction.
PLC-phospholipase C, pll5-RhoGEF- pll5 guanine nucleotide exchange factor for
Rho, IP3- inositol 1,4,5-triphosphate, DAG- diacylglycerol, cAMP- cyclicAMP, PI3K-
phosphatidylinositol 3-kinase, MAPK-mitogen activated kinase, PKC- protein kinase
C.
Adapted from Nakahata N. Thromboxane A2: Physiology/pathophysiology, cellular
signal transduction and pharmacology. Pharmacology & Therapeutics, 2008; 118, 18-
35.
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Thromboxane Aj Thromboxane Prostanoid Receptor and Renal
Inflammation
Although the link between prostanoid secretion and renal injury has
long been recognised the actual mechanisms by which this occurs are
not well understood. Increased urinary levels of thromboxane
metabolites are often found in kidney pathologies of diverse aetiologies.
Early studies showed that in normal kidneys TXA2 appears to regulate
renal haemodynamics and sodium handling (156-159). In non-diseased
animals an infusion of a TP agonist resulted in decreased glomerular
filtration rate (GFR) in rats that was due to increased vascular resistance
within the kidneys (156). TP stimulation in the kidney also directly
affects mesangial cells resulting in cell contraction, which may
contribute to the decrease in GFR (157). In both rat and human
glomerular mesangial cells, prostanoids induce a change in the cellular
ion fluxes, with an increase in inositol phosphates and intracellular
calcium and the environment becomes profibrotic with increased
production of extracellular matrix that is associated with increased
mRNA for fibronectin, collagen and laminin (160). TP stimulation also
results in increased PAI-1 production and tissue plasminogen activator
by mesangial cells (161). Given the effects of PAI-1 on fibrinolysis and
renal fibrosis discussed previously, this effect of TP stimulation adds a
further potential mechanism for the promotion of glomerular
thrombosis and renal fibrosis.
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Numerous studies have used methods to block TP or TXA2 synthesis to
examine the impact of this pathway on disease models. Many of these
studies, but not all, suggested a beneficial outcome of blocking the
prostanoid pathway, for example pathway blockade resulted in lower
levels of proteinuria in rodent models of nephrotic syndrome (162), anti-
glomerular basement membrane disease (163), membranous
nephropathy (164) and mesangioproliferative glomerulonephritis (165).
This is not always accompanied by significant improvements in the
histological appearances of the kidneys.
Following an ischaemic insult in rats, the use of a TXA2 synthase
inhibitor improved renal blood flow, GFR and urine volumes (166).
Similarly, in a mouse model of acute renal failure induced by
endotoxemic shock, blockade of TP resulted in attenuated decreases in
renal blood flow and glomerular filtration rates but it did not effect
overall survival at an early time-point (167). A human study of the use
of ibuprofen or placebo in patients with sepsis showed no improvement
in mortality rates or rates of acute renal failure, despite reduced
thromboxane urine metabolites in the ibuprofen group (168).
In rat models of diabetic nephropathy, TP stimulation contributes to the
development of albuminuria, increased glomerular and mesangial
volumes and to the increased width of the glomerular basement
membrane (169). Specific blockade of TP or the administration of a
thromboxane synthase inhibitor resulted in attenuated
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microalbuminuria, prevention of the increased glomerular volume and
lower levels of markers of oxidative stress (169, 170).
There is increased TXA2 production in lupus nephritis in both humans
and mice (171, 172). This increase correlates with the degree of lupus
activity as measured by proteinuria and histological changes on renal
biopsy. Blockade of TXA2 synthesis in mice and the use of a specific TP
antagonist in humans have renoprotective effects and improved clinical
outcomes (173,174).
Numerous studies have examined the role of thromboxane in renal
allografts and although there is an association between the prostanoid
pathway and acute rejection, functional therapeutic interventions have
not yet materialised. Coffman et al were the first to demonstrate that
acute rejection is associated with increased levels of the inactive
thromboxane metabolite TXB2 and this has been corroborated by various
other groups in both animal models and in humans (175-178). In a rat
model of renal allograft rejection, a continuous infusion of a TXA2
synthase inhibitor improved renal function and reduced urinary
thromboxane metabolites but did not affect the cellular immune
response to rejection. Furthermore, it seemed that the responses were
temporary as by day 6 there was only partial reduction in urinary
metabolites (176). Similarly, in a canine model of renal allograft
rejection, selective inhibition of TXA2 synthase improved renal blood
flow and GFR but did not affect the histological changes of rejection
(179). Staining for TXA2 synthase is increased in humans during
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episodes of acute rejection and directly correlates with a faster decline in
renal function over 6 months (180). The TXA2 synthase staining appears
to co-localise with a macrophage infiltrate. Prostanoid stimulation
contributes to the reduced blood flow seen in rejection but the exact
role(s) of the thromboxane prostanoid pathway in renal allografts is still
not clear and needs further elucidation.
Thromboxane Aj Thromboxane Prostanoid Receptor and Inflammation
of Other Organs
In the central nervous system TP is expressed by astrocytes, astrocytoma
cells and oligo dendrocytes (181-183). Stimulation of TP results in IL-6
secretion by astrocytes and enhanced proliferation and survival of
oligodendrocytes. In the peripheral nervous system, TP stimulation
elicits pulmonary and cardiovascular reflexes (184-186).
TP is implicated in the pathogenesis of asthma, both as a mediator in the
allergic responses in asthma, as well as causing contraction of bronchial
smooth muscle cells (187, 188).
TP is also involved in allergic responses in rhinitis and atopic dermatitis
(189-191), in inflammatory tachycardia (192), in metastasis of tumour
cells (193), in angiogenesis during tumour growth and chronic
inflammation (194). In addition, it plays a role in modulating acquired
immunity, by impairing the adhesion between dendritic cells and naive,
but not memory, T cells (195). TP stimulation causes contraction of
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numerous types of smooth muscle cells including those found in the
vasculature, intestine, uterus and bladder (196-199).
Thromboxane Prostanoid Receptor and Atherosclerosis (as a disease
model)
Perhaps the disease for which there is the greatest information
regarding the role of TP stimulation is atherosclerosis. Atherosclerosis is
the end result of complex inflammatory processes involving interactions
between the endothelial wall, platelets, lymphocytes and macrophages.
Oxidative stress, cytokine activation, lipid deposition, leukocyte
recruitment and smooth muscle cell proliferation all contribute to its
pathogenesis. The initial lesion is the fatty streak, beneath the
endothelium, which is made up mainly of lipid-laden macrophages,
(foam cells), with some T cells. Progression of the fatty streak results in
the formation of the atherosclerotic plaque or atheroma, an asymmetric
thickening of the arterial intima consisting of foam cells, extracellular
lipid droplets, smooth muscle cells, extracellular matrix and
inflammatory leukocytes. The atheroma has the potential to rupture and
induce thrombosis, with the consequential and often devastating, acute
vascular events such as ischemic heart disease and cerebrovascular
accident or stroke.
Ishizuka et al, found that stimulation of the TP on endothelial cells
results in increased ICAM-1 expression, which promotes monocyte cell
adhesion (200). Monocyte / macrophage infiltration is a very early
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feature of atherogenesis, being present in the fatty streak. In addition,
TP stimulation increases IL-1|3 induced VCAM-1 expression in aortic
vascular smooth muscle cells, further promoting cell adhesion to the
endothelial wall (201). In human ischemic atherosclerotic vessels,
Katugampola et al, showed increased TP receptor density in both the
aorta and in the epicardial coronary arteries (202). They also found that
the angiotensin receptor blocking agent, losartan, competed for binding
to the TP suggesting an association between the renin-angiotensin
pathway and the prostanoid pathway.
The effects of TP stimulation on platelets have been well established.
Platelet activation by TP leads to conformational change, aggregation
and secretion of granule contents including; ADP, ATP, serotonin,
calcium, von Willebrand factor, factor V and fibrinogen, with resultant
increased thrombotic tendency. This further contributes to the
pathogenesis of atherosclerosis and its clinical outcomes (202-204).
Prostaglandin I2 (PGI2) is the biological opposite of TXA2 and has platelet
inhibitory and vasodilating properties (205). It is mainly produced by
vascular endothelial cells and its synthesis is dependent on COX-2 and
prostacyclin synthase. Both TXA2 and PGI2 have increased expression
in atherosclerosis (206, 207). It is believed that changes to the
equilibrium between TXA, and PGI2 are critical for the development of
thrombus rather than the absolute amounts of each mediator. In 2004
Kobayashi et al published work examining the individual contributions
of TXA2 and PGI2 to the development of atherosclerosis (208). They
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cross-bred apolipoprotein E knock-out (Apo E-/-) mice (genetically
modified mice that develop atherosclerosis) with mice that were either
deficient for TP or for the PGI receptor (IP). The TP deficient mice had
markedly delayed atherogenesis with a significant decrease in ICAM-1
expression in the endothelial cells overlying the atheromatous lesions,
whereas the IP deficient mice had accelerated atherogenesis with
increased ICAM-1 expression. Furthermore, they found
decreased / increased platelet reactivity in the TP deficient/IP deficient
mice respectively and increased leukocyte adhesion in the IP deficient
mice.
Therapeutic interventions that aim to block the production of TXA2 are
already in widespread use, both in cardiovascular disease and in other
inflammatory conditions. As can be seen in figure 8, TXA2 is produced
via the COX-1 pathway, whereas PCI2 is produced via the COX-2
pathway. As early as 1973, Bailey et al showed that non-steroidal anti¬
inflammatory drugs (NSAIDS) decreased atherosclerotic lesions in
cholesterol fed rabbits (209). Further studies using pharmacological
blockade of COX-1 have found similar results in various models of
atherosclerosis (210-212). Low dose aspirin, which effectively blocks
COX-1, is now used daily by millions of people to prevent
atherosclerosis progression and to induce plaque stability where
atheroma is already present. Recently many COX-2 inhibitors, which
were used mainly for rheumatological conditions, were removed from
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the market because of their undesirable side effects on the
cardiovascular system, which were believed to be due to the selective
depletion of PGI2/ altering the equilibrium between PGI2 and TXA2.
An alternative therapeutic option to blocking COX-1 is to block the TP
receptor directly and various studies using TP antagonists have been
reported. In 2005 Viles-Gonzales demonstrated atherosclerosis
regression in S18886, (a TP antagonist), treated rabbits (213). In the
same year Worth et al showed that S18886 inhibited the development of
atherosclerosis in rabbits (214). Another TP antagonist and synthase
inhibitor, BM-573, decreased the development and progression of
atherosclerosis in low density lipoprotein receptor knockout mice (215).
The same investigators also showed that TP blockade decreased
macrophage infiltration, whilst increasing smooth muscle cell and
collagen content of atherosclerotic plaques rendering them more stable
(216). Furthermore, they found decreased levels of inflammatory






















Figure 8. The Pharmacological Modulation of Thromboxane A2 and Prostaglandin I2.
COX-cyclooxygenase, TXA2-thromboxane A2, PGI2-prostaglandin b, TP-
thromboxane prostanoid, IP-prostaglandin I2 receptor
Thromboxane Prostanoid Receptor Stimulation by Other Ligands
If the pathogenic effect of stimulation of TP is entirely from TXA2 then,
aspirin alone should prevent the formation of atherosclerotic plaques. If
however it is the stimulation of the TP receptor per se that causes the
inflammatory cascade then blocking the TP should provide greater
therapeutic benefits than inhibiting COX-1, as COX-1 inhibition may not
affect the production of other TP ligands. This latter hypothesis is
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supported by a study that examined the effect of aspirin and S18886 in
ApoE-/- mice. There were smaller aortic root atherosclerotic lesions
and lower serum levels of ICAM-1 in the S18886 treated mice but not in
the aspirin treated mice when compared to controls (217). These
findings were supported in a further study using SC560, a selective
COX-1 inhibitor and BM-573, a TP antagonist, in LDLR deficient mice,
which are also predisposed to the development of atherosclerosis. Both
agents individually reduced atherosclerosis formation but the effect was
increased in mice treated with both agents simultaneously (216). A
study in humans with coronary artery disease, all of whom were all
treated with aspirin, showed improved endothelial function, as
measured by flow mediated vasodilatation, after a single dose of S18886
(218).
Although TXA2 is the most common ligand for TP, others are known
about, the main group being the F2 isoprostanes, derived from the free
radical oxidation of arachidonic acid (figure 7). The F2 isoprostanes, as
well as being reliable markers of oxidative stress, increase platelet
activation, induce mitogenesis of vascular smooth muscle cells, induce
the proliferation of fibroblasts and endothelial cells and increase the
expression of endothelin-1, a vasoconstrictor, in aortic endothelial cells
all via TP stimulation (219, 220). Distinct F2 isoprostanes have been
localised in human atherosclerotic lesions (221). In addition, Tang et al
demonstrated that isoprostane F2cx-III directly promotes atherogenesis
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in both apoE-/- and LDL receptor-/- mouse models by activating TP
(222).
Thromboxane Prostanoid Receptor Stimulation and Chemokines
There is accumulating data linking TP stimulation with chemokine
activation. Over ten years ago, Schneider et al found that non-selective
COX inhibition with indomethacin, stimulated the glomerular
expression of both CCL2 and CCL5 mRNA in two different rat models
of glomerulonephritis (mesangial proliferative and anti-GBM nephritis).
This effect was not seen when they used selective COX-2 inhibition,
implying that it was a COX-1 effect. The increase in chemokine mRNA
was associated with increased chemokine activity and augmented
recruitment of monocytes and macrophges to the glomeruli (223). A
further study noted that CCL17 and CCL22 induced platelet
aggregation, which could be inhibited by aspirin (224). Hoshino et al
then used the TP antagonist AA-2414 in asthmatic patients and showed
decreased CCL5 and CCL3 in the bronchial epithelium and submucosa,
which was associated with less eosinophilic infiltration and improved
clinical outcomes (225). A year later Ishizuka et al used U46619, a TP
agonist, in human umbilical vascular endothelial cells (HUVECs) and
found augmented CCL2 expression (226). This group demonstrated
that TP stimulation induced NFkB and AP-1 binding activity through
the protein kinase C system. The same group later used Ramatroban, a
TP antagonist, in a rabbit model of arterial injury and showed dose-
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dependent decreased plasma CCL2 levels and decreased mRNA for
CCL2 in the injured aortas of the treated animals (227). Cyrus et al
initially demonstrated that low dose aspirin decreased circulating levels
of CCL2 in LDLR knockout mice (228) and then went on to show that a
combination of a selective COX-1 inhibitor with a TP antagonist, in the
same animal model, suppressed circulating CCL2 levels to a greater
extent than each drug individually (215). Finally, the TXA2 synthase
inhibitor, ozagrel, was shown to reduce CCL2 and CXCL8 mRNA
expression in a model of lung injury in guinea pigs, with an associated
decreased inflammatory response (229). Similar data is also emerging
regarding the links between stimulation of other prostanoid receptors
such as the protaglandinF2 receptor and regulation of chemokines (230,
231).
Although there is currently no data linking the stimulation of the
thromboxane prostanoid receptor and regulation of the chemokine
CX3CL1, given the preceding information and the fact that both TXA2
and CX3CLI are active early in inflammation, in overlapping clinical
scenarios, it seemed reasonable to hypothesise a possible association
between the two that would add to the increasing complexity of the
pathogenesis of inflammation.
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Hypothesis la: The chemokine CX3CL1 is mainly on the basal
membrane of renal tubular epithelial cells.
Hypothesis lb: There are signalling pathways that direct CX3CL1 to the
basal membrane.
Hypothesis lc: CX3CL1 is immobile in the cell membrane.
Hypothesis Id: CX3CL1 is a cell adhesion molecule on renal tubular
epithelial cells.
Hypothesis 2a: Stimulation of the thromboxane prostanoid receptor
increases surface cell levels of CX3CL1.
Hypothesis 2b: Stimulation of the thromboxane prostanoid receptor
alters recycling of CX3CL1.
Hypothesis 2c: Stimulation of the thromboxane prostanoid receptor
inhibits cleavage of CX3CL1.
Hypothesis la: The chemokine CX3CL1 is mainly on the basal
membrane of renal tubular epithelial cells. Previous studies have
shown increased CX3CL1 in some diseased renal tubules. The precise
intracellular location of the chemokine will have implications for its
function and this has not yet been unequivocally demonstrated in these
cells. The close proximity of the peritubular capillaries to the basal
membrane would allow circulating leukocytes to migrate towards the
transmembrane CX3CL1 and chemokine mediated adhesion would also
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be possible. The apical surface of renal tubular epithelial cells is in
contact with the urinary space and this is ordinarily devoid of
leukocytes, hence apically expressed CX3CL1 would not have any direct
contact with cells expressing its receptor under normal conditions.
Hypothesis lb: There are signalling pathways that direct CX3CL1 to
the basal membrane. Despite numerous proteins being trafficked to a
specific membrane in polarised cells there are relatively few
mechanisms employed.
Hypothesis lc: CX3CL1 is immobile in the cell membrane. CX3CL1
acts as a chemoattraction agent and as a cell adhesion molecule in
various cell types. To facilitate the cell adhesion properties, immobility
with the membrane would allow CX3CL1 to act as a firm anchor,
capturing leukocytes in the vicinity. The counter argument to this is that
a freely mobile membrane chemokine would offer some elasticity to the
stress forces present and there would be less chance of accidental
detachment of the leukocyte.
Hypothesis Id: CX3CL1 is a cell adhesion molecule on renal tubular
epithelial cells. This function has been proved in other cell types.
Hypothesis 2a: Stimulation of the thromboxane prostanoid receptor
increases surface cell levels of CX3CL1. Stimulation of the TP receptor
and chemokine release both occur early in inflammation. Both TP
stimulation and CX3CL1 have been implicated in the pathogenesis of
very similar inflammatory conditions. The thromboxane prostanoid
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pathway has been previously shown to regulate other chemokines.
Leukocyte recruitment is required for the pathogenesis of inflammation.
Therefore, stimulation of TP receptor is predicted to increase surface
levels of CX3CL1, to then promote the leukocytic infiltrate into the
damaged tissue.
Hypothesis 2b: Stimulation of the thromboxane prostanoid receptor
alters recycling of CX3CL1. CX3CL1 recycles from the cell surface to an
intracellular compartment. An increase of CX3CL1 at the cell surface
could be due to less endocytosis ± more exocytosis. This increase could
be achieved far more quickly than by new protein synthesis.
Hypothesis 2c: Stimulation of the thromboxane prostanoid receptor
inhibits cleavage of CX3CL1. CX3CL1 is cleaved at the cell membrane
by TACE and ADAM-10. Increased surface levels of CX3CL1 could be
obtained by inhibition of this cleavage.
Aims
Aim 1.1. To identify the precise intracellular location of CX3CL1 in
renal tubular cells.
Aim 1.2. To identify the mechanism responsible for directing
CX3CL1 to a particular membrane in renal tubular epithelial cells.
Aim 1.3. To evaluate the mobility of CX3CL1 within the cell
membrane.
Aim 1.4. To evaluate if CX3CL1 in renal tubular epithelial cells acts
as a cell adhesion molecule.
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Aim 2.1. To evaluate the effect of TP stimulation on total cellular
CX3CLI protein.
Aim 2.2. To evaluate the effect of TP stimulation on cell surface
CX3CL1 levels.
Aim 2.3. To evaluate the effect of TP stimulation on trafficking of
CX3CL1.
Aim 2.4. To evaluate the effect of TP stimulation on cleavage of
CX3CLI.
Aim 2.5. To evaluate the signalling pathways used by TP in the
regulation of CX3CL1.
82
Chapter 3. Methods and Materials
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Cells. HK-2 cells were a kind gift from Dr. Andras Kapus, (University
of Toronto). Madin Derby Canine Kidney-II (MDCK) cells and ECV-304
cells were from American Type Culture Collection (Manassas, VA).
MDCK cells stably expressing sodium-hydrogen exchanger 3 (NHE3)
tagged with hemagglutinin (HA) were kindly provided by Dr. Sergio
Grinstein, (University of Toronto). The preceding cells were cultured in
DMEM and Ham's F12 (Wisent, Quebec), containing 5% fetal calf serum
(FCS). MDCK cells are well-defined distal renal tubular epithelial cells
that have been used extensively for decades to assess epithelial cell
properties and function. They originated from an adult female cocker
spaniel in 1958. They form columnar monolayers in culture with tight
and gap junctions. They have provided an excellent model system for
examining cell polarity and for the study of transporters and ion
channels found on specific cell membranes (232-234). We genetically
modified the MDCK cells such that they expressed CX3CL1, as
described below, and confirmed that the cells maintained classical
epithelial cell polarity as demonstrated by the labelling of E-cadherin
(an important component of the adherens junction contributing to
epithelial cell differentiation) and ZO-1 (a component of the intercellular
tight junction) as shown in figure 1.
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CX3CL1-GFP-green
Total CX3CL1 - blue
ZO-1 - red
CX3CL1-GFP-green
Total CX3CL1 - red
E-cadherin -blue
Figure 1. MDCK-CX3CL1-GFP cells retain epithelial cell properties. A. MDCK-
CX3CL1-GFP cells were fixed and permeabilised and then labelled with an anti-
CX3CLI Ab (lug/ml) followed by a Cy-5 conjugated secondary Ab. They were
simultaneously labelled with an anti-ZO-1 Ab (1.25ug/ml) followed by a Cy-3
conjugated secondary Ab. (B) After permeabilisation, MDCK-CX3CL1-GFP cells were
simultaneously labelled with an anti-CX3CLl Ab followed by a Cy-3 conjugated
secondary Ab and an anti-E-cadherin Ab (1.25pg/ml) followed by a Cy-5 conjugated
secondary Ab.
ECV-304 cells were originally reported to be immortalised endothelial
cells of HUVEC origin but they are now acknowledged to be irrefutably
derived from the T24 bladder epithelial carcinoma cell line (235, 236).
The cells grow in flattened monolayers and form relatively tight
intercellular junctions. They have been reported to express some
endothelial markers such as Ulex europaeus agglutinin-1 51(UEA-1),
HAM-56 and PHM-5 but they do not stain for von Willebrand factor,
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which is a specific marker of endothelial cells and extensive testing,
including DNA profiling and genetic analysis, has clearly identified the
cells as being of epithelial T24 cell origin,
(http:/ / www.atcc.org/ CulturesandProducts/ CellBiology/Misidentifie
dCellLines/tabid/683/Default.aspx -).
ECV-304 cells genetically manipulated to produce CX3CL1 (ECV-
CX3CLI cells) are known to have surface levels of CX3CLI that reflect
those seen in primary activated vascular endothelial cells and for this
reason they have been used repeatedly to study the distribution and
cleavage of CX3CL1 (35, 39, 93-95, 98, 237). This was our rationale for
using these cells in experiments examining the effect of TP stimulation
on cellular CX3CL1 levels. Clearly they are not suitable for functional
studies of endothelial cells but as none of the experiments described
below specifically examined cell function, this was not deemed to be
important. (In further experiments performed after the completion of
the work in this thesis, primary endothelial cells were used to assess
functional properties of endothelial cells following TP stimulation).
K562 erythroleukemia cells and K562 cells stably expressing CX3CR1
(K562-CX3CR1) were a gift from Dr. Dhavalkumar Patel, (University of
North Carolina, Chapel Hill) and were cultured in RPMI supplemented
with HEPES and 15% FCS. Primary human RTEC (Clonetics, Cambrex,
Walkersville, MD) were a gift from Dr Jim Scholey (University of
Toronto) and were cultured, according to the manufacturer's
instructions, in renal epithelial cell basal medium (Clonetics) with the
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following added to each 500ml; hEGF 0.5ml, hydrocortisone 0.5ml,
epinephrine 0.5ml, insulin 0.5ml, triiodothyronine 0.5ml, transferrin
0.5ml, GA-1000 (gentamicin 30mg/ml and amphotericin B 15pg/ml)
0.5ml, FCS 2.5ml (238). The cell phenotype was not confirmed but could
have been checked by performing immunofluorescent staining for
gamma-glutamyl transpeptidase and alkaline phosphatase, as is
routinely done by the company supplying the cells.
Human peripheral blood mononuclear cells (PBMC) were isolated from
heparinised peripheral blood from healthy volunteers (239). Ten ml of
heparinised blood was centrifuged at 2300rpm for 10 mins at room
temperature. One ml of plasma was removed and the remaining blood
and plasma was diluted to 30ml in Dulbecco's phosphate buffered
saline (DPBS- Invitrogen). Ten ml of Ficoll Hypaque solution (density
1.077g/L - Sigma) was added to a 50ml Falcon tube and the diluted
blood was gently overlaid prior to centrifugation at 1500rpm for 30 mins
with no brake. The PBMCs were collected from the interphase of the
PBS and the Ficoll solution and transferred to a new 50ml tube and
diluted with DPBS to 40ml. This was followed by further centrifugation
at lOOOrpm for 8 mins. The supernatant was decanted and the cells
were washed again to remove the platelets. The cells were resuspended
in RPMI with 10%FBS. Cell density was assessed using a
hemacytometer. Cell viability was assessed using the trypan blue
exclusion method; O.lmL of 0.4% solution of trypan blue (Invitrogen) in
PBS was added to lmF of cells, after determination of the cell density.
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Cells were again counted using a hemacytometer and percentage
viability was calculated as:
(l-[Number of blue cells + Number of total cells]) xlOO
The cell phenotype was not formally assessed but could have been
checked by labelling the cells for markers of T cells (CD3), monocytes
(CD14) and NK cells (NK1.1) and performing flow cytometry. As the
same cells were used for the control and experimental conditions this
was not deemed to be essential.
Constructs. DNA expression plasmids for CX3CL1 or CX3CL1 tagged
with green fluorescent protein (CX3CL1-GFP) were created as
previously published and described below (37, 98, 240). cDNA for
CX3CL1 (GenBank registration no: NM-002996) was generated by PCR
from vector pCAGG- Neo-CX3CLl (gift from Dr Dhavalkumar D. Patel
lab, Department of Medicine, Duke University Medical Center, Durham,
North Carolina 27710, USA). A plasmid encoding CX3CL1-GFP was
generated by PCR using 0.2mM of the forward primer 5'-
CGGGTCGACTCAGCCATGGCTCCGATA and 5'-
CTGAGGATCCCCACGGGCACCAGGAC together with lOmL of Tsg
buffer (US biological), 5%DMSO, 200mM deoxynucleotide triphosphate,
50ng template DNA and lmL Tsg DNA polymerase (lmL/5U) (US
biological) made up to lOOmL with autoclaved distilled water.
Amplification was performed in a PTC-200 thermal cycler. A.n imtisl
cycle of 95°C for 1 min was followed by 30 cycles of 95°C for 20 seconds,
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60°C for 30 seconds and 72°C for 1.25 mins. There was a final cycle of
72°C for 10 mins. Amplified DNA was digested with Sail and BamHl
and cloned into the corresponding sites of pEGFP-N2 vector (BD
Biosciences Clontech) with a CMV promoter. The nucleotide sequence
of the full length CX3CL1 (1194 base pairs) construct was verified by
sequencing .
For the stable expression of CX3CF1 in ECV-304 cells, the expression
plasmid pCAGG- Neo-CX3CEl was transfected into the cells by
Fipofectamine (GIBCO-BRF). Cells were selected with 500ug/ml of
G418 for 1-2 weeks and the drug resistant cells were pooled and
incubated with a murine anti-CX3CFl antibody. Cells were washed
with PBS and were then stained with FITC-conjugated anti-mouse IgG.
Flow cytometry was used to separate the cells expressing membrane
bound CX3CF1.
ECV-304 cells were transfected with CX3CF1-GFP by electroporation
(Gene Pulser II, Bio-Rad) and selected in 500ug/ml G418. CX3CL1-GFP
expression was determined by flow cytometry.
MDCK cells were stably transfected with these CX3CF1 and CX3CF1-
GFP DNA expression plasmids using FuGENE™ (Roche, Indianapolis,
IN) and selected in 500mg/mE G418 (Wisent, Quebec). CX3CF1 and














Figure 2. The generation of
the CX3CL1-GFP construct.
The predicted transmembrane portion of CX3CL1 ends at amino acid
360 (PSORT II). To investigate the potential role of a cytosolic domain
motif in the targeting of CX3CL1 to a specific membrane, a mutant DNA
expression plasmid lacking amino acids 361-397, CX3CLl-360, was
generated by PCR using the common upstream primer
5'>GTGGAATTCTGCAGTCGACTC <3' and the downstream primer
5'> GCGGCCGCTCACATGGCCACCCCCAGGCAG <3'. In the
downstream primer stop codons and NotI sites were introduced. PCR
products were cloned into TOPO vector (Invitrogen, Burlington, ON)
and the appropriate clones were selected by sequencing. Inserts were
released by cutting with NotI and EcoRI, and subcloned into HA-
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pcDNA3.1 (Invitrogen, Burlington, ON) with a CMV promoter. MDCK



















Figure 3. The generation
of the CX3CL1-360
construct. Adapted from
an unpublished figure by
Min Riu Crow, with
permission.
DNA expression plasmids encoding GFP-tagged-glycosyl
phosphatidylinositol (GPI-GFP) and -Fella receptor (FcR-GFP) were a
gift from Dr S. Grinstein (University of Toronto).
Antibodies and reagents. The following antibodies were used: goat anti-
human CX3CLI directed against the chemokine region (R&D,





terminus (Santa Cruz, CA), anti-actin (Sressgen, Victoria, BC) rabbit
anti-Erk (extracellular signal-related kinase) and rabbit anti-phospho-
Erk (Cell Signaling, Danvers, MA) and anti-HA (Covance, Berkeley,
CA). The following secondary antibodies were used: horseradish
peroxidase-conjugated anti-mouse, anti-goat and anti-rabbit IgG, Cy3-
conjugated anti-goat IgG, Cy5-conjugated anti-mouse IgG,
phycoerythrin-conjugated anti-goat IgG and 18nm gold-labelled anti-
goat IgG (Jackson Immunoresearch Laboratories, Bar Harbor, ME). TP
agonists, U46619 and lS-[la,2b(5Z0,3a(lE,3S)4a]}-7-{3-[3-hydroxy-4(p-
iodophenoxy)-l-butenyl]-7-oxabicyclo(155)hept-2-yl)-5-heptenoic acid
(IBOP), as well as the specific TP antagonist, SQ29548 were from Biomol
(Plymouth Meeting, PA). The Erk inhibitor, U0126 was from LC
Laboratories (Woburn, MA). The metalloprotease inhibitors TAPI-2 and
GM6001 were from Peptides International (Louisville, KY) and
Chemicon International (Temecula, CA), respectively.
Tunicamycin, benzyl-2-acetamido-2-deoxy-a-D-galacto-pyranoside and
methyl-p-cyclodextrin (M|3CD) were from Sigma-Aldrich (St Louis,
MO). Amplex Red kit was used to measure cholesterol levels
(Molecular Probes, Eugene, Oregon). Cholera toxin B conjugated to
Alexa fluor 555 was from Molecular Probes (Eugene, OR). Tumour
necrosis factor-a was from R&D Systems (Minneapolis, MN). Mouse
monoclonal Ab directed against human TACE was a kind gift of Dr. Roy
Black (Amgen, Sherman Oaks, CA).
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Immunohistochemistry. Renal transplant biopsy specimens were
obtained in accordance with the guidelines of the Research Ethics Board
of University Health Network (University of Toronto). Frozen 7pM
sections were air-dried and fixed in acetone. After blocking with 5%
donkey serum, sections were incubated with anti-CX3CLl Ab (lpg/ml),
followed by Cy2-conjugated anti-goat IgG (1.5pg/ml).
Immunofluorescence staining of cultured cells was performed as
previously described (241). MDCK cells expressing CX3CL1 or CX3CL1-
GFP were grown to confluence on glass coverslips. To detect surface
CX3CL1, cells were washed with ice cold PBS and then fixed with 4%
paraformaldehyde for 20 minutes at 4°C. The cells were washed with
lOOmM glycine in PBS for 10 mins. The cells were blocked with 5%
donkey serum for 20 minutes and then they were then incubated with
anti-CX3CLl Ab (lpg/ml) for 45 mins at room temperature, prior to
further washing with PBS. A Cy3-conjugated secondary Ab (1.5 pg / ml)
was added for 1 hour at room temperature. After final washing, the
cells were mounted onto glass slides using DAKO medium (Dako
Corp). To detect both surface and intracellular CX3CF1, the same cells
were permeabilised with 0.1 % Triton X-100 after labelling of the surface
chemokine as described above. The cells were washed with PBS and
were again blocked with 5% donkey serum and then incubated with
anti-CX3CLl Ab (lpg/ml) at room temperature for 45 mins. Following
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further washing, they were incubated with Cy5-conjugated secondary
Ab (1.5pg/ml) for 1 hour at room temperature. In some experiments
Alexa 488-conjugated phalloidin (0.6U/ml) was added with the
secondary Ab to label F-actin. Cells were visualised using either a LSM
510 confocal microscope (Zeiss, Jena) or a spinning disk DMIRE2
confocal microscope (Leica, Wetzlar), equipped with an Hamamatsu
Backthinned EM-CCD camera. Images were acquired using lOOx oil
immersion and the appropriate filters. Z stacks were constructed and
images deconvolved using Volocity™ software (Improvision, Lexington,
MA). All experiments included some cells without the application of a
primary antibody but ideally an irrelevant isotype antibody of the same
species as the primary antibody being investigated should also have
been used to confirm the specificity of the results.
RNA Isolation and PCR. RNA was isolated from HK-2 cells using
TRIzol (Life Technologies, Burlington, ON). Cells were grown to
confluence on a 10cm2 culture dish and rinsed with ice cold PBS. One
ml of TRIzol reagent was added and the cells were scraped prior to
pipetting into a test tube and vortexing. The homogenised sample was
incubated at room temperature for 5 minutes prior to the addition of
0.2ml of chloroform and the sample was vortexed for 15 sees. Samples
were incubated at room temperature for 2-3 mins. The samples were
then centrifuged at lOOOOg for 15 mins in the cold room (4°C).
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Following this phase separation, the upper aqueous layer was
transferred into a new tube. To precipitate the RNA, 0.5ml of isopropyl
alcohol was added to the aqueous phase and the samples were
incubated for lOmins at room temperature. The samples were
centrifuged at 10,000g for 10 mins in at 4°C. The supernatant was
discarded and the RNA pellet was washed with 75% ethanol.
RT-PCR for CX3CL1 was performed using oligo(dT) and specific
primers; sense primer 5'-CCTGGATGCAGCCTCACAGT and antisense
primer 5'-GGACAATCCAAGGGAGAGGTG (9). Two microlitres of
each of the DNA primers (lOpM) were mixed with lOpL buffer (200mM
Tris-HCl, 500mM KC1), 3pL MgCl2 (50mM), lpL taq (Tsg) DNA
polymerase (5U/pL) (US Biological, Swampscott MA), 2pL
deoxynucelotide triphosphate (lOmM) and 50ng of the cDNA.
Autoclaved, distilled water was added to give a final volume of lOOpL.
Amplification was performed in a PTC-200 thermal cycler. An initial
denaturation (5 mins at 94°C) was followed by 40 PCR cycles, consisting
of 1 min denaturation at 94°C, 1 min annealing at 58°C and an extension
time of 5 minutes at 72°C, with a final extension of 10 minutes at 72°C.
One microlitre of cDNA was size fractionated on a gel of 1% agarose in
a Tris borate EDTA (TBE) buffer. The cDNA was visualised using
ethidium bromide. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA was used as an internal control.
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Immunoblotting. Cells were lysed with 1% TritonX-100 lysis solution
(NaCl 150mM, HEPES 25mM, MES 25mM, EDTA 0.5mM, TritonX-100
1%, mammalian protease inhibitor 8%) on ice for 6 minutes. After
centrifuging for 1 minute at 1300 rpm, an equal volume of 2x Laemmli
solution (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004%
bromophenol blue, 0.125M Tris HC1) was added to each lysate and the
samples were boiled for 5 minutes. Bradford assays were performed,
according to published protocol and the manufacturers instructions,
using Bio-Rad Protein Assay solution (242). One hundred micrograms
of protein per lane were resolved by 10% SDS-polyacrylamide gel
electrophoresis and transferred onto nitrocellulose membranes. The
blots were blocked overnight at 4HC with 5% milk PBS/0.1% Tween 20.
The blots were then incubated for 4 hours at room temperature with
primary antibody (anti-CX3CLl antibody 0.2pg/ml, anti-Erk 0.01 pg/ ml,
anti-phospho-Erk 0.2pg/ml, anti-GFP lpg/ml, anti-TACE 0.5pg/ml or
anti-ADAMlO antibody 2pg/ml). Anti-actin (lpg/ml) or anti-GAPDH
(0.125pg/ml) antibodies were used to control for protein loading.
Following extensive washes with PBS containing 0.1% Tween 20, the
blots were incubated with anti-goat or anti-mouse IgG (0.8|ig/ml)
conjugated with horseradish peroxidase (HRP) for 1 hour at room
temperature. Immunoreactive bands were visualised by enhanced
chemiluminescence (Amersham Pharmaceuticals, UK) recorded on X-
ray film.
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To assess detergent resistance, cells were lysed with 1% TritonX-100
lysis solution as above, without scraping (241). The supernatant was
removed and a volume of 4x Laemmli was added to effectively dilute to
an equivalent of lx Laemmli. lx Laemmli solution was added to the
remaining cells. The cells were scraped and then spun down to create a
pellet. A total cell lysate was used to compare the TritonX-100 soluble
and insoluble components.
For some experiments the band intensities of the immunoblots were
quantified and mean values were calculated for at least 3 experiments.
Electron microscopy. MDCK-CX3CL1 cells were grown to confluence on
25mm coverslips. The cells were fixed with 4% paraformaldehyde at 4°C
for 30 mins, washed and then labelled with anti-CX3CLl Ab (lpg/ ml) in
PBS for 1 hour at room temperature. After further washing, cells were
incubated with 18nm gold-labelled anti-goat IgG secondary antibody
(1:20 dilution) for 1 hour at room temperature. The cells were again
washed prior to enhancement of the gold particles with a Goldenhanced
EM Kit (Nanoprobes, Yaphank, NY). Samples were dehydrated and
then mounted on stubs. They were coated with carbon before analysis
with an XL30environmental ESM (ESEM) from FEI (Hillboro, Oregon).
Images were generated through the combination of signals from the
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gaseous secondary electron detector and the backscatter electron
detector.
Fluorescence recovery after photobleaching (FRAP). Experiments were
performed as previously described (232, 243). MDCK-CX3CL1-GFP cells
or ECV-CX3CLI-GFP cells were grown to confluence on 25mm
coverslips. Cells were treated with lOpM GM6001 4 hours prior to the
photobleaching to prevent constitutive cleavage of CX3CL1. The
coverslip was placed into an Attafluor chamber at 37°C and the cells
were maintained in RPMI containing 5% fetal calf serum and 25mM
HEPES.
To assess the lateral mobility of CX3CL1 in the cell membrane of
epithelial cells, the apical surface of the MDCK-CX3CL1-GFP cells was
brought into focus on a confocal microscope and two 2.5pm diameter
areas of similar fluorescent intensity were selected per cell. After
acquiring baseline measurements, one of the defined areas was
irreversibly photobleached using a 30 milliwatt LASOS argon laser and
the fluorescence of both selected areas was measured over time.
Fractional fluorescence recovery of the bleached area was determined
relative to pre-bleach measurements. The unbleached area was used to
control for inadvertent bleaching during repeated image acquisition.
Results are expressed as the mean fluorescence recovery for at least 5
experiments, with standard errors of the mean (SEM). This same
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protocol was used in ECV-CX3CL1 cells to assess the lateral mobility of
CX3CLI following TP stimulation.
To assess the endocytosis of CX3CL1 in ECV cells, cells were again
grown to confluence on 25mm coverslips. Four hours prior to transfer
into an Attafluor chamber, the cells were treated with lOpM GM6001, a
metalloprotease inhibitor, to prevent potential shedding of cell surface
CX3CL1. The live cells were analysed by confocal microscopy and the
entire juxtanuclear CX3CL1 containing compartment was photobleached
as described above. In other experiments, a 2pm region of the plasma
membrane was irreversibly photobleached. Recovery of fluorescence of
the bleached areas was recorded over time. The fluorescence of defined
non-bleached areas of the plasma membrane of the same cell was also
measured as a control to quantify the amount of bleaching induced by
repeated image acquisition. The results are again expressed as the mean
normalised fluorescence recovery, with standard errors of the mean.
Adhesion assays - renal tubular epithelial cells. Experiments were
performed as described elsewhere with minor modifications as outlined
(58). MDCK-CX3CL1-GFP cells were grown to confluence on 25mm
coverslips and pre-treated with lOpM TAPI-2 for 2 hours to maximize
cell surface expression of CX3CL1. K562-CX3CR1 cells were labelled with
cholera toxin B-555 (0.5pg/ml) for 20 mins at room temperature and
lxlO6 cells were added to wells of either MDCK-WT or MDCK-CX3CL1-
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GFP cells with gentle rocking at 10 cycles per minute for 30 mins. Non¬
adherent cells were washed away and remaining cells were fixed and
mounted onto slides. Using a Leica deconvolution microscope, at least
50 high power fields (x63) were examined to count the number of
adhered cells. The data was graphed to show a normal distribution for
each experiment.
Results are the mean of 4 separate experiments with SEMs and were
compared using the Student's t-test. Cells were also examined using a
spinning disk confocal microscope, after being fixed and mounted onto
glass slides. Experiments were repeated using primary RTECs and
peripheral blood mononuclear cells isolated from healthy volunteers as
outlined above. The PBMCs were labelled with calcein-AM (15pM for
30 mins at 37°C) and lxlO4 PBMCs were added to 25mm coverslips with
confluent primary RTEC for 30 mins with rocking at 10 cycles per
minute. The cells were washed and fixed as above. In parallel
experiments, a functional anti-CX3CLl Ab (lpg/ml) was added to the
wells 30 mins prior to the addition of the PBMCs.
Flow cytometry. ECV-CX3CL1-GFP cells were grown on 10 cm dishes
and treated with TP agonists, IBOP (lOOnM) or U46619 (20pM), for
various time periods. Cells were lifted by briefly incubating with 5%
EDTA at 4°C, washed and fixed in 4% paraformaldehyde. After further
washing, cells were incubated with 5% donkey serum for 20 mins at
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room temperature, followed by incubation with anti-CX3CLl Ab
(lpg/ml) for 1 hr at room temperature. After further washing, cells
were incubated with PE-conjugated donkey anti-goat IgG (2.5pg/ ml) for
1 hr at room temperature. Cells were suspended in PBS and analysed
using a fluorescence-activated cell scanner (FACScan; BD Biosciences,
San Jose, CA). Experiments were done without the use of primary
antibody in some cases but ideally an irrelevant isotype antibody of the
same species as the experimental antibody should also have been used
to confirm the specificity of the results.
The mean fluorescence intensity was normalised to control and given as
a percentage. Repeated measures analysis of variance (ANOVA) was
used to compare means for repeated tests such as the effect of TP
stimulation for different time periods and one-way ANOVA was used
to compare the means of independent groups, for example TP
stimulation in the presence or absence of TAPI-2.
CXjCLl shedding experiments. Small interfering RNA (siRNA) directed
against human ADAM-10, human TACE, and control non-targeting
siRNA were purchased from Santa Cruz Biotechnology. ECV-CX3CL1
cells were grown in two 75cm2 flasks with DMEM and 5% FBS until
confluent. The cells were then trypsinised and washed with PBS. The
cells were centrifuged and the cell pellet had lOOpL of AMAXA kit V
solution added plus lOpL of lOpM stock siRNA for TACE, ADAM-10 or
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scrambled siRNA (=100pmol of siRNA). The cells were electroporated
using program A23 of the AMAXA kit, (Amaxa, Gaithersburg, MD) on
Day 0 and Day 2. After the first electroporation 0.5ml of DMEM with
5% FCS was added to the cuvette. Following resuspension, cells were
added to 10cm culture dishes with 10ml of DMEM and incubated for 2
days before undergoing a second electroporation with siRNA. After the
second electroporation, cells were plated in 6-well tissue culture plates
at a density of lxlO3 cells/well and cultured for 48 h.
Two electroporations were done as it was found that after one the
transfection rate was only 40-50%. By doing two electroporations this
figure increased to 80%. Having started with approximately 10 million
cells, around 30% were killed following the first electroporation.
Following electroporation cells were incubated with IBOP (2.5 jig/ml)
for 30 min at 37°C, and conditioned medium collected. Cells were
washed once with PBS and lysed by adding 0.5 ml RIPA buffer.
Protease inhibitor cocktail (Sigma) was added (1:100) to both harvested
conditioned medium and to cell lysis buffer to prevent protein
degradation. Supernatants and cell lysates were cleared by
centrifugation at 13,000 rpm at 4°C for 10 min. Using fresh samples,
CX3CL1 was detected in conditioned medium and cell lysates using a
CX3CLI ELISA Kit (R&D Systems, Minneapolis, MN), according to the
manufacturer's specifications. Three independent experiments were
performed, and the data were expressed as the mean ± SEM of the
103
percentage of soluble CX3CL1 released into the medium in relation to
the total amount of CX3CL1 (soluble and cell-associated).
Acid-stripping experiments. The rate of delivery of internalised CX3CL1
back to the plasma membrane was assessed using previously published
protocols as described below (98, 244). ECV-CX3CL1-GFP cells were
grown to confluence on 25mm coverslips. To prevent potential
shedding of cell surface CX3CL1, cells were treated with the
metalloprotease inhibitor GM6001 (20pM) for 4 hours prior to
incubating with anti-CX3CLl Ab (lpg/ml) for 1 h at 37°C (93). Cells
were then washed with ice cold PBS. Membrane-associated Ab was
removed by acid wash (0.15M NaCl, 50 mM glycine, 0.1% BSA, pH 2.5)
on ice for 2 mins. Cells were then bathed in recovery solution (150mM
NaCl, 20mM HEPES, ImM CaCl2, 5mM KC1, ImM MgCl2, pH 7.4) for 3
mins and were allowed to recover for time periods of 5-15 mins in the
presence of TP agonist or in media alone. Cells were washed, fixed in
4% paraformaldehyde, and incubated with Cy3-conjugated secondary
Ab (1.5pg/ml) for 1 hour at room temperature. After further washing,
the cells were mounted onto glass slides using DAKO. Images were
captured using a Leica DMIRE2 microscope and OpenLab software
(Improvision Inc., Lexington, MA). Cell surface immunofluorescence
intensity was measured using Volocity imaging software for at least 30
cells for each condition (Improvision, INC., Waltham, MA). The results
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represent the mean of 3 experiments with SEMs. The data was graphed
initially to demonstrate normal distribution and then the difference
between means was analysed using the Student's t-test.
Statistical Analyses. All the results were reviewed and analysed by a
University of Sydney statistician. For all techniques a minimum of 3
experiments were performed. The data were analysed by comparing
the mean values using the Student's t-test for data with a normal
distribution and using analysis of variance (ANOVA) for non-normally




Chapter 4. Results part 1
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The Expression and Targeting of CX3CL1 in Renal Tubular
Epithelial Cells
2. CX3CL1 is expressed in renal tubular epithelial cells (RTEC).
To define the functions of CX3CL1 in RTEC, we first examined CX3CL1
expression in five human renal allograft biopsy specimens. Three
specimens had a histologic diagnosis of acute rejection and two of acute
tubular necrosis. Cockwell et al have previously used
immunohistochemistry to show CX3CL1 expression in human renal
biopsy specimens with acute allograft rejection (49). We used
immunofluorescent probes to label the CX3CL1. In all 5 specimens we
detected CX3CL1 expression in renal tubules, particularly on the apical
surface, which was against our hypothesis of basal expression (Figure
IB, C &F-K). In addition to being expressed on tubular epithelium,
CX3CL1 expression was noted within glomeruli and on vascular
endothelium, (Figure 1A, F &G), which is in keeping with Cockwell's
previous published report (49). Again, similar to the previous report,
we found that some tubules had more staining than others. We were
unable to correlate the clinical severity with the degree of CX3CL1
expression, as this information was not available. Further experiments
were done using the addition of DAPI staining to facilitate orientation
within the kidney. To verify the specificity of staining, we omitted
primary anti-CX3CLl Ab from some experiments. When secondary
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antibody alone was used, very little background immunofluorescence
was observed (Figure ID). At the Hospital for Sick Children in Toronto,
where this work was performed, donor pre-implantation renal
transplant biopsies are not taken routinely and therefore could not be
used as an additional negative control. We did however repeat the
experiments at a later date and included a normal renal biopsy
specimen, which showed minimal staining for CX3CL1 (Figure IE).
Using the same anti-CX3CLl Ab as the one used in our study, other
investigators previously reported minimal immunohistochemical
expression of CX3CL1 in normal renal biopsy tissue (49, 59).
(Renal biopsy specimens were provided by Dr Andrew Herzenberg, staining was done
by Michael Ho, pathology technician, and by Guang-Ying Liu and the microscopy was














Figure 1. CX3CL1 is expressed in human renal tubular epithelial cells.
Immunofluorescent labelling of CX3CL1 in human renal allograft biopsy specimens,
with histologic diagnoses of acute tubular necrosis (A, C, D & F-H) and acute tubular
rejection (B, I-K). Biopsy specimens were labelled with anti-CX3CLl Ab and Cy3
conjugated secondary Ab. A glomerulus is shown in figure 1A and tubules are shown
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in figures 1 B and C. In experiments D-K DAPI was also used to label cell nuclei. No
primary antibody was used in figure ID and a normal kidney biopsy specimen was
stained in figure IE. * denotes tubular lumen and arrows mark glomeruli.
To examine the expression and subcellular distribution of CX3CL1 more
closely, we selected HK-2 cells, a human RTEC line, as we felt that this
was the most appropriate to reflect the in vivo situation in human
kidneys. Using RT-PCR, we detected CX3CL1 mRNA (Figure 2A). To
verify CX3CL1 protein expression we performed immunofluorescence
staining and again found the chemokine predominantly at the apical
surface (Figure 2C&D). We encountered some difficulty with the HK-2
cells, as they tended to grow in flattened monolayers, rather than as tall
cuboidal or columnar cells that are typical of epithelial cells. We needed
to clearly demarcate the apical from the basolateral surface, particularly
when using immunofluorescent microscopy to examine the cells. Using
confocal microscopy we took multiple images in the XY plane at various
depths through the cell, thus creating a Z stack, which is essentially a 3
dimensional reconstruction of the cell. The Z stacks created with the
HK-2 cells were sub-optimal because of the flattened phenotype so we
sought an alternative model to enable unequivocal differentiation of the
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Figure 2. CX3CL1 is expressed in HK-2 renal tubular epithelial cells. (A) Total RNA
was isolated from HK-2 cells and CX3CL1 amplified by RT-PCR using specific
published primers. The PCR products were size-fractionated on 1% agarose. GAPDH
is shown as a control. (B-C) Immunofluorescence staining of HK-2 cells using anti-
CX3CLi antibody and a Cy2-conjugated secondary antibody. Actin was labelled with
rhodamine-conjugated phalloidin in figure 2C. No primary antibody was used in
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figure 2B as a negative control. (D) Immunofluorescence staining of HK-2 cells using
anti-CX3CLl antibody and a Cy3-conjugated secondary antibody. Actin was labelled
with Oregon green 488-conjugated phalloidin.
(The RT-PCR was done by Guiseppe Femia, a summer student and the
immunofluorescence staining and microscopy was done by Anne Durkan.)
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2. CX3CL1 is expressed in the apical membrane ofRTEC.
Madin Derby Canine Kidney II (MDCK) cells are renal tubular cells that
have a classical cuboidal morphology typical of epithelial cells. They
have been used extensively to study epithelial cell structure and
function and because of their morphology permit clear differentiation of
the apical and basolateral membranes (232, 245). In the absence of an
anti-canine CX3CL1 antibody, we initially stained the wild type cells
with the anti-human CX3CL1 Ab, followed by a fluorescent-conjugated
secondary Ab. No CX3CL1 was detected (Figure 3). This was confirmed









We therefore created a stable cell line of MDCK cells expressing full-
length CX3CLI or CX3CLI with a GFP tag at the C-terminus, (MDCK-
CX3CLI and MDCK-CX3CLI-GFP respectively). The GFP tagged
CX3CLI has been used previously by members of our laboratory in a
different cell line with no effect on cellular levels or distribution of
CX3CLI (98).
Using Western analysis and anti-CX3CLl Ab, both MDCK-CX3CL1 and
MDCK-CX3CLI-GFP cells displayed bands of appropriate molecular
weight (90kDa and 117kDa respectively) (Figure 4A). To confirm these
findings cell lysates from control MDCK cells and from MDCK-CX3CL1-
GFP cells were probed with an anti-GFP antibody and again a band at









Figure 4. CX3CL1 and CX3CL1-GFP in MDCK cells.
Western analysis was performed using cell lysates from MDCK-WT, MDCK-CX3CL1
and MDCK-CX3CLI-GFP cells. The lysates were labelled with anti-CX3CLl antibody
(A) or anti-GFP antibody (B) and HRP conjugated secondary antibody.
(The stable MDCK-CX3CL1 and MDCK-CX3CL1-GFP cell lines created by Guang-Ying




To assess the subcellular localization of CX3CL1, MDCK-CX3CL1-GFP
cells were fixed and incubated with anti-CX3CLl Ab, which labelled
only the apical surface (Figure 5F&J). To visualize intracellular CX3CL1,
the same cells were then permeabilised with 0.1% Triton X-100 and
incubated with anti-CX3CLl Ab followed by a different secondary Ab.
This confirmed an intracellular pool of CX3CL1 in subapical vesicles,
with a small proportion on the basolateral membrane (Figure 5D, E, H, I
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L&M). To confirm that any labelling of MDCK-CX3CL1-GFP cells with
anti-CX3CLl Ab was specific for CX3CL1, we incubated untransfected
cells with the same Ab. In these experiments there was no
immunofluorescence staining observed (Figure 3). Furthermore,
incubation of MDCK-CX3CL1-GFP cells with secondary Ab alone, after
omitting the primary Ab, again yielded no immunofluorescence
staining (Figure 5B). These data demonstrate that CX3CL1 is expressed
on the apical plasma membrane as well as within subapical vesicles and
to a lesser degree on the basolateral membrane in RTEC. This was in
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Figure 5. CX3CL1 is found largely on the apical surface and in subapical vesicles in
MDCK-CX3CL1-GFP cells, with only a small proportion on the basolateral
membrane. MDCK-CX3CL1-GFP cells were fixed and labelled with an anti-CX3CLl Ab
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applied to the apical surface, followed by a Cy-3 conjugated secondary Ab. The cells
were then permeabilised and again labelled with an anti-CX3CLl Ab followed by a Cy-
5 conjugated secondary Ab. Low power images of two different experiments in the XY
plane (figures 5A&C) and in the XZ plane (figures 5D&E). Higher power images of
single cells showing the apical and subapical distribution of CX3CL1 (figures 5F-M).
The XZ plane is shown above and the XY plane below. Control experiment using no
primary Ab confirms the specificity of the Ab (figure 5B).
(Experiments done by Anne Durkan).
In MDCK-CX3CLI-GFP cells, GFP is attached to the cytoplasmic tail of
the chemokine. Since the tagged construct was recognised by the
antibody directed against the extracellular domain of CX3CL1, the
protein expressed must traverse the apical membrane (Figures 5D, E, I &
M). We also noted a second pool of GFP, present in the basolateral
membrane (Figures 5D-F & J). This pool did not completely overlap
with the total CX3CL1 staining seen following permeabilisation of the
cells (figures 5D, E, I & M). To determine the source of this we used a
second anti-CX3CLl Ab that recognised the C-terminal region of
CX3CL1, rather than the chemokine domain against which the first Ab
was directed. Following permeabilisation, the basolateral pool of GFP
could be labelled by this C-terminal domain anti-CX3CLl Ab suggesting
that at the very least the C-terminal domain of CX3CL1 was present
(Figure 6I-L). These results were confirmed in MDCK-CX3CL1 cells
without the GFP tag (Figure 6E-H).
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Figure 6. The entire basal pool of CX3CL1 can be labelled with an antibody
recognising the C-terminal of the protein. After fixation, MDCK-CX3CL1 cells were
labelled with a primary antibody recognising the C-terminal of CX3CL1, followed by
Cy-3 conjugated secondary Ab. The cells were permeabilised and re-labelled with the
C-terminal Ab, followed by a Cy-5 conjugated secondary Ab (Fig 6E-H). As a negative
control the primary Ab was omitted in some experiments (Fig 6A-D). The experiments
were repeated in MDCK-CX3CL1-GFP cells using only the permeabilised cells, as the
previous experiments had demonstrated no surface CX3CL1 staining (Fig 6I-K). In a
repeat experiment the total CX3CL1 was labelled with the anti-C-terminal CX3CL1 Ab
followed by a Cy-3 conjugated secondary Ab (Fig 6L).
(Experiments done by Anne Durkan).
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It could be argued that the basolateral CX3CL1 could not be properly
labelled in our initial experiments as we used an apical application of an
antibody directed against the chemokine (extracellular) domain. To
investigate this, we grew MDCK-CX3CL1-GFP cells on filters and after
fixation, applied the Ab recognising the chemokine domain to the basal
medium, with no Ab application to the apical medium. The cells were
then labelled with a Cy-3 secondary Ab. The total CX3CL1 content was
labelled as previously following permeabilisation. This showed that
there was very little basal surface staining of CX3CL1, despite the basal
application of the antibody (figure 7). (Unfortunately the format in
which these images were stored does not allow further manipulation










Surface CX3CL1 (basolateral application
of antibody)
Total CX3CL1 Surface CX3CL1 (apical application of
antibody)
Figure 7. Basal application of the anti-CX3CLl Ab does not demonstrate significant
basal full-length CX3CL1. MDCK-CX3CL1-GFP cells were grown on filters and after
fixation, were labelled with an anti-CX3CLl Ab applied to the basal surface. This was
followed by the application of a Cy-3 conjugated secondary Ab. The cells were then
permeabilised and re-labelled with the anti-CX3CLl Ab. A Cy-5 secondary Ab was
then applied (fig 7A-C). Control experiments used apical application of the anti-
CX3CL1 Ab (fig 7D-F).
(Experiments done by Anne Durkan).
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We believe that basolateral GFP largely represents the intracellular
portion of CX3CL1, which remains after the extracellular segment has
been proteolytically released. In agreement with this supposition is the
Western analysis of MDCK-CX3CL1-GFP cells using an anti-GFP Ab,
which consistently revealed two separate bands. The molecular masses
of these bands correlated with the full-length CX3CL1-GFP fusion
protein (Figure 4A&B) or a fusion protein corresponding to the
intracellular region of CX3CL1 together with GFP (-36 kDa; Figure 4B).
To ensure that the GFP tag did not alter subcellular traffic of CX3CL1,
we examined MDCK cells expressing the untagged chemokine. After
labelling both surface and total CX3CL1 we found a similar distribution,
primarily on the apical membrane but also in subapical vesicles (Figure
8). This was consistent with our findings using the anti-CX3CLl
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Figure 8. The distribution of CX3CL1 is not affected by the addition of the GFP tag.
MDCK-CX3CLI cells were fixed and labelled with anti-CX3CLl Ab, followed by a Cy-3
conjugated secondary Ab. The cells were permeabilised and then relabelled with an
anti-CX3CLl Ab followed by a Cy-5 conjugated Ab. Figures 8A&C represent two
different experiments. The specificity of the primary antibody was assessed by
omission in some experiments (fig 8B).
(Experiments done by Anne Durkan).
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Electron microscopy was then used to examine the apical microvilli.
After labelling the surface CX3CL1 of MDCK-CX3CL1-GFP cells with a
gold-conjugated Ab we subjected the cells to scanning electron
microscopy. As shown in Figure 9, this provided further evidence that
CX3CL1 is associated with microvilli on the apical surface of RTEC.
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Figure 9. Electron microscopy of apical CX3CL1 in MDCK-CX3CL1-GFP cells. MDCK-
CX3CLI-GFP cells were labelled with anti-CX3CLl antibody and gold-conjugated
secondary antibody and examined using scanning electron microscopy. Arrows show
the association of the CX3CL1 with apical microvilli (fig 9A). MDCK-
WT cells were used as control cells (fig 9B).
(The cells were stained by Anne Durkan. The electron microscopy images were taken
by technicians in the electron microscopy facility at the University of Toronto).
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3. CX3CL1 is targeted to the apical membrane by N-glycosylation.
Having been somewhat surprised by the apical distribution of CX3CL1,
we next investigated the signals that targeted the protein to this
membrane in RTEC. Apical sorting of transmembrane proteins can be
determined by signals conferred by the cytoplasmic tail of the protein
(246, 247), by O- or N-glycosylation (248), or by membrane anchoring of
the protein to lipid microdomains in the cell membrane, through GPI or
by direct binding of the transmembrane domain of the protein to lipid
rafts (249). We examined each of these potential mechanisms in turn.
There are various signalling mechanisms that are found in the cytosolic
domain of proteins such as tyrosine-based signals, leucine or dileucine
motifs and PDZ domains. To determine if any of these were important
for the apical targeting of CX3CL1, we generated a mutant construct
lacking the cytoplasmic domain (CX3CLl-360). (In the initial description
of CX3CL1 by Bazan et al, the predicted signal peptide amino acid
sequence was numbered from -24 to -1 and therefore the cytoplasmic
tail began at amino acid 361 (35)). To confirm the accuracy of the DNA
expression plasmid, it was gene sequenced. We examined the
distribution of CX3CL1 in MDCK cells stably expressing "tail-less"
CX3CL1 using immunofluorescent microscopy but found that the
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Figure 10. Deletion of the cytoplasmic tail of CX3CL1 does not affect its apical
distribution. MDCK cells expressing a mutant CX3CL1 DNA expression plasmid that
lacks the cytoplasmic tail (MDCK-CX3CLl-360) were fixed, incubated with anti-
CX3CL1 antibody and a Cy3-conjugated secondary antibody, to visualise cell surface
CX3CL1. To further visualise intracellular CX3CL1, the same cells were then
permeabilised, labelled with anti-CX3CLl antibody and then Cy5-conjugated
secondary antibody. After permeabilisation, cells were incubated with Alexa-488
conjugated phalloidin to label F-actin. Slides were examined using a spinning disk
confocal microscope.
(The CX3CLl-360 construct was created by Min Rui. The transfections, staining and
microscopy were done by Anne Durkan.)
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We next assessed the potential associations of CX3CL1 with lipid rafts or
caveolae. Lipid rafts are microdomains within the plasma membrane
that are rich in cholesterol and sphingolipids. Caveolae are similarly
rich in cholesterol and sphingolipids but also contain caveolin, hence the
name. Partitioning of proteins into these microdomains is believed to
have implications on the function of the protein, for example the cell
adhesion molecule CD44 co-partitions with protein tyrosine kinases,
which are required for its activation (250). Methyl-|3-cyclodextrin
(M(3CD) selectively extracts cholesterol by directly binding to it and
incorporating it in a cavity of cyclic oligmers of glucopyranoside (251).
It has advantages over other methods of cholesterol binding in that it
neither binds to the plasma membrane, nor does it become incorporated
into the membrane. It has been used in several cell types to disrupt
sphingolipid microdomains (252-254). Moreover, M|3CD was used in
MDCK cells to demonstrate the association of influenza virus
haemagluttinin with lipid rafts to target to the apical plasma membrane
(255). We therefore treated cells with M|3CD to disrupt lipid rafts and
caveolae in our MDCK-CX3CL1-GFP cells. To ensure M|3CD treatment
was effective, we measured cholesterol spectrophotometrically, using a
commercially available kit and compared the cell cholesterol levels with
the provided standards (256). M|3CD depleted total cellular cholesterol





















B . » 1
jr.:, j















Figure 11. Apical targeting of CX3CL1 is not disrupted by cholesterol depletion. To
deplete cholesterol and disrupt lipid rafts, MDCK-CX3CL1-GFP cells were incubated
for 30 minutes at 37°C with methyl-p-cyclodextrin and the cholesterol content
measured by spectrophotometry, using Amplex Red (Molecular Probes). Values for
cholesterol content are expressed as a percentage of untreated controls and represent a
mean of 3 experiments (Fig 11A). MDCK-CX3CL1-GFP cells were incubated for 30
mins with methyl-p-cyclodextrin, prior to fixation and incubation with anti-CX3CLl
Ab and a Cy-3 conjugated secondary Ab. Following permeabilisation the cells were re-
incubated with the anti-CX3CLl Ab and a Cy-5 conjugated secondary Ab (Fig 11B-F).
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Control cells were not pre-treated with M(3CD. Slides were examined using a spinning
disk confocal microscope.
(Experiments done by Anne Durkan).
We next examined glycosylation of CX3CL1 as a determinant of apical
targeting. O-glycosylation was inhibited with benzyl-2-acetamido-2-
deoxy-a-D-galacto-pyranoside, which acts as a competitive inhibitor
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Figure 12. Inhibition of O-glycosylation does not affect the cellular distribution of
CX3CL1. MDCK-CX3CLI-GFP cells were treated with benzyl-2-acetamido-2-deoxy-a-
D-galacto-pyranoside to inhibit O-glycosylation. Surface CX3CL1 was then labelled
with an anti-CX3CLl Ab, followed by a Cy-3 conjugated secondary Ab (fig 12 E&I).
Total CX3CL1 was labelled, after permeabilisation, with the same anti-CX3CLl Ab and
a Cy-5 conjugated secondary Ab (fig 12 F&J). The merged images are shown for
several experiments (fig 12 A, B, G & K). In control experiments, no benzyl-2-
acetamido-2-deoxy-a-D-galacto-pyranoside was used (fig 12C).
(Experiments done by Anne Durkan).
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To inhibit N-glycosylation of CX3CL1, we treated cells with 2.5pg/ml
tunicamycin overnight. Tunicamycin is a homologous mix of antibiotics
that prevents the formation of polyisoprenyl N-acetyl glucosaminyl
pyrophosphate. This compound functions as a sugar donor in the N-
glycosylation process and in this manner glycosylation is inhibited
(258). Tunicamycin treatment resulted in intracellular retention of
CX3CL1 with virtually no expression observed on the apical surface
(Figure 13D,H&L). These results were confirmed using both the
antibody directed against the chemokine domain of CX3CL1 and the
antibody directed against the N-terminal domain. The dose of
tunicamycin used was derived from the literature using studies that had
treated MDCK cells with tunicamycin to inhibit N-glycosylation of
various proteins. There was general consistency amongst the studies
that l-2.5pg/ml for 12-18 hours was sufficient to inhibit N-glycosylation
(259-261). Titration assays were not done, though I accept the examiners
comments that this would have been appropriate and improved the
precision of the results. To verify the observed effects were not due to
non-specific disruption of apical protein traffic, we evaluated the effects
of tunicamycin on targeting of NHE3, an apical protein whose targeting
does not require N-glycosylation. As expected, tunicamycin treatment
did not affect the normal apical distribution of NHE3 (Figure 13M-P).
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Figure 13. N-glycosylation of CX3CL1 directs it to the apical membrane. MDCK-
CX3CLI-GFP cells were treated with tunicamycin to inhibit N-glycosylation. Surface
CX3CLI was labelled with anti-CX3CLl Ab against the chemokine domain, followed by
a Cy-3 conjugated Ab and total CX3CL1 was labelled with a Cy-5 conjugated Ab (fig
13A-D and fig 13E-H). The experiments were repeated using an antibody directed
against the C-terminal domain of CX3CL1 (fig 13 I-L). As a negative control MDCK-
NHE3 cells were also treated with tunicamycin. Surface NHE3 was labelled with a Cy-
3 conjugated Ab, total NHE3 was labelled with a Cy-5 conjugated Ab and F-actin was
labelled with phalloidin-488 (fig 13 M-P).
(Experiments done by Anne Durkan).
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Collectively, these data indicate that the signals directing apical
trafficking of CX3CL1 are not conferred by the protein's cytoplasmic
domain, O-glycosylation of the protein nor by associations with lipid
rafts, but rather, apical localisation of CX3CL1 is determined by N-
glycosylation.
4. CX3CL1 is anchored to the apical membrane in RTEC.
To determine whether CX3CL1 is anchored in the luminal surface, we
used fluorescence recovery after photobleaching (FRAP) to study the
mobility characteristics of apical CX3CL1-GFP in MDCK-CX3CL1-GFP
cells. FRAP has been extensively used to assess protein mobility within
membranes (262, 263). It is a single cell technique utilising an intense
laser beam to acutely photobleach a defined area of the cell membrane.
The protein of interest is labelled with a fluorophore. Fluorescence
recovery over time is then measured and this represents lateral
movement of the unbleached fluorophore labelled protein within the
cell membrane into the area of interest and movement away from the
area of bleached protein. Figure 14A shows the cell before bleaching;
14B, immediately after bleaching; and 14C, 5 min after bleaching. As a
control, MDCK cells were transfected with a DNA expression plasmid
encoding GPI-GFP, which is freely mobile in the apical plasma
membrane. A region of the apical membrane was similarly bleached
and the recovery of fluorescence observed over time (Figure 14D-F).
CX3CL1-GFP recovered with significantly slower kinetics than GPI-GFP
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(Figure 14G). For CX3CL1-GFP, the bleached area recovered to 10.5±
4.3% of pre-bleached fluorescence intensity by 4 min, compared to
61.1±11.9% for GPI-GFP (p<0.01). As an additional control, MDCK cells
were transfected with DNA encoding the single transmembrane protein,
FcR-GFP. When FRAP was similarly performed, the bleached area in the
membrane recovered significantly faster than CX3CL1-GFP, with 4 min
recovery of 51.5+6.1% for FcR-GFP (p<0.01) (Figure 14G). These data
demonstrate that the ability of CX3CL1 to diffuse laterally within the
apical membrane is impeded, suggesting that transmembrane CX3CL1 is
immobile under basal conditions.
As discussed earlier, some single pass transmembrane proteins are
tethered to the apical membrane by direct association with lipid rafts
(264). To determine whether CX3CL1 is anchored in such a manner we
disrupted lipid rafts by treating cells with M(3CD and repeated the
FRAP experiments. However, this treatment only marginally increased
the mobility of CX3CL1 in the apical membrane and the effect was lost
by 370 seconds (Figure 14G). To study whether apical CX3CL1 is
immobile because it is directly tethered to the actin cytoskeleton, we
fractionated cellular proteins between two distinct fractions - TritonX-
100 soluble and TritonX-100 insoluble, as previously described (241). In
polarised epithelial cells, proteins directly anchored to the actin
cytoskeleton, as well as those directly bound to the lipid component of
the membrane, preferentially remain in the TritonX-100 insoluble
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fraction. We found, however, that CX3CL1 was largely soluble in
TritonX-100 solution, suggesting that it is not directly tethered to the
actin cytoskeleton (Figure 14H). Collectively, these data indicate that
after sorting to the apical surface, CX3CL1 is held immobile there, but
this is not achieved by direct tethering to the actin cytoskeleton or by
association with lipid rafts or caveolae.
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Figure 14. CX3CL1 is anchored to the apical membrane in renal tubular epithelial
cells. To examine the mobility of CX3CL1 in the apical membrane, FRAP was
performed as described in 'Methods'. Using an argon laser and a scanning confocal
microscope a 2.5pM region of the apical membrane expressing CX3CL1-GFP was
irreversibly photobleached (circles) and recovery of fluorescence monitored over time.
(Fig 14A) MDCK-CX3CLI-GFP cell before bleaching (fig 14B) shows the same cell
immediately after photobleaching and (fig 14C) depicts the cell 5 mins later. Control
areas of the same diameter in the plasma membrane were examined at each time point.
(Figsl4D-F) As a control, FRAP was similarly performed in MDCK cells expressing
freely mobile glycosyl phosphatidylinositol conjugated to GFP (MDCK-GPI-GFP). (Fig
14D) MDCK-GPI-GFP cells before bleaching, (fig 14E) the same cell immediately after
bleaching and (fig 14F) after 5 mins of recovery. (Fig 14G) As an additional control
FRAP was performed in MDCK cells expressing the single transmembrane protein, Fc
gamma Ha receptor tagged with GFP (FcR-GFP). Recovery of fluorescence after
photobleaching of apical CX3CL1-GFP, GPI-GFP, FcR-GFP or CX3CL1-GFP after
cholesterol depletion using methyl-p-cyclodextrin (MBCD) (Fig 14G). Points represent
the mean ± SEM of recovery at serial time points from at least 6 experiments. (Fig 14H)
Lysates from MDCK-CX3CL1-GFP cells were obtained after separating into TritonX-
100 soluble and TritonX-100 insoluble fractions, as described in the 'Methods' section.
Western blotting was performed using anti-CX3CLl antibody and HRP-conjugated
secondary antibody.
(Experiments done by Anne Durkan).
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5. CX3CL1 expressed on the apical surface of RTEC promotes adhesion
of leukocytes.
Transmembrane CX3CL1 can act as a cell adhesion molecule, facilitating
the binding of leukocytes (39, 41). We therefore hypothesised that
CX3CL1 might perform a similar function when expressed on the apical
surface of RTEC. These experiments were performed under low shear
conditions to mimic the in vivo environment. K562 leukocytes do not
constitutively express CX3CR1 and therefore leukocytes that had been
genetically modified to express the CX3CL1 receptor were obtained in
addition to unmodified cells. We found significant binding of K562-
CX3CR1 leukocytes to MDCK-CX3CL1-GFP cells compared to MDCK-
WT control cells (Figure 15A-D). When CX3CF1 was present on the
apical membrane, leukocyte adhesion was almost three times greater
than when CX3CL1 was absent (Figure 15G, pcO.OOl). There was
minimal binding of control K562 leukocytes to either MDCK-WT or
MDCK-CX3CF1-GFP cells (Figure 15G).
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Figure 15. CX3CL1 on MDCK cells promotes binding of leukocytes bearing the
receptor CX3CR1. K562-leukocytes expressing the CX3CR1 receptor (K562-CX3CR1)
were labelled with rhodamine-conjugated cholera toxin B to visualise them. One
million K562-CX3CR1 cells were added to MDCK-WT or MDCK-CX3CL1-GFP
monolayers, growing on 25mm cover slips, under conditions of low shear stress. After
20 minutes, the non-adherent cells were removed by washing and the remaining cells
were fixed. Serial fields (x63) were examined, using a Leica deconvolution microscope,
and the number of adherent leukocytes counted. K562-CX3CR1 cells applied to
MDCK-CX3CL1-GFP cells, fluorescence images (A) and DIC images (B). K562-CX3CR1
cells applied to MDCK-WT cells, fluorescence images (C) and DIC images (D).
Photomicrographs of labelled K562-CX3CR1 cells, (red), binding to MDCK-CX3CL1-
GFP monolayers. Images shown in x versus y (E) and x versus z (F) optical sections.
(G) Graph depicting the number of K562-control cells or K562-CX3CR1 leukocytes
bound to either MDCK or MDCK-CX3CL1-GFP cells. The values represent the mean
number of adherent cells per high power field (x63). Values represent the mean of at
least 3 experiments ± SEM (*p<0.001). (The number of adherent cells per field was
plotted to prove the normal distribution of the data and comparisons between means
was analysed using the Student's t-test).
(Experiments done by Anne Durkan).
To verify that any observed responses were not an idiosyncratic feature
of transformed cell lines, we performed the same experiment using both
primary epithelial and primary leukocytic cells. Human peripheral
blood mononuclear cells (PBMC) were isolated from the heparinized
blood of healthy volunteers. PBMC contain multiple leukocyte subsets,
including CD8+ T cells, monocytes and NK cells, all of which express
the CX3CR1 receptor. PBMC efficiently adhered to the apical surface of
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monolayers of primary human RTEC. When primary RTEC were pre-
incubated with a function-blocking anti-CX3CLl Ab, binding of PBMC
was inhibited significantly (Figure 16). Collectively, these data suggest
that CX3CLI expressed on the luminal surface of RTEC promotes the
adhesion of leukocytes that bear the complementary receptor CX3CR1.
Our results are in keeping with a previous report in which blockade of













Figure 16. CX3CRl-expressing leukocytes adhere to CX3CL1 in the apical membrane of
renal tubular epithelial cells. Adhesion assays were repeated using primary RTEC and
human peripheral blood mononuclear cells (PBMC) that were isolated from the blood
of healthy volunteers and labelled with Calcein-AM (A&B). In parallel experiments,
primary RTEC monolayers were pre-incubated with function blocking anti-CX3CLl Ab
(ltig/ml) for 30 min before addition of PBMC (C&D). A graph depicting the mean
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number of adherent PBMCs per x40 field. Experiments were performed six times for
each condition and the means compared with controls using the Student's t-test
(*p<0.0001 versus control). Note that the original images were lost in a laboratory
move. The images shown in A-D above were re-done in 2010 and the numbers shown
in the graph do not reflect these images.
(The original experiments were done by Todd Alexander after being requested for
publication. The repeat staining and adhesion assays were done by Jerry Pan and the
microscopy was done by Anne Durkan).
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Chapter 5. Results Part 2
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The Regulation of CX3CL1 by Thromboxane Prostanoid
Receptor Stimulation
1. Stimulation of the TP receptor decreases surface and total expression
of CX3CL1. TXA2 has a very short half-life of about 30 seconds and,
thus, for these studies we used two distinct and stable pharmacologic
agonists of TP, namely, U46619 and IBOP (265, 266). Both of these
agonists have been used extensively in previous studies in numerous
cell types including ECV-304 cells. The dose of 20pM of U46619 was
chosen based on studies that had used between 1 and 20pM in cells to
induce platelet aggregation, phosphoinositide hydrolysis and
inhibition of monocyte adhesion (265, 267-270). Mean EC50 values of
4.8nM, 82nM and 30nM have been found for shape change in human
platelets, human platelet aggregation and phosphoinositide hydrolysis
in CHO cells respectively (271). Bishop-Bailey et al used lOpM U46619
and did not induce endothelial cell toxicity or affect cell viability (268).
The IBOP dose used in our experiments was lOOnM and again this was
taken from published studies in the scientific literature. Yan et al used
50nM IBOP for 15 minutes in HEK cells to induce phosphorylation of
ERK and glycogen synthase kinase-3 (272). They also induced HEK
cell aggregation and changes to the cell shape. Gao et al found that
lOOnM IBOP resulted in a 4-5 times increase in phosphorylation of
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ERK in ECV-304 cells (273). Gallet et al also used lOOnM IBOP to
induce phosphorylation of ERK in Hek-293 cells and Kinsella et al
used the same dose to assess thromboxane prostanoid receptor
binding in human erythroleukaemia cells (274, 275). Platelet
aggregation is induced by IBOP with an EC50 value of 0.34nM (276)
and in HEK-293 cells ERK activation is induced with an EC50 value of
0.16nM for the TPa receptor and 0.6nM for the TP(3 receptor (277).
The dose used of SQ29548, a specific TP antagonist, was also taken
from previously published studies. Numerous studies had used 10pM
SQ29548 to antagonise the TP receptor in endothelial and epithelial
cells (226, 277). Human platelet aggregation induced by U46619 was
inhibited by SQ29548 with an IC50of 0.06pM (278).
To evaluate the effect of stimulation of the TP receptor on CX3CL1
expression, cells were treated with the TP receptor agonist U46619 for
various time periods and immunoblotting of whole cell lysates was
performed. The total expression of CX3CL1 fell after just 10 min of TP
stimulation, with lowest levels observed by 30-60 min (figure 1A).
Total levels of CX3CL1 recovered to near baseline values by 4 h (figure
1A). To verify these results, cells were treated with the second TP
agonist, IBOP, and similar results were obtained (figures 1B&C).
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Figure 1. Stimulation of TP results in an early decrease in total cellular CX3CL1.
ECV-CX3CLI-GFP cells were incubated with 20pM U46619 for various time periods.
Cell lysates were harvested and immunoblotting performed using anti-CX3CLl Ab
and HRP conjugated secondary Ab. To control for protein loading, blots were
stripped and re-probed with anti-GAPDH Ab and HRP-conjugated secondary Ab
(fig 1A). Cells were incubated with lOOnM IBOP and immunoblotting performed as
in 1A. To control for protein loading, blots were stripped and re-probed with anti-
actin Ab and HRP-conjugated secondary Ab (fig IB). Experiments were performed
as in IB. Band intensities for CX3CL1 were quantified and normalized to actin (fig
1C). Values represent mean values ± SEM for 4 separate experiments. *, p = 0.05. t,
p < 0.01 vs untreated. (Experiments done by Anne Durkan).
To assess the effect of TP activation specifically on cell surface levels of
CX3CL1, cells were treated with TP agonist and surface CX3CL1 was
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measured by flow cytometry. There was again an initial decrease in
surface CX3CL1 levels, with full recovery to baseline by 4 hours of TP
receptor stimulation (figure 2).
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Figure 2. Stimulation of TP results in a decrease in surface CX3CL1. ECV-CX3CL1-
GFP cells were incubated with 20pM U46619 for varying time periods, labelled with
anti-CX3CLl Ab and PE-conjugated secondary Ab, and cell surface CX3CL1
expression was measured using flow cytometry. The result shown is representative
of 8 separate experiments. The data for all the experiments was analysed using
ANOVA. *, pcO.OOl compared to control for timepoints 10, 30 and 60 mins.
(Experiments done by Anne Durkan and the flow cytometry analysis performed by
the technicians of the flow facility at the University of Toronto).
To ensure that any observed effects were specific to stimulation of TP,
cells were incubated with IBOP together with the specific TP
antagonist, SQ29548 and analysed by both Western blotting and flow
cytometry (figure 3). SQ29548 abrogated the rapid decrease in CX3CL1
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Figure 3. The effect of TP stimulation on total CX3CL1 is abrogated by the TP
antagonist, SQ29548. Cells were incubated with IBOP (lOOnM for 30 mins) in the
presence or absence of TP antagonist, SQ29548 (lOpM). Cell lysates were harvested
and immunoblotting performed using anti-CX3CLl Ab and HRP conjugated secondary
Ab. To control for protein loading, blots were stripped and re-probed with anti-
GAPDH Ab and HRP-conjugated secondary Ab (figure 3A). Experiments were
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performed as in 3A. Band intensities for CX3CL1 were quantified and normalized to
actin (figure 3B). Values represent mean values + SEM for 3 separate experiments.
% p <0.05.
(Experiments done by Anne Durkan and Soumitra Tole).
2. Stimulation of the TP receptor induces cleavage of CX3CL1 by TACE.
Since both total and surface levels of CX3CL1 decreased following TP
stimulation, we hypothesised that CX3CL1 was inducibly cleaved from
the plasma membrane, a process mediated by the metalloprotease,
TACE (92, 93). To test this hypothesis, we compared the subcellular
distribution of CX3CL1 with that of TACE. We initially stimulated the
cells with phorbol-12 myristate 13-acetate (PMA) lOOng/ml, a protein
kinase C agonist and a known activator of TACE and other proteins
(92). There was poor co-localisation of TACE and CX3CL1 at the
baseline but after 5 mins of stimulation with PMA there was
significant co-localisation of the two proteins. We then went on to
stimulate the cells with U46619. By labelling the proteins with
different fluorescent antibodies we could then assess co-localisation
using specific software. In resting cells CX3CL1 and TACE expressed
on the cell surface did not co-localise (Pearson's coefficient = 0.429 ±
0.042; p > 0.05). After 5 min of TP stimulation there was co-
localisation of the two proteins, yielding a statistically significant
Pearson's correlation coefficient greater than 0.5, (r=0.645 ± 0.031,
p<0.01) (figure 4).
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Figure 4. TP stimulation induces co-localisation of TACE with CX3CL1. ECV-
CX3CL1 cells were treated with control medium (A) or PMA lOOng/ml (B) for 5 min.
Cells were fixed with 4% paraformaldehyde, washed, and permeabilised with 0.1%
triton. Cells were washed again and labeled with goat anti-human CX3CL1 Ab and
M220 mouse anti-human TACE Ab. Cells were washed and incubated with Cy3-
conjugated anti-goat IgG and Cy2-conjugated anti-mouse IgG secondary antibodies
to visualise CX3CL1 and TACE respectively. Slides were examined using a spinning
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disk confocal microscope (lOOx). The degree of co-localization between
CX3CL1/Cy3 and TACE/Cy2 was determined using OpenLab 5.0 co-localization
software, before (C) and after (D) treatment with PMA. A minimum of 25 cells for
each condition were examined in this manner. Experiments were repeated using
U46619 (20pM) to stimulate the cells for 5 mins. After labeling with goat anti-human
CX3CL1 Ab and M220 mouse anti-human TACE Ab, the cells were labeled with a
Cy-3 conjugated anti-goat Ab and a Cy-5 conjugated anti-mouse secondary Ab (E-J).
Slides were visualised as in the previous experiments.
(Experiments A-D done by Guang-Ying Liu and Anne Durkan. Experiments E-J
done by Anne Durkan).
In mammalian cells, TACE becomes activated when its cytoplasmic
tail is phosphorylated by the intracellular signalling molecule
extracellular-regulated kinase (Erk) (279-281). Stimulation of TP
results in the activation of various second messenger systems
including inositol triphosphate, cAMP, small G proteins, protein
kinase C (PKC) and protein kinase A (PKA) depending on the G
protein to which it couples and the cell involved (282). Furthermore,
stimulation of TP has been reported to phosphorylate Erk 1/2 (270,
283). We therefore hypothesised that stimulation of TP resulted in the
activation and phosphorylation of Erk, which then activated TACE.
To examine whether this was the case, cells were stimulated with TP
agonists, U46619 or IBOP and the phosphorylation of Erk determined
by Western blot of cell lysates. There was rapid phosphorylation of
Erk in the stimulated cells (Figure 5A-C). Following stimulation of TP
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for 4-6 hours there was a return to baseline levels of phosphorylated
Erk (Figure 5A). To verify this finding we simultaneously used the
Erk inhibitor, U0126, with TP stimulation. U0126 is a chemically
synthesised compound that is highly selective in its inhibition of
MEK1 and MEK2, also called mitogen-activated protein kinase
(MAPK)/Erk kinase. MEK1/2 are upstream of Erk and stimulate its
enzymatic activity (284). Concurrent use of U0126 with TP stimulation
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Figure 5. Stimulation of TP activates phosphorylation of ERK. ECV-CX3CL1 cells
were incubated with PMA (lOOng/ml), U46619 (20I.IM), or IBOP (lOOnM) for 1 hr or
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6 hrs (A) or 30 min (B). Cell lysates were harvested and immunoblotting performed
using anti-phospho-Erk Ab and HRP conjugated secondary Ab. Blots were stripped
and re-probed with anti-Erk Ab and anti-actin Ab to control for protein loading.
Figure 5C, Experiments were performed as in (B). Band intensities for phospho-Erk
were quantified and normalised to total Erk. Values represent mean values ± SEM
for 3 separate experiments. *p < 0.01.



















































Figure 6. U0126, a specific inhibitor of MAPK/Erk kinase, abrogates the effect of TP
stimulation on surface CX3CL1 levels. ECV-CX3CL1-GFP cells were incubated with
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U46619 for various time periods in the presence or absence of U0126 (lOuM). Cells
were fixed, labelled with anti-CX3CLl Ab and PE-conjugated secondary Ab, and
analysed by flow cytometry. Representative individual dot plots are shown (fig 6A)
with a graph for the mean of 4 separate experiments (fig 6B). The results of the 4
experiments were analysed by ANOVA (* p < 0.001).
(The experiments done by Anne Durkan).
We further inhibited TACE activity using the matrix metalloprotease
inhibitor, TAPI-2 (93). In the presence of TAPI-2, total levels of
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Figure 7. TAPI-2, an inhibitor of TACE attenuates the effect of TP stimulation on
cellular CX^CLl levels. ECV-CX3CL1-GFP cells were incubated with 1BOP in the
presence or absence of metalloprotease inhibitor, TAPI-2, and immunoblotting
performed using anti-CX3CLl Ab and HRP-conjugated secondary Ab (figure 7A).
Experiments were performed as in 7A. Band intensities for CX3CL1 were quantified
and normalised to actin (figure 7B). Values represent mean values ± SEM for 4
separate experiments, f p < 0.02. (C) ECV-CX3CL1-GFP cells were incubated with
U46619 in the presence or absence of TAPI-2. Cells were labelled with anti-CX3CLl
Ab followed by a PE-conjugated secondary Ab and surface fluorescence was
measured using flow cytometry and normalised to control fluorescence. Results
represent the mean of 3 separate experiments ± SEM and statistical analysis was
done using ANOVA (figure 7C). * p<0.001
(Western blot done by Soumitra Tole and flow cytometry staining done by Anne
Durkan).
161
Although TAPI-2 inhibits TACE activity, its actions are not entirely
specific, as it also inhibits activation of ADAMI 0, a closely-related
metalloprotease which constitutively cleaves CX3CL1 (94). To
determine whether TP stimulation promotes proteolytic shedding of
CX3CLI by TACE and/or by ADAM10, we used siRNA to selectively
knock down expression of each of these metalloproteases. As
demonstrated in figure 8A, expression of TACE and ADAM10 was
efficiently knocked down using the corresponding siRNA. There were
also some off target effects as the use of ADAM-10 siRNA also
reduced the amount of TACE in comparison to the scrambled and
mock siRNA. We tried to minimise the off target effects by using a
minimum amount of siRNA (lOOpmol) to prevent saturation of the
RNAi cellular machinery. We also used a commercially available
siRNA which contained a pool of 3 target specific 19-25 nucleotide
siRNAs designed to knock down gene expression of TACE or ADAM-
10 (285, 286). The AMAXA nucleofection kit was used to avoid the
need for a viral vector and it is also promoted as being less harmful to
the cells although we found that approximately 30-40% cells died after
the first electroporation, but given a transfection rate of around 80%
after two electroporations and a starting number of approximately 10
million cells, there were ample surviving cells with which to do the
experiments.
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Following siRNA transfection, we then used ELISA to measure the
levels of soluble CX3CL1 generated, and to thereby ascertain the
relative contribution of each protease to TP-induced shedding of
CX3CLI from the cell surface (93). In the presence of control, non-
targeting siRNA, TP stimulation significantly increased levels of
soluble CX3CLI (figure 8B). Similarly, when ADAM10 expression was
knocked down, stimulation of TP also resulted in significant
generation of soluble CX3CL1 (figure 8B). However, when TACE
expression was inhibited, TP stimulation did not result in proteolytic
release of transmembrane CX3CL1 from the plasma membrane (figure
8B). (Arbitrary units were used for the results of this experiment, as
there was significant variability in the absolute amounts of soluble
CX3CLI found in different experiments).
Collectively, these data suggest that TP stimulation induces rapid




















Figure 8. Knock doivn of TACE and ADAM-10 gene expression using siRNA results
in attenuated response of CX3CL1 to TP stimulation. ECV-CX3CL1 cells were
electroporated with TACE siRNA, ADAM10 siRNA, or control, non-targeting
(scrambled) siRNA by nucleofection on Days 0 and 2. After 48 h, cell lysates were
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harvested. Immunoblotting was performed using specific Ab directed against TACE
and ADAM10. To control for protein loading, blots were stripped and re-probed
with Ab directed against actin (figure 8A). Cells were electroporated with TACE
siRNA, ADAM10 siRNA, or control, non-targeting (scrambled) siRNA, as described
in 8A. Forty-eight hours after the second electroporation, cells were incubated with
IBOP (2.5 pig/ml) for 30 min at 37°C, conditioned medium collected, and cell lysates
harvested. Protease inhibitor cocktail was added to conditioned medium and to cell
lysis buffer to prevent protein degradation. Supernatants and cell lysates were
cleared by centrifugation. Using fresh samples, CX3CL1 was measured using a
CX3CLI ELISA Kit (R&D Systems), according to the manufacturer's specifications.
Three independent experiments were performed and the data were expressed as the
mean ± SEM of the percentage of soluble CX3CL1 released into the conditioned
medium in relation to the total amount of CX3CL1 (soluble and cell-associated)
(figure 8B). *p < 0.03. (Experiments done by Yi-Wei Huang).
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3. Stimulation of TP does not alter recycling of CX3CL1 to and from the
cell surface. Co-workers in my research group have previously shown
that CX3CLI rapidly recycles between the plasma membrane and a
juxtanuclear compartment (98). We therefore questioned whether
stimulation of TP might affect this process, shifting the distribution of
the chemokine from the superficial to the intracellular pool. To
examine endocytosis of CX3CL1 we used fluorescence recovery after
photobleaching (FRAP). To prevent inadvertent shedding of CX3CL1
from the cell surface, ECV-CX3CL1-GFP cells were pre-incubated with
metalloprotease inhibitor, TAPI-2. The entire juxtanuclear CX3CL1-
containing intracellular compartment was irreversibly photobleached
and recovery of fluorescence, an index of the rate of internalisation of
CX3CL1 from the plasma membrane, was recorded over time.
Fluorescence of the plasma membrane pool, which remained largely
unaffected by the bleaching procedure, was also monitored. Figure
9A depicts an ECV-CX3CL1-GFP cell prior to bleaching, and figures 9B
and 9C illustrate the same cell immediately after and 5 min after
bleaching, respectively. The plasmalemmal fluorescence decreased as
the juxtanuclear fluorescence recovered, consistent with delivery of
unbleached CX3CL1-GFP from the former to the latter compartment.
The rate of recovery of endomembrane fluorescence was quantified
(figure 9D). In ten similar experiments, the juxtanuclear CX3CL1-GFP
compartment recovered to 21.5 ± 3.1% of its original fluorescence by
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170 seconds. When TP was stimulated, the rate and degree of




























Figure 9. Stimulation of the TP receptor does not alter the rate of endocytosis of
CX3CL1. ECV-CX3CLI-GFP cells were grown on glass coverslips and incubated for 4
hrs with TAPI-2 (10 uM) to prevent inadvertent shedding of CX3CL1 from the cell
surface. Cells were incubated with U46619 for 30 min, and using an argon laser and
scanning confocal microscope, the entire juxtanuclear CX3CLl-containing
compartment was irreversibly photobleached, and recovery of fluorescence was
determined at 5-200 s intervals. To control for inadvertent photobleaching associated
with serial image acquisition, non-bleached areas in the plasma membrane were
serially observed in parallel. Fig 9A represents a cell before bleaching, fig 9B depicts
the same cell immediately after photobleaching, and fig 9C depicts the cell 5 minutes
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later. At each timepoint, the ratio of the fluorescence intensity of the internal
compartment to the mean control membrane fluorescence intensity was calculated.
Each point represents mean values ± SEM for at least 6 separate experiments (fig 9D).
(Experiments done by Anne Durkan).
To test whether TP stimulation had any effect on the rate of delivery of
internalised CX3CL1 back to the plasma membrane, the endomembrane
pool was loaded by incubation with CX3CL1 Ab at 37 °C for 1 hour.
Antibody bound to the surface was stripped by a short exposure to an
acidic solution. The cells were allowed to recover for varying periods of
time and the re-insertion of CX3CL1 in the plasma membrane was
determined by quantifying the reappearance of Ab using
immunofluorescence microscopy (98). For these experiments, cells were
pre-treated with metalloprotease inhibitor, GM6001, to prevent rapid
proteolytic shedding of CX3CL1 from the cell surface. As shown in figure
10, fluorescence at the cell surface increased progressively after acid
stripping, confirming that CX3CL1 within the endomembrane
compartment undergoes exocytosis to the plasma membrane. Stimulation
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Figure 10. TP stimulation does not alter the rate of delivery of internalised CX3CL1
back to the plasma membrane. ECV-CX3CL1 cells were incubated with anti-CX3CLl
Ab at 37 °C for 1 h, then membrane-associated Ab was removed by acid wash (pH 2.5)
at 4°C for 2 min. Cells were allowed to recover for 30 min in the presence or absence
of IBOP, then washed, fixed and stained with Cy3-conjugated secondary Ab. In all
experiments, cells were pre-incubated with metalloprotease inhibitor, TAPI-2 (10 pM),
to prevent cleavage of CX3CL1 from the cell surface. Shown are immunofluorescent
images of cells before acid-stripping (fig 10A), of cells immediately after acid stripping
(fig 10B), of cells 30 min after recovering from acid shock (fig IOC), and of cells 30 min
after recovering from acid shock in the presence of IBOP (fig 10D). Cell surface
immunofluorescence was quantified using Volocity software. Results represent mean
values of at least 30 fields per condition from 3 separate experiments (fig 10E). The
data was initially graphed to prove a normal distribution and then differences between
means was compared using the Student's t test. *, p < 0.02 (Experiments done by Anne
Durkan and Soumitra Tole).
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In summary we found that stimulation of TP resulted in decreased total
and surface CX3CL1, with a maximal effect at 30-60 minutes and full
recovery of cellular levels of CX3CL1 by 4 hours. TP stimulation had no
effect on the recycling of CX3CL1 but it did activate TACE via
phosphorylation of Erk, which induced cleavage of surface CX3CL1. We
hypothesised that this would result in functional changes for the cell
with decreased leukocyte adhesion and this will be discussed further in
the next chapter as the experiments were done after the experimental






This work was designed to examine the intracellular location and
function of CX3CL1 in polarised renal tubular epithelial cells and to
examine the effect of thromboxane prostanoid receptor stimulation on
the regulation of CX3CL1.
The presence and function of CX3CL1 in endothelial cells have been well
described (37, 41, 98, 111). In the kidney, an important role for CX3CL1
has been found in diseases involving glomerular inflammation and
endothelial injury (46, 49, 50, 55, 59). Importantly, CX3CL1 is also up-
regulated in renal tubulointerstitial inflammation, most notably in acute
allograft rejection suggesting that CX3CL1 also functions in renal tubular
epithelial cells (287). The specific localisation of the chemokine in these
cells (apical vs basolateral) has been somewhat unclear (59). We initially
demonstrated mainly apical CX3CL1 in human renal biopsy specimens
with tubular disease. In keeping with previous studies, we also found
that not all tubules stained for CX3CL1 but we were unable to correlate
clinical severity with our immunofluorescence results as ethical
permission had not been obtained. We accept the examiners comments
that more images including H&E stains of the biopsies would be helpful
but we were unable to obtain these due to the untimely and tragic death
of the pathologist involved.
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We next moved to a cell-line model to examine the precise location of
CX3CLI. Our original model used HK-2 cells, which are a human renal
tubular cell line but these cells tend to grow in flattened monolayers,
which meant it was very difficult to differentiate the apical from the
basal membrane using fluorescent confocal microscopy. We therefore
switched to MDCK-2 cells, a canine renal tubular cell line that has
typical epithelial cell morphology. These cells do not constitutively
express CX3CL1 therefore we transfected CX3CL1±GFP into the wild
type cells and created stable cell lines. We did not perform extensive
functional cell testing after transfection, but the cells were shown to
retain epithelial cell morphology as demonstrated by ZO-1 and E-
cadherin immunofluorescence staining.
Unexpectedly, we found that transmembrane CX3CL1 was expressed on
the apical, but not the basolateral surface of RTEC. We had anticipated
basolateral CX3CL1 as this could then attract circulating leukocytes from
the peritubular capillaries into areas of injury. The apical pattern of
expression seen mirrors that found in epithelial cells of biliary ductules
(288), but differs markedly from that of intestinal epithelial cells, where
CX3CL1 is largely expressed in the basolateral membrane and in regions
of intercellular contact (289, 290). In the intestine, as in the kidney,
expression of CX3CL1 is highly enhanced in disease states marked by
active inflammation (121, 290, 291).
We next examined how CX3CL1 is sorted to the apical membrane.
Polarised cells are ubiquitous in biology and allow proteins to be
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differentially trafficked to either the apical or basolateral membrane.
Despite the diversity of polarised cells and synthesised proteins, there
are relatively few intrinsic protein sorting signals to direct the protein to
the desired destination. The sorting determinant may lie within any
domain of the protein. Basolateral membrane proteins use largely motifs
in the cytoplasmic domain such as tyrosine based motifs, for example
the low density lipoprotein receptor, or (di)leucine based motifs, for
example the IgG Fc receptor (247, 292). Apically sorted proteins use
signals mainly in the extracellular or transmembrane domains, but some
proteins, such as rhodopsin and the cystic fibrosis transmembrane
regulator (CFTR) use cytoplasmic domain signals, for example the CFTR
uses a PDZ domain signal (136, 246). By genetically deleting the
cytoplasmic tail of CX3CL1 we excluded an apical targeting signal in this
region. Other transmembrane proteins, such as Thy-1, apically target
through direct or indirect associations with lipid rafts (293). Lipid rafts
are rich in sphingolipids and cholesterol and are disrupted by extracting
cholesterol (294). However when we disrupted any potential association
with rafts by extracting cholesterol we found no change in the
distribution of CX3CL1. Although we did not completely deplete the
cholesterol content of the cell, we feel that it was sufficiently reduced to
affect a difference in surface staining of CX3CL1 if an association with
lipid rafts had been the mechanism responsible for apical targeting.
Carbohydrate modification of the protein backbone may also direct
trafficking of transmembrane proteins, as is the case for sucrase
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isomaltase, which requires O-glycosylation for apical targeting (248).
CX3CLI has 26 O-glycosylation sites in the mucin stalk. However, when
we inhibited O-glycosylation, CX3CL1 still trafficked to the apical
membrane. We did not perform any formal testing to check that
inhibition of O-glycosylation was complete and this would have added
to the robustness of the result.
For other proteins, such as endolyn and the glycine transporter GLYT2,
N-glycosylation is the crucial determinant of apical targeting (143, 145).
CX3CLI has a single N-glycosylation site, located in the chemokine
domain (35). Our studies indicate that glycosylation of this site is the
key signal which directs CX3CL1 to the apical membrane. We used
tunicamycin, an antibiotic mixture to inhibit N-glycosylation as this has
been used widely for this purpose (147, 295-297). Tunicamycin prevents
the formation of the sugar donor compound required for glycosylation
(258). We did not perform a titration assay for the dose of tunicamycin
as we used a dose previously given to inhibit N-glycosylation in
cultured kidney epithelial cells, but accept that this would have been
useful to identify the minimum concentration required for inhibition
(295). Furthermore, to confirm our findings that N-glycosylation was
indeed responsible for the apical targeting of CX3CL1, we could have
performed genetic modification to delete or mutate the N-glycosylation
site. As with other proteins that require glycosylation for apical
targeting, it is not known whether the oligosaccharides are recognised
directly by the sorting machinery of the membrane or if glycosylation
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results in a conformational change in the protein which then exposes a
sorting motif (134).
We postulated that after translocating to the apical membrane, CX3CL1
would become anchored there, positioning it to act as a cellular
adhesion molecule (39, 41, 58, 298). Firm anchoring of the chemokine
within the membrane would allow it to tether passing cells that express
the receptor, CX3CR1. Our experiments indicate that CX3CL1 is indeed
immobile, similar to other adhesion molecules, such as CD44 and
ICAM(264, 299, 300). Interestingly, subsequent experiments by our
group have shown that although CX3CL1 is relatively immobile in the
basal state, upon stimulation of TP, CX3CL1 becomes more freely mobile
within the cell membrane (301).
We next considered how CX3CL1 might be physically anchored to the
apical membrane. Some adhesion molecules, including CD44, are
tethered to the cell membrane by direct association with lipid rafts,
whereas some cell adhesion molecules, such as VCAM-1, ICAM-2, CD43
and also CD44 bind to the ERM proteins (ezrin, moesin and radixin)
which act as cross-linkers between the plasma membrane and actin
filaments (264, 302, 303). ICAM-1 on the other hand is known to be
directly associated with a-actinin (304). We, initially, examined the
effect of cholesterol depletion and disruption of rafts on apical tethering
of CX3CL1. Disruption of lipid rafts did not increase the lateral mobility
of CX3CL1, in contrast to previous work with CD44, suggesting that this
is not how CX3CL1 is held immobile (264). Moreover, CX3CL1 mainly
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segregated with the detergent-soluble, rather than the detergent-
insoluble, cellular fraction, further refuting a direct association with
lipid rafts or the presence of a glycosylphosphatidylinositol (GPI)
anchor (294). These data also suggest that CX3CL1 is only weakly
anchored to the actin cytoskeleton. As CX3CL1 was largely detergent
soluble we did not proceed with experiments to examine potential
associations with the ERM proteins or a-actinin but these could have
been done using immunoprecipitation and Western blotting.
A recent model of membrane fluidity proposes that transmembrane
proteins might be corralled into discrete regions of the membrane, with
the actin cytoskeleton acting as a fence and the proteins anchored to the
cytoskeleton acting as pickets. Movement between compartments
would require the protein to "hop" over the fence (305). Such a
mechanism might account for the limited lateral mobility of CX3CL1.
Alternatively, CX3CL1 could be indirectly anchored to the actin
cytoskeleton by one or more TritonX-100 soluble adaptor protein(s). It
is also conceivable that since CX3CL1 is expressed in so many different
cell types, like CD44 it may have different TritonX-100 solubilities, and
perhaps varying mobility characteristics, according to the type of cell in
which the protein in present (306). More work is clearly required to
clarify exactly how CX3CL1 is held immobile in the apical membrane of
epithelial cells. Initial studies could try to establish the region of
CX3CL1 that is responsible for its immobility. We have already created
a mutant CX3CL1 with no cytosolic tail (CX3CLl-360), the mobility of
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which could be investigated using the FRAP technique implemented in
our experiments. Further studies could examine the role of the
transmembrane region of CX3CL1. Hermand et al published their work
showing that the transmembrane domain is crucial for clustering of
CX3CL1 within the membrane after our thesis experiments had been
completed (307). This was the first work to show that, like several other
cell adhesion molecules, CX3CL1 did indeed cluster and that this
improved the adhesive potency of the chemokine.
Although our studies demonstrate that CX3CL1 is targeted and
anchored within the apical membrane, the key question is what role it
might play there. CX3CL1 in intestinal epithelium has been shown to
recruit leukocytes in inflammation and to regulate cell survival and
wound repair (39, 106, 290). In intestinal epithelium CX3CL1 is
predominantly expressed on the basolateral surface, where it is in direct
contact with CX3CR1-expressing host leukocytes, including
macrophages, lymphocytes, and dendritic cells. In the lamina propria,
basolateral CX3CL1 tethers dendritic cells to intestinal epithelium.
Adherent dendritic cells then form transepithelial protrusions, which
they extend into the gut lumen facilitating immunosurveillance and
defence against entero-invasive bacteria (289).
In contrast, no such immunosurveillance was thought to occur within
the kidney or the intrahepatic biliary tree. However the recent work of
Soos et al elegantly demonstrated a network of CX3CR1+ dendritic cells
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extending throughout the renal interstitium, encasing Bowman's
capsule and present within the glomerular extracellular matrix (308).
No protrusions into the urinary space were seen and this was attributed
to either the urine being normally sterile or to an inadequate
experimental technique. In biliary ductular epithelial cells, CX3CL1 is
expressed both apically and basolaterally (288, 291, 309). CX3CL1 on the
apical surface of regenerating biliary epithelial cells has been shown to
facilitate repair of the biliary tree following acute injury, presumably by
recruiting hepatic stem cells, which express CX3CR1 (291). In RTEC, a
similar role has been proposed for the cell adhesion molecule CD44.
CD44 is normally expressed on the basolateral membrane, where it
participates in cell-matrix interactions. However, following renal
tubulointerstitial injury, CD44 is expressed apically, where it is thought
to promote regeneration and repair (310, 311). Our experiments
demonstrate that CX3CL1 is also expressed on the apical surface of
RTEC. We have further found that CX3CL1 on the apical membrane
promotes tethering of leukocytes that bear the complementary receptor.
During tubulointerstitial renal inflammation tight junctions break down,
potentially allowing leukocytes to escape into the urinary space. We
postulate that apical CX3CL1 facilitates recruitment and retention of
these leukocytes, redirecting them to the site of injury. In this manner
CX3CL1 may play an important role in tubulointerstitial nephritis,
pyelonephritis and renal allograft rejection, diseases processes in which
the production of CX3CL1 is markedly increased (9, 49, 59, 60). As with
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biliary epithelial cells, CX3CL1 may also participate in the regeneration
of tubules following inflammatory injury. In a model of ischemia-
reperfusion injury to the kidney, there was an initial increase in
endothelial cell levels of CX3CL1 and this was later followed by
increased tubular expression of the chemokine, which was found to be
protective to the kidney (65). This may well reflect the biphasic nature
of the CX3CL1 / CX3CR1 axis, in that it is implicated both in acute
inflammation and in subsequent repair. To examine the role of renal
tubular cell CX3CL1 more closely specific tubulointerstitial injury could
be induced in CX3CL1 knockout mice and the effects on acute and
chronic histology and function compared with wild type mice. The
nature of the inflammatory infiltrate would be predicted to be different
between the two groups assuming that CX3CL1 / CX3CR1 plays an
important role in leukocyte recruitment in this condition.
Having demonstrated the location and a potential role of CX3CL1 in
RTEC, we next investigated the possible regulation of CX3CL1 by
stimulation of the thromboxane prostanoid receptor. Given that both
thromboxane A2 and CX3CL1 are upregulated early in inflammation, we
hypothesised that there was a direct link between the two inflammatory
agents. For these studies, we used CX3CL1-expressing ECV-304 cells.
As discussed earlier, these cells were initially thought to be from a
human endothelial cell line but were subsequently proved to be a
bladder epithelial carcinoma cell. However, they have been used
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extensively to study the distribution, cleavage and function of the
CX3CLI, because the surface levels of chemokine mirror those seen in
cytokine-activated primary vascular endothelial cells (35, 39, 93, 94, 98,
237). The cells are suitable for preliminary studies but the experiments
should then be repeated with primary cells and ideally with in vivo
studies.
We found that TP stimulation acutely reduces total and surface
expression of CX3CL1, reaching a nadir at 30-60 minutes, and regaining
baseline levels of CX3CL1 after 4 hours. Although there are no
comparative published studies of the acute effects of TP stimulation on
cell surface molecules, several groups have investigated the effects of
long-term TP stimulation on cell surface expression of vascular adhesion
molecules and found augmented expression of vascular adhesion
molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and
endothelial adhesion molecule-1 (ELAM-1; E-selectin) (312, 313).
However in these studies, adhesion molecule levels were examined only
after sustained periods of TP stimulation (4 to 24 hr), and the resultant
increase in expression likely reflected enhanced transcription and new
protein synthesis (312, 313). Supporting this is the finding, in one study,
that inhibition of nuclear factor (NF)-KB-induced transcription
prevented increased expression of ICAM-1 and ELAM-1 at the level of
both mRNA and protein (312). Genetically modified mice lacking both
TP and apo-E, have a significant reduction in ICAM-1 expression again
underscoring the role of TP in promoting adhesion molecule expression
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(208). The effects of prolonged TP stimulation on the expression of the
chemokine, CCL2 (monocyte chemoattractant protein-1; MCP-1) have
also been determined. After 6 hours of TP stimulation, expression of the
CCL2 was enhanced, again through the actions of protein kinase C and
NF-KB-induced transcription (226). To our knowledge, no other study
has examined how TP activation acutely modulates cell surface
expression of an adhesion molecule or a chemokine. We did not
perform experiments after 4 hours of TP stimulation to allow any
comparison with the published literature. A further limitation of this
work is that in a clinical scenario there is more likely to be sustained TP
stimulation following an acute insult and therefore the effects of this on
CXjCLl may be more clinically relevant.
It has previously been demonstrated that CX3CL1 undergoes recycling
between the cell membrane and a juxtanuclear compartment in ECV
cells (98). Moreover, the overall exposure of CX3CL1 at the cell surface
reflects the balance between recycling and shedding or cleavage of the
soluble chemokine. Therefore, the initial decrease in CX3CL1 expression
at the plasma membrane could potentially be achieved through three
distinct mechanisms: a) increased endocytosis of CX3CL1 from the cell
surface, b) decreased traffic of internalised CX3CL1 back to the plasma
membrane, and/or c) increased shedding of CX3CL1 from the cell
surface. We systematically established that TP stimulation did not
acutely alter the rate of traffic of the chemokine between the cell surface
and the intracellular endocytic compartment, but rather it enhanced
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shedding of the chemokine from the cell surface by the metalloprotease,
TACE. Previous studies have shown that CX3CL1 is cleaved by TACE
or ADAM-10 (92-94) and therefore to delineate precisely which of the
two enzymes was responsible for the shedding of CX3CL1 we used
siRNA against both TACE and ADAM-10 and demonstrated that TACE
was the crucial enzyme involved in the TP stimulated cleavage of
CX3CL1, however we did see some off-target effects, despite trying to
minimise these with our experimental protocol.
There are several methods by which we could have further established
TACE as the responsible enzyme for the TP induced cleavage of full-
length CX3CL1. The first of these would be to use a commercially
available kit to measure TACE activity. Indeed we did try this but
despite the best efforts of myself and several other members of the
laboratory team, we could not get consistent, reproducible results and
eventually abandoned this assay. Other investigators have used a
mutant dominat negative form of TACE to inhibit TACE activity in cell
cultures (314, 315). A potential future model could use a TACE
knockout mouse to assess any effect of TP stimulation on CX3CL1, but
this was outside of our planned study. However, adding to our
evidence that TACE is indeed the agent responsible for the TP induced
cleavage of CX3CL1 is the finding that blocking the activation of TACE
by inhibiting Erk activation also prevented shedding of CX3CL1. These
results are supported by work demonstrating that one of the
mechanisms of action of TP stimulation is activation of protein kinase C
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and consequent Erk phosphorylation (273, 316-319). Moreover, others
have shown that Erk phosphorylates the cytoplasmic tail of TACE at
positions Thr 735 and Ser 819, resulting in conformational change and
consequent activation of the protease (279-281). Blocking this
phosphorylation prevents activation of TACE and ectodomain shedding
of its biologic substrates, including TNF-oc and L-selectin (279-281).
Thus we have demonstrated that TP stimulation results in
phosphorylation of Erk, which then phosphorylates TACE, activating
the enzyme and inducing cleavage of transmembrane CX3CL1. In
summary, our experiments demonstrated that TP stimulation causes
rapid loss of CX3CL1 from the cell surface, by promoting TACE-induced
shedding, rather than by altering the recycling dynamics of the
chemokine.
Other members of the research team continued this work, as we were
aware that we had not answered a functional question regarding the
effect of TP stimulation on CX3CL1. The full length transmembrane
CX3CL1 acts as a cell adhesion molecule and because TP activation
caused rapid loss of surface CX3CL1, we predicted that it would result
in decreased adhesion of leukocytes expressing CX3CR1, the only
known receptor for CX3CL1. However the opposite was found to be
true and there was in fact increased cell adhesion after only 20 to 30 min
of TP stimulation (301). Ishizuka et al have demonstrated by several
methods that stimulation of TP results in increased expression of ICAM-
1, VCAM-1 and E-selectin by stimulated human vascular endothelial
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cells (HUVECs) (200, 312, 320) and we therefore wondered whether TP
stimulation might cause a rapid increase in cell surface adhesion
molecules other than CX3CL1, which would account for the increased
cell adhesion seen. Although ECV-304 cells do not have VCAM-1, E-
Selectin or PECAM-1, they do have ICAM-1 (321). However further
experiments demonstrated no increased binding of leukocytes to control
untransfected ECV-304 cells stimulated with TP agonist, suggesting that
the enhanced binding to ECV-CX3CL1 cells was specifically due to the
presence of CX3CL1 itself. To ensure that observed results were not an
idiosyncratic feature of the cell line used, the experiments were repeated
using primary human vascular endothelial cells. Once again, TP
stimulation induced rapid shedding of CX3CL1 from endothelial cells,
yet still enhanced binding of leukocytes. In the experiments by Ishizuka
et al TP agonists were used for 6 hours to assess E-selectin expression
and for 24 hours to assess ICAM-1 and VCAM-1 expression (312).
Again, it is entirely feasible that the increased cell adhesion molecule
expression was due to new protein synthesis as the effect could be
abrogated by the inhibition of NFkB induced transcription, and this
would explain why we did not see the same increase in our more acute
experiments.
Given that TP stimulation promoted loss of CX3CL1 from the cell
surface, yet enhanced the adhesion of cells expressing CX3CR1, it was
hypothesized that TP stimulation must somehow also increase the
avidity of the remaining available CX3CL1 for its receptor. Other cell
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adhesion molecules such as ICAM-1 are known to cluster in the cell
membrane following stimulation (322). It therefore seemed reasonable
to postulate that mobilization of plasmalemmal CX3CL1 and subsequent
clustering of the chemokine within the cell membrane could promote
adhesion of appropriate leukocytes. In this way, the avidity of adhesive
interactions between leukocytes and membrane-bound CX3CL1 would
be strengthened. To verify this prediction, FRAP experiments in the
presence of TP agonists were performed and accordingly, it was found
that CX3CL1 was relatively immobile within the cell membrane under
basal conditions, but it became highly mobile following stimulation of
TP. This observation of poor resting state membrane mobility is
supported by our previous work, in the first half of this thesis, using
MDCK cells, in which we found that plasmalemmal CX3CL1 is similarly
immobile under basal conditions. The expression of CX3CL1 at sites of
contact with adherent leukocytes was then examined using quantitative
immunofluorescence. Following stimulation with TP there was indeed
clustering of CX3CL1 at contact interfaces with bound leukocytes. At
the time that these experiments were performed there was no published
literature regarding the clustering of CX3CL1, though since then
Plermand et al have published the results of their work examining the
aggregation of CX3CL1 using the techniques of bioluminescence
resonance energy transfer (BRET) and homogeneous time-resolved
fluorescence (HTRF) (307). They found that CX3CL1 clustered within
the cell membrane in human embryonic kidney (HEK) cells and that this
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phenomenon was mainly due to the transmembrane region of the
protein, though they were unable to establish the exact sequence motif
involved. They suggested that the aggregation of CX3CL1 in the cell
membrane corresponded to oligomerisation of the protein. Importantly
they found that clustering of CX3CL1 increased its adhesive properties
for cells bearing CX3CR1. To our knowledge, there are no prior
descriptions of regulation of CX3CL1 expression and mobility by a G
protein-coupled receptor.
Given the timeframe of events that we have investigated, it is
conceivable that early in the inflammatory cascade, stimulation of TP
induces shedding of membrane-anchored CX3CL1 to release the soluble
chemoattractant molecule, thereby recruiting circulating leukocytes.
This is then followed by a period where the balance is subtly altered to
facilitate adhesion of recruited leukocytes to the area of vascular or
tissue injury.
In summary this work demonstrates that CX3CL1 is apically expressed,
utilising N-glycosylation to traffic to this membrane, in renal tubular
epithelial cells. CX3CL1 is relatively immobile in the cell membrane
under basal conditions and is able to adhere to cells expressing CX3CR1.
Stimulation of the thromboxane prostanoid receptor results in an acute
reduction in surface and total CX3CL1 levels and this is due to enhanced
cleavage of the full-length protein by TACE.
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Future studies should aim to examine the in vivo implications of TP
regulation on CX3CL1 regulation. These could be achieved with the
various genetically modified mouse models that are already available
such as the TP knockout mouse, the CX3CL1 knockout mouse and the
TACE knockout mouse. The use of these mice could be combined with
specific disease states such as experimental models of ischaemic
reperfusion injury. The nature of the inflammatory infiltrate, especially
the type and number of monocyte / macrophages could also be affected
by the amount of CX3CL1 either secreted or present on the cell
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Expression and Targeting of CX3CL1 (Fractalkine) in Renal
Tubular Epithelial Cells
Anne M. Durkan,*+ R. Todd Alexander,*+ Guang-Ying Liu,+ Min Rui,+ Giuseppe Femia/
and Lisa A. Robinson*+
*Division of Nephrology and fResearch Institute, Hospital for Sick Children, Toronto, Ontario, Canada
The chemokine CX3CL1 plays a key role in glomerulonephritis and can act as both chemoattractant and adhesion molecule.
CX3CLI also is upregulated in tubulointerstitial injury, but little is known about the subcellular distribution and function of
CX3CLI in renal tubular epithelial cells (RTEC). Unexpectedly, it was found that CX3CL1 is expressed predominantly on the
apical surface of tubular epithelium in human renal transplant biopsy specimens with acute rejection or acute tubular
necrosis. For studying the targeting of CX3CL1 in polarized RTEC, MDCK cells that expressed untagged or green fluorescent
protein-tagged CX3CL1 were generated. The chemokine was present on the apical membrane and in subapical vesicles. Apical
targeting of CX3CL1 was not due to signals that were conferred by its intracellular domain, to associations with lipid rafts, or
to O-glycosylation but, rather, depended on N-linked glycosylation of the protein. With the use of fluorescence recovery after
photobleaching, it was found that CX3CL1 is immobile in the apical membrane. However, CX3CL1 partitioned with the
triton-soluble rather than -insoluble cellular fraction, indicating that it is not associated directly with the actin cytoskeleton
or with lipid rafts. Accordingly, disruption of rafts through cholesterol depletion did not render CX3CL1 mobile. For
exploration of potential functions of apical CX3CL1, binding of CX3CRl-expressing leukocytes to polarized RTEC was
examined. Leukocyte adhesion to the luminal surface was enhanced significantly when CX3CL1 was present. These data
demonstrate that CX3CL1 is expressed preferentially on the apical membrane of RTEC and suggest a novel function for the
chemokine in recruitment and retention of leukocytes in tubulointerstitial inflammation.
] Am Soc Nephrol 18: 74-83, 2007. doi: 10.1681 /ASN.2006080862
Renal tubulointerstitial inflammation is characterized byrecruitment of circulating leukocytes to the site of in¬jury. Traffic signals for leukocyte migration are pro¬
vided by chemokines, a family of small molecular weight pro¬
teins (1). Among the chemokines, CX3CL1 (fractalkine) has a
unique role in the inflammatory cascade because of its struc¬
ture: an extracellular chemokine domain and mucin stalk, teth¬
ered to a transmembrane region and a 37-amino acid cytoplas¬
mic tail. Transmembrane CX3CL1 is cleaved proximal to the
membrane by metalloproteinases of the A disintegrin and met-
alloproteinase (ADAM) family to release a soluble species (2-5).
Soluble CX3CL1 acts as a chemoattractant, whereas the trans¬
membrane protein acts as a cell adhesion molecule for mono¬
cytes, natural killer (NK) cells, and subsets of CD8+ T cells, all
of which express CX3CR1, the receptor for CX3CL1. In this way,
CX3CL1 and CX3CR1 promote leukocyte infiltration at sites of
injury (2,6,7). In vivo, CX3CL1 is strongly implicated in inflam¬
mation, including allograft rejection and, most notably, athero-
genesis (8-13).
Numerous organs express CX3CL1, including brain, lung,
heart, intestine, and kidney (10,14-17). In humans and rodents,
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Published online ahead of print. Publication date available at www.jasn.org.
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Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada. Phone:
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CX3CL1 expression is prominent in renal glomerular disease,
particularly in endothelial and mesangial cells (18-20). The role
of CX3CL1 in mediating glomerular injury is well described in
animal models of systemic lupus erythematosus nephritis, me-
sangioproliferative glomerulonephritis, and crescentic glomer¬
ulonephritis (21-23). In these disease processes, blockade of
either CX3CL1 or CX3CR1 prevents renal injury and leukocyte
infiltration (21-23). Little is known, however, regarding the role
of CX3CL1 in tubulointerstitial renal disease. Expression of
CX3CL1 clearly is enhanced in tubulointerstitial injury, includ¬
ing that associated with tubular protein overload and acute
allograft rejection (19,24,25). However, knowledge regarding
the subcellular distribution and function of CX3CL1 in renal
tubular epithelial cells (RTEC) is rudimentary.
We demonstrate here that CX3CL1 is present on the apical
membrane of RTEC, where it is anchored firmly. We further
demonstrate that CX3CL1 is targeted to the apical membrane
via N-glycosylation of the chemokine. The implications of api¬
cal targeting of CX3CL1 for the pathogenesis of tubulointersti¬
tial inflammation are discussed.
Materials and Methods
Cells and Constructs
HK-2 cells were a gift from Dr. Andras Kapus, (University of To¬
ronto, Toronto, ON, Canada). MDCK cells were from American Type
Culture Collection (Manassas, VA). MDCK cells that stably expressed
sodium-hydrogen exchanger 3 (NHE3) tagged with hemagglutinin
(HA) were provided by Dr. Sergio Grinstein (University of Toronto).
Copyright © 2007 by the American Society of Nephrology ISSN: 1046-6673/1801-0074
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The preceding cells were cultured in DMEM and Ham's F12 (Wisent,
St-Bruno, Quebec, Canada) that contained 5% FCS. K562 erythroleuke-
mia cells and K562 cells that stably expressed CX3CR1 (K562-CX3CR1)
were from Dr. Dhavalkumar Patel (University of North Carolina,
Chapel Hill, NC) and were cultured in RPMI supplemented with
HEPES and 15% FCS. Primary human RTEC (Clonetics, Cambrex,
Walkersville, MD) were a gift from Dr. Jim Scholey (University of
Toronto) and were cultured according to the manufacturer's instruc¬
tions (26). CX3CL1 expression in these cells was verified by Western
blotting (27). Human peripheral blood mononuclear cells (PBMC) were
isolated from heparinized peripheral blood from healthy volunteers
(28).
DNA constructs for CX3CL1 or CX3CL1 tagged with green fluores¬
cent protein (CX3CL1-GFP) were created as described previously
(6,27,29). MDCK cells were stably transfected with these constructs
using FuGENE (Roche, Indianapolis, IN) and selected in 500 /eg/ml
G418 (Wisent).
The predicted transmembrane portion of CX3CL1 ends at amino acid
360 (PSORT II). A mutant construct that lacked amino acids 361 to 397,
CX3CLl-360, was generated by PCR using the common upstream
primer 5'-GTGGAATTCTGCAGTCGACTC-3' and the downstream
primer 5'-GCGGCCGCTCACATGGCCACCCCCAGGCAG-3'. In the
downstream primer, stop codons and NotI sites were introduced. PCR
products were cloned into TOPO vector (Invitrogen, Burlington, ON,
Canada) and sequenced. Inserts were released by cutting with NotI and
EcoRI and subcloned into HA-pcDNA3.1 (Invitrogen). MDCK cells
were transfected using FuGENE and selected in 500 /rg/ml G418
(MDCK-CX3CLl-360). DNA constructs that encoded GFP-tagged gly-
cosyl phosphatidylinositol (GP1-GFP) and FcRIIa receptor (FcR-GFP)
were a gift from Dr. S. Grinstein (University of Toronto) (30,31).
Antibodies and Reagents
The following antibodies were used: Goat anti-human CX3CL1 di¬
rected against the extracellular chemokine region (R&D Systems, Min¬
neapolis, MN) (19,32), goat anti-human CX3CL1 against the intracellu¬
lar carboxy terminus (Santa Cruz Biotechnology, Santa Cruz, CA),
anti-actin (Sressgen, Victoria, BC, Canada), and anti-HA (Covance,
Berkeley, CA). Cy3- and horseradish peroxidase-conjugated anti-goat
IgG, anti-mouse IgG, and 18 nm gold-labeled anti-goat IgG were from
Jackson Immunoresearch Laboratories (Bar Harbor, ME). Tunicamycin,
benzyl-2-acetamido-2-deoxy-a-D-galacto-pyranoside, and methyl-/3-cy-
clodextrin (M/3CD) were from Sigma-Aldrich (St. Louis, MO). Amplex
Red kit was used to measure cholesterol levels (Molecular Probes,
Eugene, OR). Cholera toxin B conjugated to Alexa fluor 555 was from
Molecular Probes. The metalloprotease inhibitors TAPI-2 and GM6001
were from Peptides International (Louisville, KY) and Chemicon Inter¬
national (Temecula, CA), respectively. TNF-a was from R&D Systems.
Immunohistochemistry
Renal transplant biopsy specimens were obtained in accordance with
the guidelines of the Research Ethics Board of University Health Net¬
work (University of Toronto). Frozen 7-f/.M sections were air-dried and
fixed in acetone. After blocking with 5% donkey serum, sections were
incubated with anti-CX3CLl antibody (Ab), followed by Cy3-conju-
gated anti-goat IgG.
Immunofluorescence staining of cultured cells was performed as
described previously (33). For detection of surface CX3CL1, cells were
fixed and labeled with anti-CX3CLl Ab and Cy3-conjugated secondary
Ab. For detection of surface and intracellular CX3CL1, the same cells
were permeabilized with 0.1% Triton X-100 and incubated again with
anti-CX3CLl Ab and Cy5-conjugated secondary Ab. In some experi¬
ments, Alexa 488-conjugated phalloidin was added with the secondary
Ab to label F-actin. Cells were visualized using either an LSM 510
confocal microscope (Zeiss, Toronto, ON, Canada) or a spinning disk
DMIRE2 confocal microscope (Leica Microsystems, Toronto, ON, Can¬
ada), equipped with an Hamamatsu backthinned EM-CCD camera.
Images were acquired using 100 X oil immersion and the appropriate
filters. Z stacks were constructed and images deconvolved using Ve¬
locity software (Improvision, Lexington, MA).
PCR
RNA was isolated from HK-2 cells using Trizol (Life Technologies,
Burlington, ON, Canada), and reverse transcriptase-PCR for CX3CL1
was performed using oligo(dT) and specific primers (24). PCR products
were size-fractionated on 1% agarose in TBE gels and stained with
ethidium bromide.
Immunoblotting
SDS-PAGE and immunoblotting were performed using anti-CX3CLl
Ab (0.2 /rg/ml) (27,34). Immunoreactive bands were visualized by
enhanced chemiluminescence (Amersham Biosciences UK Limited,
Buckinghamshire, UK) recorded on x-ray film. Detergent resistance
was assessed as described previously (34). Triton-soluble and -insolu¬
ble components were compared with total cell lysate.
Electron Microscopy
Scanning electron microscopy (EM) was performed as described
previously using anti-CX3CLl Ab (1 /j.g/ml) and 18 nm of gold-labeled
anti-goat IgG secondary antibody (34).
Fluorescence Recovery after Photobleaching
Experiments were performed as described previously (34,35). Briefly,
the apical surface was brought into focus on a confocal microscope, and
two 2.5-^im diameter areas of similar fluorescence intensity were se¬
lected per cell. After acquisition of baseline measurements, one defined
area was photobleached irreversibly, and fluorescence of both areas
was measured over time. Fractional fluorescence recovery of the
bleached area was determined relative to prebleach measurements. The
unbleached area was used to control for inadvertent bleaching during
repeated image acquisition. Results are expressed as the mean fluores¬
cence recovery for at least six experiments, with SEM.
Adhesion Assays
Experiments were performed as described elsewhere with minor
modifications (10). Briefly, MDCK-CX3CL1-GFP cells were grown to
confluence on 25-mm coverslips and pretreated with 10 |xM TAPI-2 for
2 h to maximize cell surface expression of CX3CL1. K562-CX3CR1 cells
were labeled with cholera toxin B-555, and 1 X 106 cells were added to
wells of either MDCK or MDCK-CX3CL1-GFP cells with gentle rocking
at 10 cycles/min. Nonadherent cells were washed away, and remaining
cells were fixed and mounted onto slides. Using a Leica deconvolution
microscope, we examined at least 50 high-power fields (X63) to count
the number of adhered cells. Results are the mean of three separate
experiments with SEM and were compared using paired f test. Cells
also were examined using a spinning disk confocal microscope.
Results
CX3CL1 Is Expressed in RTEC
To define the functions of CX3CL1 in RTEC, we first exam¬
ined CX3CLI expression in five human renal allograft biopsy
specimens. Three specimens had histologic diagnosis of acute
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rejection and two of acute tubular necrosis. In all five speci¬
mens, we detected CX3CL1 expression in renal tubules, partic¬
ularly on the apical surface (Figure 1, A and B). In addition to
being expressed on tubular epithelium, modest CX3CL1 expres¬
sion was noted within the glomeruli and on vascular endothe¬
lium (data not shown). This is in keeping with a previously
published report (19). To verify the specificity of staining, we
omitted primary anti-CX3CLl Ab from some experiments.
When the secondary Ab alone was used, very little background
immunofluorescence was observed (data not shown). At our
institution, donor preimplantation renal transplant biopsies are
not performed routinely and therefore could not be used as an
additional negative control. However, using the same anti-
CX3CL1 Ab as the one used in our study, other investigators
previously reported minimal immunohistochemical expression
of CX3CL1 in normal renal biopsy tissue (19,32). We then ex¬
amined expression and subcellular distribution of CX3CL1 in
HK-2 cells, a human RTEC line. Using reverse transcriptase-
PCR, we detected CX3CL1 mRNA (Figure 1C). To verify
CX3CL1 protein expression, we performed immunofluores¬
cence staining and again found the chemokine predominantly
at the apical surface (Figure ID).
CX3CL1 Is Expressed in the Apical Membrane of RTEC
Because HK-2 cells, unlike other tubular epithelial lines,
grow in flattened monolayers, we adopted another approach,
Figure 1. CX3CL1 is expressed in human renal tubular epithelial
cells (RTEC). Immunofluorescent labeling of CX3CL1 in human
renal allograft biopsy specimens, with histologic diagnoses of
acute tubular rejection (A) and acute tubular necrosis (B). Sam¬
ples were labeled with anti-CX3CLl antibody (Ab) and Cy3-
conjugated secondary Ab. (C) Total RNA was isolated from
HK-2 cells, and CX3CL1 was amplified by reverse transcripta-
se-PCR using specific published primers. The PCR products
were size-fractionated on 1% agarose. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) is shown as a control. (D)
Immunofluorescence staining of HK-2 cells using anti-CX3CLl
Ab and a Cy2-conjugated secondary Ab. Actin was labeled
with rhodamine-conjugated phalloidin. Arrows demonstrate
CX3CL1 labeling on the apical surface of cells.
stably expressing full-length CX3CL1 or CX3CL1-GFP in MDCK
cells, a renal cell line with cuboidal morphology that is typical
of epithelial cells, facilitating distinction between apical and
basolateral surfaces. Using Western analysis and anti-CX3CLl
Ab, MDCK-CX3CLI and MDCK-CX3CL1-GFP cells each dis¬
played a single band of appropriate molecular weight (Figure
2A). For assessment of the subcellular localization of CX3CL1,
MDCK-CX3CL1-GFP cells (Figure 2B) were fixed and incubated
with anti-CXjCLl Ab, which labeled only the apical surface
(Figure 2C). For visualization of intracellular CX3CL1, the same
cells then were permeabilized and incubated with anti-CX3CLl
Ab followed by a different secondary Ab. This confirmed an
intracellular pool of CX3CL1 in subapical vesicles (Figure 2D).
To confirm that any labeling of MDCK-CX3CL1-GFP cells with
anti-CX3CLl Ab was specific for CX3CL1, we incubated un-
transfected MDCK cells with the same Ab. In this instance, no
immunofluorescence staining was observed (data not shown).
To control further for any background staining of Cy3- or
Cy5-conjugated secondary Ab used, we also performed exper¬
iments in which the primary Ab was omitted. Once again,
incubation with secondary Ab alone yielded no immunofluo¬
rescence labeling (data not shown). Collectively, these results
demonstrate that CX3CL1 is expressed on the apical plasma
membrane as well as within subapical vesicles.
In MDCK-CX3CL1-GFP cells, GFP is attached to the cytoplas¬
mic tail of the chemokine. Because the tagged construct was
recognized by the Ab directed against the extracellular domain
of CX3CL1, the protein expressed must traverse the apical
membrane (Figure 2, B and E). We also noted a second pool of
GFP, present in the basolateral membrane (Figure 2B). After
permeabilization, the basolateral pool of GFP could be labeled
by an anti-CX3CLl Ab directed against the intracellular domain
of the chemokine (data not shown). We believe that basolateral
GFP represents the intracellular portion of CX3CL1 that re¬
mains after the extracellular segment has been proteolytically
released. Accordingly, Western analysis of MDCK-CX3CL1-
GFP cells using anti-GFP Ab consistently revealed two separate
bands. The molecular masses of these bands correlated with
full-length CX3CL1-GFP fusion protein (Figure 2A) or a fusion
protein corresponding to the intracellular region of CX3CL1
together with GFP (35 kD; data not shown). To ensure that the
GFP tag did not alter subcellular traffic of CX3CL1, we exam¬
ined MDCK cells that expressed the untagged chemokine and
found a similar distribution (Figure 2F).
We used scanning EM to confirm that CX3CL1 is expressed
on the apical membrane of RTEC. As shown in Figure 2G,
CX3CL1 is associated with microvilli on the apical surface.
CX3CLI Is Targeted to the Apical Membrane by
N-Glycosylation
We next investigated the signals that target CX3CL1 to the
apical membrane. Apical sorting of transmembrane proteins
can be determined by signals that are conferred by the cyto¬
plasmic tail of the protein (36,37), by O- or N-glycosylation (38),
or by membrane anchoring of the protein through GPI or
directly to lipid rafts (39). We examined each of these potential
mechanisms.









Figure 2. CX3CL1 is expressed on the apical surface of RTEC.
(A) Western analysis was performed using cell lysates from
control wild-type MDCK cells (WT), MDCK-CX3CL1-GFP, and
MDCK-CX3CLI cells, using anti-CX3CLl Ab and horseradish
peroxidase (HRP)-conjugated secondary Ab. For MDCK-
CX3CLI-GFP and MDCK-CX3CLI cells, bands of predicted mo¬
lecular weight were obtained, namely 116 and 90 kD, respec¬
tively. (B through E) Immunofluorescence labeling of MDCK-
CX3CFI-GFP cells was performed as in Materials and Methods,
and cells were examined by spinning disk confocal microscopy.
(B) Spinning disk confocal image of MDCK-CX3CL1-GFP cells.
(C) For visualization of CX3CLI at the cell surface, MDCK-
CX3CLI-GFP cells were fixed before incubation with anti-
CX3CFI Ab and Cy3-conjugated anti-goat IgG secondary Ab.
(D) For visualization of both surface and intracellular CX3CL1,
cells were fixed and permeabilized before incubation with anti-
CX3CLI Ab and Cy5-conjugated secondary Ab. (E) Merged
images B through D. Images are shown as x versus y and x
versus z optical sections. (F) Examination of the subcellular
distribution of untagged CX3CL1. For visualization of cell sur¬
face CX3CLI, MDCK-CX3CLI cells were fixed, then incubated
with anti-CX3CFl Ab, followed by Cy3-conjugated anti-goat
IgG secondary Ab. For visualization of any intracellular
CX3CLI present, the same cells then were permeabilized and
incubated again with anti-CX3CLl Ab followed by Cy5-conju-
gated secondary Ab. (G) MDCK-CX3CLI-GFP cells were la¬
beled with anti-CX3CLl Ab and gold-conjugated secondary Ab
and examined using scanning electron microscopy. Arrows
show the association of the CX3CF1 with apical microvilli.
Reverse-phase images are shown. Magnification, X100 in B
through E.
To determine whether the cytosolic tail of CX3CL1 mediates
apical targeting, we generated a mutant construct that lacked
the cytoplasmic domain (CX3CLl-360). We examined the dis¬
tribution of CX3CLI in MDCK cells that stably expressed "tail¬
less" CX3CLI but found that the protein still was directed to the
apical membrane (Figure 3A).
We next assessed potential associations of CX3CL1 with lipid
rafts. We treated cells with M0CD to extract cholesterol,
thereby disrupting lipid rafts (40). To ensure that M0CD treat¬
ment was effective, we measured cholesterol spectrophoto-
metrically (41). M0CD depleted total cellular cholesterol by
58% (P < 0.05; Figure 3B) but had no effect on apical targeting
of CX3CLI (Figure 3C).
We next examined glycosylation of CX3CL1 as a determinant
of apical targeting. O-glycosylation was inhibited with benzyl-
2-acetamido-2-deoxy-a-D-galacto-pyranoside. Again, CX3CL1
targeting to the apical membrane remained intact (Figure 3D).
To inhibit N-glycosylation of CX3CL1, we treated cells with
tunicamycin. This treatment resulted in intracellular retention
of CX3CLI with virtually no expression observed on the apical
surface (Figure 3E). To verify that the observed effects were not
due to nonspecific disruption of apical protein traffic, we eval¬
uated the effects of tunicamycin on NHE3, a protein that does
not require N-glycosylation for its apical targeting. As ex¬
pected, tunicamycin treatment did not affect the normal apical
distribution of NHE3 (Figure 3F).
Collectively, these data indicate that the signals that direct
apical trafficking of CX3CL1 are not conferred by the protein's
cytoplasmic domain, O-glycosylation of the protein, or associ¬
ations with lipid rafts. Rather, apical localization of CX3CL1 is
determined by N-glycosylation.
CX3CL2 Is Anchored to the Apical Membrane in RTEC
To determine whether CX3CL1 is anchored in the luminal
surface, we used fluorescence recovery after photobleaching to
study the mobility characteristics of apical CX3CL1-GFP in
MDCK-CX3CLI-GFP cells (see Materials and Methods) (Figure
4, A [before bleaching], B [immediately after bleaching], and C
[5 min after bleaching]). As a control, MDCK cells were trans-
fected with a DNA construct that encoded GPI-GFP, which is
freely mobile in the apical plasma membrane. A region of the
apical membrane was bleached similarly, and the recovery of
fluorescence was observed over time (Figure 4, D through F).
CX3CLI-GFP recovered with significantly slower kinetics than
GPI-GFP (Figure 4G). For CX3CL1-GFP, the bleached area re¬
covered to 10.5 ± 4.3% of prebleached fluorescence intensity by
4 min, compared with 61.1 ± 11.9% for GPI-GFP (P < 0.01). As
an additional control, MDCK cells were transfected with DNA
that encoded the single transmembrane protein FcR-GFP.
When fluorescence recovery after photobleaching was per¬
formed similarly, the bleached area in the membrane recovered
significantly faster than CX3CL1-GFP, with 4-min recovery of
51.5 ± 6.1% for FcR-GFP (P < 0.01; Figure 4G). These data
demonstrate that the ability of CX3CL1 to diffuse laterally
within the apical membrane is impeded, and, therefore, trans¬
membrane CX3CLI is immobile.
Some single-pass transmembrane proteins are tethered to the
apical membrane by direct association with lipid rafts (42). To
determine whether CX3CL1 is anchored in such a manner, we
disrupted lipid rafts by treating cells with M0CD. Flowever,
this treatment did not mobilize CX3CF1 in the apical membrane
(Figure 4G). To study whether apical CX3CL1 is immobile
because it is tethered directly to the actin cytoskeleton, we













Figure 3. Targeting of CX3CL1 to the apical membrane of RTEC. (A) MDCK cells that expressed a mutant CX3CL1 construct that lacks
the cytoplasmic tail (MDCK-CX3CLl-360) were fixed and then incubated with anti-CX3CLl Ab and a Cy3-conjugated secondary Ab to
visualize cell surface CX3CL1. For further visualization of intracellular CX3CL1, the same cells then were permeabilized and then labeled
with anti-CX3CLl Ab and then Cy5-conjugated secondary Ab. After permeabilization, cells were incubated with Alexa 488-conjugated
phalloidin to label F-actin. Slides were examined using a spinning disk confocal microscope. Images are shown as x versus y and x versus
z optical sections. (B) For depletion of cholesterol and disruption of lipid rafts, MDCK-CX3CL1-GFP cells were incubated for 30 min at
37°C with methyl-/3-cyclodextrin (M/3CD), and the cholesterol content was measured by spectrophotometry using Amplex Red
(Molecular Probes). Values for cholesterol content are expressed as a percentage of untreated controls and represent a mean of three
experiments (*P < 0.05). (C) MDCK-CX3CL1-GFP cells were incubated for 30 min with M/3CD before fixation and incubation with
antibodies as in A. (D) MDCK-CX3CL1-GFP cells were labeled with anti-CX3CLl Ab, as in A, after treatment with benzyl-2-acetamido-
2-deoxy-a-D-galacto-pyranoside overnight to inhibit O-glycosylation. (E) MDCK-CX3CL1-GFP cells were labeled with anti-CX3CLl Ab
as in A after overnight treatment with tunicamycin to inhibit N-glycosylation. (F) MDCK cells that expressed HA-tagged NHE3
(MDCK-NHE3) were incubated overnight with tunicamycin. The cells then were fixed and incubated with anti-FLA Ab and then
Cy3-conjugated secondary Ab. For visualization of intracellular NHE3, the same cells were permeabilized and then incubated with
anti-HA Ab and then Cy5-conjugated secondary Ab. After permeabilization, the cells also were incubated with Alexa 488-conjugated
phalloidin to label F-actin.
fractionated cellular proteins between two distinct fractions—
triton soluble and triton insoluble—as described previously
(33). In polarized epithelial cells, proteins that were anchored
directly to the actin cytoskeleton preferentially remain in the
triton-insoluble fraction. We found, however, that CX3CL1
largely was soluble in triton solution, suggesting that it is not
tethered directly to the actin cytoskeleton (Figure 4H). These
data also confirm that CX3CL1 is not associated with lipid rafts
(Figures 3C and 4G). Collectively, these data indicate that after
sorting to the apical surface, CX3CL1 is held immobile there,
but this is not achieved by direct tethering to the actin cytoskel¬
eton or by association with lipid rafts.
CX3CL1 Expressed on the Apical Surface of RTEC Promotes
Adhesion of Leukocytes
CX3CL1 can act as a cell adhesion molecule, facilitating the
binding of leukocytes (7,43). We therefore hypothesized that
CX3CL1 might perform a similar function when expressed on




























the apical surface of RTEC. Under the low-shear conditions
used, there was minimal binding of control K562 leukocytes to
either MDCK or MDCK-CX3CL1-GFP cells (data not shown).
We found significant binding of K562-CX3CR1 leukocytes to
MDCK-CX3CLI-GFP cells (Figure 5, A and B). When CX3CL1
was present on the apical membrane, leukocyte adhesion was
almost three times greater than when CX3CL1 was absent (P <
0.001; Figure 5C).
To verify that any observed responses were not an idiosyn¬
cratic feature of transformed cell lines, we performed the same












Figure 4. CX3CL1 is anchored to the apical membrane in RTEC. For
examination of the mobility of CX3CL1 in the apical membrane,
fluorescence recovery after photobleaching (FRAP) was performed as
described in Materials and Methods. Using an argon laser and a
scanning confocal microscope, a 2.5-/xM region of the apical mem¬
brane that expressed CX3CL1-GFP was photobleached irreversibly
(circles), and recovery of fluorescence was monitored over time. (A)
MDCK-CX3CL1-GEP cell before bleaching. (B) The same cell imme¬
diately after photobleaching. (C) The same cell 5 min later. Control
areas of the same diameter in the plasma membrane were examined
at each time point. (D through F) As a control, FRAP was performed
similarly in MEXIK cells that expressed freely mobile glycosyl phos-
phatidylinositol conjugated to GFP (MDCK-GPI-GFP). (D) MEXZK-
GPI-GFP cells before bleaching. (E) The same cell immediately after
bleaching. (F) The same cell after 5 min of recovery. (G) As an
additional control, FRAP was performed in MDCK cells that ex¬
pressed the single transmembrane protein Fcylla receptor tagged
with GFP (FcR-GFP). Recovery of fluorescence after photobleaching
of apical CX3CL1-GFP, GPI-GFP, FcR-GFP, and CX3CL1-GFP after
cholesterol depletion was done with M/3CD. Points represent the
mean ± SEM of recovery at serial time points from at least six
experiments. (H) Lysates from MDCK-CX3CL1-GFP cells were ob¬
tained after separation into triton-soluble and triton-insoluble frac¬
tions, as described in Materials and Methods. Western blotting




Figure 5. CX3CRl-expressing leukocytes adhere to CX3CL1 in
the apical membrane of RTEC. K562 cells that expressed the
CX3CRI receptor (K562-CX3CR1) were labeled with rhodam-
ine-conjugated cholera toxin B to visualize them. K562-CX3CR1
cells (1 X 106) were added to MDCK or MDCK-CX3CL1-GFP
monolayers, growing on 25-mm cover slips, under conditions
of low-shear stress. After 20 min, nonadherent cells were re¬
moved by washing, and the remaining cells were fixed. Serial
fields (X63) were examined, using a Leica deconvolution mi¬
croscope, and the number of adherent cells were counted. (A
and B) Photomicrographs of labeled K562-CX3CR1 cells (red)
binding to MDCK-CX3CL1-GFP monolayers. Images shown in
x versus y (A) and x versus z (B) optical sections. (C) Graph
depicting the number of K562-CX3CR1 leukocytes bound to
either MDCK or MDCK-CX3CL1-GFP cells. Values represent
the mean number of adherent cells per high-power field (X63).
Values represent the mean of three experiments ± SEM (*P <
0.001). (D) Adhesion assays were repeated using primary RTEC
and human peripheral blood mononuclear cells (PBMC) that
were isolated from the blood of healthy volunteers. In parallel
experiments, primary RTEC monolayers were preincubated
with function-blocking anti-CX3CLl Ab (1 ^tg/ml) for 30 min
before addition of PBMC. Values represent the mean number of
adherent PBMC per X40 field. Experiments were performed six
times for each condition (*P < 0.0001 versus control).
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were isolated from heparinized blood of healthy volunteers.
PBMC contain multiple leukocyte subsets, including CD8+ T
lymphocytes, monocytes, and NK cells, all of which express the
CX3CR1 receptor. PBMC efficiently adhered to the apical sur¬
face of monolayers of primary human RTEC. When primary
RTEC were preincubated with function-blocking anti-CX3CL1
Ab, binding of PBMC was inhibited significantly (Figure 5D).
Collectively, these data suggest that CX3CL1 expressed on the
luminal surface of RTEC promotes adhesion of leukocytes that
bear the complementary receptor CX3CR1. Our results are in
keeping with previous reports in which blockade of CX3CL1 /
CX3CR1 impaired binding of THP-1 monocytic cells to primary
proximal RTEC (32).
Discussion
The expression and the function of CX3CL1 in endothelial
cells have been well described (6,7,27,43). In the kidney, an
important role for CX3CL1 has been found in diseases that
involve glomerular inflammation and endothelial injury
(19,20,22,23). CX3CL1 also is upregulated in renal tubulointer-
stitial inflammation, most notably in acute allograft rejection
(19), but the specific localization of the chemokine (apical versus
basolateral) has been somewhat unclear (32). The purpose of
these studies, therefore, was to ascertain the subcellular distri¬
bution and targeting of CX3CL1 in polarized tubular epithelial
cells. Unexpectedly, we found that transmembrane CX3CL1
was expressed predominantly on the apical surface of RTEC.
This pattern of expression mirrors that found in epithelial cells
of biliary ductules (44) but differs markedly from that of intes¬
tinal epithelial cells, where CX3CL1 largely is expressed in the
basolateral membrane and in regions of intercellular contact
(45,46). In the intestine, as in the kidney, expression of CX3CL1
is highly enhanced in disease states that are marked by active
inflammation (14,45,47).
We next examined how CX3CL1 is sorted to the apical mem¬
brane. In polarized cells, several signals can sort transmem¬
brane proteins to either the basolateral or the apical membrane.
The sorting determinant may lie in the cytoplasmic, transmem¬
brane, or extracellular domain of the protein. Sorting signals in
the cytoplasmic tail include PDZ domains and dileucine motifs,
used by the cystic fibrosis transmembrane regulator and the
IgG Fc receptor, respectively (36,37). By deleting the cytoplas¬
mic tail of CX3CL1, we excluded an apical targeting signal in
this region. Other transmembrane proteins, such as Thy-1, api-
cally target through direct or indirect associations with lipid
rafts (48). However, when we disrupted any potential associa¬
tion with rafts by extracting cholesterol, we found no change in
the distribution of CX3CL1.
Carbohydrate modification of the protein backbone also may
direct trafficking of transmembrane proteins, as is the case for
sucrase isomaltase, which requires O-glycosylation for apical
targeting (38). CX3CL1 has 26 O-glycosylation sites in the mu¬
cin stalk. However, when we inhibited O-glycosylation,
CX3CL1 still trafficked to the apical membrane. For other pro¬
teins, such as endolyn and the glycine transporter GLYT2,
N-glycosylation is the crucial determinant of apical targeting
(49,50). CX3CL1 has a single N-glycosylation site, located in the
chemokine domain (2). Our studies indicate that glycosylation
of this site is the key signal that directs CX3CL1 to the apical
membrane.
We postulated that after translocating to the apical mem¬
brane, CX3CL1 would become anchored there, positioning it to
act as a cellular adhesion molecule (7,10,43,51). Firm anchoring
of the chemokine within the membrane would allow it to tether
passing cells that express the receptor CX3CR1. Our experi¬
ments indicate that CX3CL1 indeed is immobile, similar to
another adhesion molecule, CD44 (42,52).
We next considered how CX3CL1 might be physically an¬
chored to the apical membrane. Some adhesion molecules,
including CD44, are tethered to the cell membrane by direct
association with lipid rafts. We therefore examined the effect of
cholesterol depletion and disruption of rafts on apical tethering
of CX3CL1. Disruption of lipid rafts did not increase the lateral
mobility of CX3CL1. Moreover, CX3CL1 segregated with the
detergent-soluble, rather than -insoluble, cellular fraction, fur¬
ther refuting a direct association with lipid rafts. These data
also suggest that CX3CL1 is not anchored directly to the actin
cytoskeleton. A recent model of membrane fluidity proposed
that transmembrane proteins might be fenced into discrete
regions of the membrane (53). Such a mechanism might account
for the limited lateral mobility of CX3CL1. Alternatively,
CX3CL1 could be anchored indirectly to the actin cytoskeleton
by one or more triton-soluble adaptor proteins (54).
Although our studies demonstrate that CX3CL1 is targeted
and anchored within the apical membrane, the key question is
what role it might play there. CX3CL1 in intestinal epithelium
has been shown to recruit leukocytes in inflammation and to
regulate cell survival and wound repair (7,45,55). In intestinal
epithelium, CX3CL1 is expressed predominantly on the baso¬
lateral surface, where it is in direct contact with CX3CRl-ex-
pressing host leukocytes, including macrophages, lympho¬
cytes, and dendritic cells. In the lamina propria, basolateral
CX3CL1 tethers dendritic cells to intestinal epithelium. Adher¬
ent dendritic cells then form transepithelial protrusions, which
they extend into the gut lumen, facilitating immunosurveil-
lance and defense against enteroinvasive bacteria (46). In con¬
trast, no such immunosurveillance is known to occur within the
kidney or the intrahepatic biliary tree. In biliary ductular epi¬
thelial cells, CX3CL1 is expressed both apically and basolater-
ally (44,47). CX3CL1 on the apical surface of regenerating bili¬
ary epithelial cells has been implicated in repair of the biliary
tree after acute injury, presumably by recruiting hepatic stem
cells, which express CX3CR1 (47). In RTEC, a similar role has
been proposed for CD44. CD44 normally is expressed on the
basolateral membrane, where it participates in cell-matrix in¬
teractions. However, after renal tubulointerstitial injury, CD44
is expressed apically, where it is thought to promote regener¬
ation and repair (56,57).
Conclusion
We have found that CX3CL1 on the apical membrane pro¬
motes tethering of leukocytes that bear the complementary
receptor. During tubulointerstitial renal inflammation, tight
junctions break down, potentially allowing leukocytes to es-
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cape into the urinary space. We postulate that apical CX3CL1
facilitates recruitment and retention of these leukocytes, redi¬
recting them to the site of injury. In this manner, CX3CL1 may
play an important role in tubulointerstitial nephritis, pyelone¬
phritis, and renal allograft rejection, disease processes in which
expression of CX3CL1 is highly upregulated. As with biliary
epithelial cells, CX3CL1 also may participate in regeneration of
tubules after inflammatory injury. Further work is needed to
ascertain the in vivo functions of CX3CL1 located on the apical
membrane of RTEC.
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Tole S, Durkan AM, Huang YW, Liu GY, Leung A, Jones LL,
Taylor JA, Robinson LA. Thromboxane prostanoid receptor stimu¬
lation induces shedding of the transmembrane chemokine CX3CLI
yet enhances CX3CLI-dependent leukocyte adhesion. Am J Physiol
Cell Physiol 298; C1469-C1480, 2010. First published March 17,
2010; doi; 10.1152/ajpcell.00380.2009.—In atherosclerosis, chemo-
kines recruit circulating mononuclear leukocytes to the vascular wall.
A key factor is CX3CLI, a chemokine with soluble and transmem¬
brane species that acts as both a chemoattractant and an adhesion
molecule. Thromboxane A2 and its receptor, TP, are also critical to
atherogenesis by promoting vascular inflammation and consequent
leukocyte recruitment. We examined the effects of TP stimulation on
processing and function of CX3CLI, using CX3CLI-expressing hu¬
man ECV-304 cells and primary human vascular endothelial cells. TP
agonists promoted rapid shedding of cell surface CX3CLI, which was
inhibited by pharmacological inhibitors or specific small interfering
RNA targeting tumor necrosis factor-a-converting enzyme (TACE).
Because it reduced cell surface CX3CLI, we predicted that TP
stimulation would inhibit adhesion of leukocytes expressing the
CX3CLI cognate receptor but, paradoxically, saw enhanced adhesion.
We questioned whether the enhanced ability of the remaining mem¬
brane-associated CX3CL] to bind targets was caused by changes in its
lateral mobility. Using fluorescence recovery after photobleaching, we
found that plasmalemmal CX3CLI was initially tethered but ulti¬
mately mobilized by TP agonists. TP stimulation provoked clustering
of transmembrane CX3CLI at sites of contact with adherent leuko¬
cytes. These data demonstrate that TP stimulation induces two distinct
effects: a rapid cleavage of surface CX3CLI, thereby releasing the
soluble chemoattractant, plus mobilization of the remaining trans¬
membrane CX3CLI to enhance the avidity of interactions with ad¬
herent leukocytes. The dual effect of TP allows CX3CLI to recruit
leukocytes to sites of vascular inflammation while enhancing their
adhesion once recruited.
leukocytes; inflammation; endothelial cells
atherosclerosis is a chronic inflammatory disease involving
the vascular wall, leukocytes, and platelets. Thromboxane A2
(TXA2), a prostanoid formed from the metabolism of arachi-
donic aciu via the cyclooxygenase (COX) pathway, has long
been implicated in the pathogenesis of atherosclerosis and
induces platelet aggregation, vasoconstriction, and vascular
smooth muscle cell (VSMC) proliferation (42). It is produced
mainly by platelets but also by monocytes/macrophages,
VSMC. and endothelial cells (37, 41, 42). TXA2 mediates its
effects through the thromboxane prostanoid (TP) receptor, a G
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protein-coupled receptor expressed in diverse hematopoietic
cell types, including platelets and monocytes, as well as in
endothelial cells, fibroblasts, and VSMC (15, 41). COX inhib¬
itors, which decrease TXA2 production, protect against vascu¬
lar inflammation and acute vascular events in patients at high
risk (3). Mice deficient in TP or treated with a TP antagonist
show markedly decreased leukocyte accumulation within the
vascular wall (5, 22).
In atherogenesis, chemokines recruit circulating leukocytes
and other cells to the injured vascular wall. The chemokine
CX3CLI (fractalkine) plays a key role by recruiting mono¬
cytes, T lymphocytes, and other inflammatory cells (6, 24, 28,
29, 32, 40). Most chemokines are small, secreted proteins.
CX3CLI is one of only two chemokines that have soluble and
membrane-anchored species (2, 10, 27). Soluble CX3CLI
consists of a chemokine domain and mucin stalk and is re¬
leased from the plasma membrane following cleavage of the
full-length protein by ADAM (a disintegrin and metallopro-
tease)-10 and ADAM 17/TACE (tumor necrosis factor-a-con-
verting enzyme) metalloproteases (12, 17, 43). The soluble
species thus generated is chemoattractant for monocytes/mac-
rophages, natural killer cells, T lymphocytes, and VSMC, all of
which express CX3CRI, the unique receptor for CX3CLI (10.
18. 26).
CX3CLI-CX3CRI-mediated cellular traffic is critically im¬
plicated in coronary atherosclerosis and stroke. In affected
coronary arteries, CX3CLI protein expression is increased
throughout the vascular wall in endothelium, intima, media,
and adventitia (26, 45, 47). CX3CLI is also expressed in
macrophages, foam cells, and VSMC and acts to recruit mono¬
cytes, memory T lymphocytes, and additional VSMC to the
injured arterial wall (26. 45. 47). Thus, within the atheroscle¬
rotic lesion, CX3CLI is expressed by and can recruit cells
capable of secreting large amounts of extracellular matrix
proteins, thereby favoring formation of stable atherosclerotic
plaques (10, 18, 47). By recruiting monocytes to the injured
vessels, CXsCLi promotes formation of macropnage-rich, un¬
stable plaques. Genetic targeting of CXjCLI or CXjCRl in
atherosclerosis-prone mice highly protects them from vascular
disease (6, 24, 40). In humans, gene polymorphisms in
CXjCRI that impair leukocyte chemotaxis and binding of the
receptor to cell surface CX3CLI protect against myocardial
infarction, unstable angina, cardiac death, and stroke (13,
28, 32).
It is widely recognized that important links exist between the
thrombotic events and the vascular inflammation that define
atherosclerosis. The precise nature of these links has not yet
been well elucidated. TXA2, acting through TP, potently in-
CI4690363-6143/10 Copyright © 2010 the American Physiological Society
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duces vascular inflammation, promoting leukocyte recruitment
to the injured vascular wall. We studied whether TP mediates
these effects by enhancing the exposure and activity of the
chemokine CX3CLI. We found that TP stimulation causes
rapid shedding of CX3CLI from the cell surface yet. unexpect¬
edly, promotes enhanced CX3CLI-dependent leukocyte adhe¬
sion. TP stimulation mobilizes remaining membrane-associ¬
ated CX3CLI, allowing it to cluster at sites of contact with
adherent leukocytes. The potential implications of these dual
mechanisms of regulation of CX3CLI function by TP for the
development of vascular inflammation are discussed.
MATERIALS AND METHODS
Cell culture. ECV-304 cells were obtained from the American
Type Culture Collection (Manassas. VA), and the generation of cells
expressing green fluorescent protein-tagged CX3CLI (ECV-CX3CLI-
GFP) or untagged CX3CLI (ECV-CX3CLI) has been described
previously (8, 25). A cDNA construct encoding mCherry-tagged
CX3CLI was generated by PCR amplification of full-length CX3CLI
with EcoK\ and BamH\ sites at the NH2 and COOH terminus,
respectively, and subcloning into the corresponding restriction sites of
pmCherry-Nl vector (Clontech Laboratories, Mountain View, CA).
The resulting CXjCLl-mCherry cDNA construct was verified hy
sequencing and was expressed in ECV-304 cells using FuGene HD
transfection reagent according to the manufacturer's specifications
(Roche Diagnsotics, Laval, PQ. Canada). Cells were grown in DMEM
and Ham's F12 (Wisent, St-Bruno, QC, Canada) supplemented with
5% fetal calf serum. Human K562 erythroleukemia cells that stably
express CX3CRI (K562-CX3CRI) were cultured in RPMI supple¬
mented with HEPES and 10% fetal calf serum (8, 10). Primary human
umbilical vein endothelial cells (HUVEC) were obtained from Clo-
netics (La Jolla, CA) and cultured in endothelial cell growth medium
(Clonetics) (10). Peripheral blood mononuclear cells (PBMC) were
isolated from the blood of healthy volunteers as previously described (8).
Antibodies and reagents. The following primary antibodies were
used: goat anti-human CX3CLI (R&D Systems, Minneapolis, MN),
rabbit anti-Erk (extracellular signal-related kinase) and rabbit anti-
phospho-Erk (Cell Signaling Technology, Danvers, MA), mouse
anti-actin (Stressgen, Victoria, BC, Canada), mouse anti-GAPDH
(Chemicon. Temecula, CA), and mouse anti-Bcr (Santa Cruz Biotech¬
nology, Santa Cruz, CA). Rabbit anti-phospho-c-Raf, rabbit anti-
phospho-MEKl/2, and rabbit anti-MEKl/2 were all obtained from
Cell Signaling Technology. Rabbit anti-c-Raf was obtained from
Santa Cruz Biotechnology. Mouse monoclonal antibody (Ab) directed
against human TACE was a kind gift of Dr. Roy Black (Amgen,
Sherman Oaks, CA). The following secondary antibodies were used:
horseradish peroxidase-conjugated anti-mouse, anti-goat and anti-
rabbit IgG, Cy3- and Cy5-conjugated anti-goat IgG. Cy5-conjugated
anti-mouse IgG, and phycoerythrin-conjugated anti-goat IgG (Jackson
ImmunoResearch Laboratories, Bar Harbor, ME), as well as
Alexa488-conjugated anti-mouse IgG (Invitrogen, Burlington, ON,
Canada). TP agonists 9.11-dideoxy-l la,9a-epoxymethanoprostag-
landin F2„ (U46619) and [lS-loi^pfSZUJadEO/^MctH-LHS-
hydroxy-4-(4'-iodophenoxy)-l-butenyl)-7-oxabicyclo-[2.2.1]heptan-
2-yl]-5-heptenoic acid (IBOP), as well as the specific TP antagonist
SQ29548 were obtained from Biomol (Plymouth Meeting, PA). The
Erk inhibitor U0126 was obtained from LC Laboratories (Woburn,
MA). The metalloprotease inhibitors TAP1-2 and GM6001 were
obtained from Peptides International (Louisville, KY) and Chemicon
International (Temecula, CA), respectively. DNA expression con¬
structs encoding GFP-tagged glycosylphosphatidylinositol (GPI-GFP)
and FcyRIIa receptor (FcyRIIa-GFP) were a gift from Dr. Sergio
Grinstein (The Hospital for Sick Children Research Institute, Toronto,
ON, Canada), and cells were transfected using FuGene (Roche Diag¬
nostics).
Immunoblotting. SDS-PAGE and immunoblotting were performed,
as previously described, using anti-CXrCLl Ab (0.2 p-g/ml) and
anti-Erk (0.01 p.g/ml) or anti-phospho-Erk Ab (0.2 p.g/ml) (8, 25).
Anti-actin or anti-GAPDH Ab was used to control for protein loading.
Immunoreactive bands were visualized by enhanced chemilumines-
cence (Amersham Biosciences, Little Chalfont, UK) recorded on
X-ray film.
Flow cytometry. ECV-CX3CLI-GFP cells were grown in 10-cm
dishes and treated with the TP agonists IBOP or U46619 for various
time periods. Cells were lifted by briefly incubating with 5% EDTA
at 4°C, washed, and fixed in 4% paraformaldehyde. Cells were
incubated with 5% donkey serum followed by anti-CX3CLl Ab for 1
h at room temperature. After further washing, cells were incubated
with phycoerythrin-conjugated anti-goat IgG for 1 h at room temper¬
ature. Cells were suspended in PBS and analyzed using a fluorescence-
activated cell scanner (FACScan; BD Biosciences, San Jose, CA).
Immunofluorescence staining. ECV-CX3CLI-GFP cells were grown
on glass coverslips, fixed using 4% paraformaldehyde, washed, and
blocked with 5% donkey serum at room temperature for 1 h. Cells were
incubated with anti-CXsCLl Ab (2.5 pg/ml) and anti-TACE Ab (2.7
p.g/ml) at room temperature for 1 h followed by Cy3-conjugated anti-goat
IgG and Cy5-conjugated anti-mouse IgG for 1 h. Cells were mounted
onto glass slides and visualized using a spinning disk DMIRE2 confocal
microscope (Leica Microsystems, Toronto, ON, Canada) equipped with
a Hamamatsu backthinned charge-coupled device (EM-CCD) camera.
Images were acquired using XI00 oil immersion and appropriate filters
(8, 25).
Fluorescence recovery after photobleaching. Fluorescence recov¬
ery after photobleaching (FRAP) was performed as previously de¬
scribed (8, 25). Briefly ECV-CX3CLI-GFP cells or ECV-CX3CLI
cells transfected with GPI-GFP or FcyRIIa-GFP cDNA were grown
on 25-mm coverslips, mounted into Attafluor chambers, and incu¬
bated in RPMI containing 5% fetal calf serum and 25 mM HEPES at
37°C (8, 25). Live cells were analyzed by confocal microscopy. A
30-mW LASOS argon laser was used to irreversibly photobleach the
entire juxtanuclear CX3CLI-containing compartment (8, 25). To pre¬
vent potential shedding of cell surface CX3CLI, cells were treated
with the metalloprotease inhibitor GM6001 for 4 h before assays were
performed. In other experiments, a 2-p.m region of the plasma mem¬
brane was irreversibly photobleached. Recovery of fluorescence was
measured over time. Control, nonbleached areas of the plasma mem¬
brane of the same cell were also serially monitored to quantify the
amount of bleaching caused by repeated image acquisition. Results
are expressed as the mean (±SE) normalized fluorescence recovery.
Acid-stripping experiments. The rate of delivery of internalized
CX3CLI back to the plasma membrane was assessed as previously
described (25, 44). To prevent potential shedding of cell surface
CX3CLL cells were pretreated with the metalloprotease inhibitor
GM600I before incubation with anti-CXrCLl Ab for 1 h (43).
Membrane-associated Ab was removed by acid wash (0.15M NaCl,
50 mM glycine, 0.1% BSA, pH 2.5) on ice for 2 min and then allowed
to recover for various time periods in the presence of TP agonist. Cells
were washed, fixed, and incubated with Cy3-conjugated secondary
Ab. Images were captured using a Leica DMIRE2 microscope and
OpenLab software (Improvision, Lexington, MA). Cell surface im¬
munofluorescence intensity was measured using Volocity imaging
software (Improvision, Waltham, MA).
Adhesion assays. Stamper-Woodruff assays were performed as
described elsewhere with minor modifications (8, 35, 36). Briefly,
ECV-304, ECV-CX3CLI-GFP, or HUVEC cells were grown to con¬
fluence on 25-mm coverslips and treated with the TP agonist IBOP for
30 min. In some experiments, HUVEC were incubated with TNF-a
(100 U/ml) for 4 h, followed by incubation with function-blocking
anti-CXiCLl Ab (1 p-g/ml) for 30 min before addition of leukocytes.
Control human K562 or K562-CX3CRI cells were labeled with
Alexa555-conjugated cholera toxin to easily visualize them. Cells
(5 X 10s) were incubated with either ECV-304 or ECV-CX3CLI-GFP
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Fig. I. Thromboxane prostanoid (TP) receptor stimulation decreases surface and total levels of CX3CLI. A\ ECV-304 cells expressing green fluorescent protein-tagged
CX3CLI (ECV-CX3CLI-GFP) were incubated with U46619 (20 pM) for the indicated time periods. Cell lysates were harvested, and immunoblotting was performed
using anti-CXrCLl antibody (Ab; 0.2 pg/ml) and horseradish (HRP)-conjugated secondary Ab. To control for protein loading, blots were stripped and reprobed with
anti-GAPDH Ab and HRP-conjugated secondary Ab. B: cells were incubated with IBOP (0.1 pg/ml), and immunoblotting was performed as described in A. To control for protein
loading, blots were stripped and reprobed with anti-actin Ab and HRP-conjugated secondary Ab. C: experiments were performed as described in B. Band intensities for CX3CLI
were quantified and normalized to actin. Values are means ± SE for 4 separate experiments. *P = 0.05; tP < 0.01 vs. untreated. D: ECV-CX3CLI cells were incubated with
IBOP (0.1 pg/ml) for 30 min, and immunoblotting was performed as described in B. £: experiments were performed as described in D. Band intensities for CX3CLI were
quantified and normalized to actin. Values are means ± SE for 3 separate experiments. *P < 0.01. F: ECV-CX3CLI-GFP cells were incubated with U46619 (20 pM) for the
indicated time periods, fixed, and labeled with anti-CXT'l.l Ab (2.5 pg/ml) and PE-conjugated secondary Ab, and cell surface CX3CLI expression was measured using flow
cytometry. Results are means ± SE expressed as a percentage of control fluorescence for 5 separate experiments. iP < 0.05. G: cells were incubated with IBOP (0.1 pg/ml)
for 30 min after preincubation with the specific TP antagonist SQ29548 (10 pM for 15 min), and immunoblotting was performed as described in B, H: experiments were
performed as described in G. Band intensities for CX3CLI were quantified and normalized to actin. Values are means ± SE for 3 separate experiments. HP < 0.05.
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cells using gentle rocking at 10 cycles/min. Nonadherent cells were
washed away, and remaining cells were fixed and mounted onto slides.
Using a Leica deconvolution microscope, we examined at least 50
high-power fields (X63) to count the number of adherent cells. Results
represent the mean values (±SE) and were compared using Student's r-test.
To examine localized changes in CX3CLI expression at the point
of contact with adherent leukocytes, ECV-304 cells were plated in
six-well plates and grown to 50% confluence. Cells were transfected
with CXsCLl-mCherry cDNA (1.0 p,g) using FuGene HD (Roche
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bating ECV-CX3CLl-mCherry cells with K562-CX3CR1 cells (5 X
105 cells/well) in the presence or absence of IBOP (2.5 pg/ml). To
prevent inadvertent shedding of CX3CLI from the plasma membrane.
ECV-CXjCLl-mCherry cells in some wells were incubated with the
metalloprotease inhibitor GM6001 for 4 h before experiments were
performed. To rule out any inadvertent effects of TP stimulation on
cell surface expression and mobility of the CX3CL1 receptor
CX3CRI, K562-CX3CR1 cells were fixed using 4% paraformalde¬
hyde and washed with glycine (100 mM) in PBS just before adhesion
assays were performed. K562-CX3CR1 cells were allowed to adhere
for 30 min at 37°C under gentle rocking conditions and then gently
washed twice with PBS to remove nonadherent cells. Cells were fixed
and permeabilized using 0.1% Triton, and K562-CX3CR1 cells were
labeled by incubation with anti-Bcr Ab (2 |xg/ml) followed by Alexa-
Fluor 488-conjugated anti-mouse IgG secondary Ab (23). Spinning
disk confocal microscopy was performed, and Z-stack images were
captured. XY or KZ dimensions of the Z-stack images were used to
compare the localized fluorescence intensity CX-sCLl-mCherry signal
on transfected ECV-304 cells at the point of interface with adherent
K562-CX3CR1 cells with the CX3CLl-mCherry fluorescent signal in
an adjacent region of similar size in the plasma membrane, where no
leukocyte was attached. Fluorescent signals were quantified using
ImageJ software (National Institutes of Health), and the ratio of signal
intensities between site of contact and site of no contact was measured
for 24 randomly chosen cells for each treatment condition. Experi¬
ments were performed three separate times.
CXjCLI shedding experiments. Small interfering RNA (siRNA)
directed against human ADAM 10, human TACE, and control nontar-
geting siRNA were purchased from Santa Cruz Biotechnology. ECV-
CX3CL1 cells were electroporated with siRNA by nucleofection
(Amaxa, Gaithersburg, MD) on day 0 and day 2. After the second
electroporation, cells were plated in six-well tissue culture plates at a
density of 1 X 105 cells/well and cultured for 48 h. Cells were
incubated with IBOP (2.5 pg/ml) for 30 min at 37°C, and conditioned
medium was collected. Cells were washed once with PBS and lysed
by adding 0.5 ml of R1PA buffer. Protease inhibitor cocktail (Sigma)
was added (1:100) to both harvested conditioned medium and cell
lysis buffer to prevent protein degradation. Supernatants and cell
lysates were cleared by centrifugation at 13,000 rpm at 4°C for 10
min. With the use of fresh samples, CX3CL1 was detected in condi¬
tioned medium and cell lysates using a CX3CL1 ELISA kit (R&D
Systems, Minneapolis, MN) according to the manufacturer's specifi¬
cations. Three independent experiments were performed, and the data
are expressed as the mean (±SE) percentage of soluble CX3CL1
released into the medium in relation to the total amount of CX3CL1
(soluble and cell associated).
Statistical analyses. The data were analyzed by comparing the mean
values using Student's /-test. A value of P < 0.05 was considered
significant.
RESULTS
Stimulation of the TP receptor decreases stttface and total
levels ofCX3CLI. When ECV-CX3CFI-GFP cells were treated
with two distinct TP agonists, total levels of CX3CLI, mea¬
sured by immunoblotting, fell after just 10 min, with the nadir
observed at 30 min (Fig. 1, A-C). When experiments were
performed using cells that express untagged CX3CFI, TP
stimulation provoked a similar fall in the levels of CX3CLI
(Fig. 1. D and E, P < 0.02). Cell surface CX3CLI, measured
by flow cytometry, also rapidly fell, reaching minimum levels
by 30 min (Fig. IF; P < 0.05). Although TP stimulation
promoted a significant decrease in both total and cell surface
CX3CFI, the magnitude of the changes was not identical,
presumably because the inherent differences in the two meth¬
odologies used resulted in a differential ability to detect
CX3CL1. We further found that the specific TP antagonist
SQ29548 prevented loss of CX3CLI, verifying the specificity
of the response (Fig. 1. G and H). Thus TP activation promotes
reduction of surface and total levels of CX3CLI.
TP stimulation induces cleavage of CX3CEI by TACE. We
questioned whether TP stimulation results in shedding of
CX3CFI from the plasma membrane, a process mediated by
ADAM 10 and TACE (12, 17, 43). Consistent with this notion,
the metalloprotease inhibitors TAP1-2 and GM6001, which
inhibit both ADAM 10 and TACE, prevented TP-induced loss
of CX3CFI (Fig. 2A, P < 0.02; data not shown for GM6001).
To verify these findings, we performed immunoblotting using
an antibody directed against GFP, conjugated to the cytoplas¬
mic domain of CX3CLI (Fig. 2B). TP stimulation resulted in
loss of full-length CX3CLI (P < 0.01) and appearance of a
small cell-associated species of CX3CFI (P < 0.01) after
shedding of the extracellular domain of the chemokine (Fig.
2B). These events were prevented by TAP1-2 (Fig. 25). To
determine whether ADAM 10 and/or TACE induced the ob-
Fig. 2. TP stimulation induces cleavage of CX3CLI by tumor necrosis factor-a-converting enzyme (TACE). A, top: ECV-CXjCLl cells were incubated with
metalloprotease inhibitor TAPI-2 (10 p.M for 2 h) and then with IBOP (0.1 pg/ml for 30 min), and immunoblotting was performed using anti-CX3CLl Ab. Blots
were stripped and reprobed with anti-actin Ab. Bottom, CX3CLI band intensities normalized to actin. Values are means ± SE for 4 separate experiments.
UP < 0.02. B, top: experiments were performed as described in A. and immunoblotting was performed using anti-GFP Ab. Bottom, proportion of full-iength and
cleaved CX3CLI detected for each experimental condition. Values are means ± SE for 3 separate experiments. For full-length and cleaved CX3CLI: P < 0.01,
untreated vs. IBOP: P < 0.0001, IBOP vs. IBOP + TAPI-2. C: cells were electroporated with TACE small interfering RNA (siRNA), ADAM10 siRNA, or
control, nontargeting (scrambled) siRNA on days 0 and 2. After 48 h, cell lysates were harvested, and immunoblotting was performed using anti-TACE and
anti-ADAMlO Ab. D: cells were electroporated with the indicated siRNA and incubated with IBOP (30 min), conditioned medium was collected, and cell lysates
were harvested. Protease inhibitor cocktail was added to conditioned medium and to cell lysis buffer to prevent protein degradation. Supernatants and cell lysates
were cleared by centrifugation. With the use of fresh samples, CX3CLI was measured using a CX3CLI ELISA kit (R&D Systems). Values are means ± SE,
expressed as the percentage of soluble CX3CLI released into the conditioned medium relative to the total amount of CX3CLI (soluble and cell associated), for
3 separate experiments. *P < 0.03. E: cells were incubated with IBOP (5 min), and cell surface CX3CLI and TACE were immunofluorescently labeled. Images
at right show a magnified view of the indicated areas. Colocalization between CX3CLI and TACE was assessed using Volocity software. Representative
photographs show 16 cells from 3 independent experiments. F: cells were incubated with PMA (1 pM), U46619, or IBOP for 30 min, cell lysates were harvested,
and immunoblotting was performed using anti-phospho-Erk Ab. To control for protein loading, blots were stripped and reprobed with anti-Erk Ab and anti-actin
Ab. Phospho-Erk band intensities were normalized to total Erk. Values are means ± SE for 3 separate experiments. *P < 0.01 vs. control. G: cells were incubated
with PMA or IBOP, and immunoblotting was performed using anti-phospho-MEKl/2 and anti-phospho-c-Raf Ab. Blots were stripped and reprobed with
anti-MEKl/2 Ab and anti-c-Raf Ab. Phospho-MEKl/2 and phospho-c-Raf band intensities were normalized to total MEK1/2 and total c-Raf, respectively. Values
are means ± SE for 4 separate experiments. *P < 0.01; **P < 0.05 vs. control. H: cells were incubated with U46619 after pretreatment with the Erk inhibitor
U0126 (5 pM for 30 min). Cell surface CX3CLI was detected by flow cytometry. Values are means ± SE, expressed as the percentage of control fluorescence
intensity, for 4 separate experiments. iP < 0.05.
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served proteolysis of CX3CLI, we used siRNA to selectively
knock down expression of each protease (Fig. 2C) and mea¬
sured soluble levels of CX3CLI generated. In the presence of
nontargeting siRNA or ADAM 10 siRNA, TP stimulation pro¬
moted release of soluble CX3CLI (Fig. 2D, P < 0.03). In the
absence of TACE, TP failed to promote shedding of CX3CLI
(Fig. 2D). In keeping with these observations, CX3CLI and
TACE, which did not colocalize on the cell surface under basal
conditions, coassociated after 5 min of TP stimulation, yielding
a Pearson's correlation coefficient (r) greater than 0.5 (Fig. 2£;
hasal: r = 0.429 ± 0.042, P > 0.05; IBOP: r = 0.645 ± 0.031,
P < 0.01). After TP stimulation, the increase in soluble
CX3CLI detected in the medium was not the same as the
decrease in the amount of cell-associated chemokine. Although
the magnitude of the individual changes is statistically signif¬
icant, there is likely differential sensitivity of the two assays
used to detect soluble and cell-associated CX3CLI present. It is
further possible that some of the soluble CX3CLI released by
proteolytic shedding could be bound to the surface of cells or
to the underlying extracellular matrix, resulting in a failure to
detect it by ELISA.
Since TP can activate a number of signaling pathways, we
studied the intracellular mechanisms whereby TP causes shed¬
ding of CX3CLI. TP promoted rapid phosphorylation of Erk
(Fig. 2F, P < 0.01) and its upstream effectors, MEK1/2 (Fig.
2G, P < 0.01) and c-Raf (Fig. 2G, P < 0.05) (7). Erk inhibition
prevented TP-induced loss of surface CX3CLI (Fig. 2H, P <
0.05). Overall, TP stimulation causes cleavage of plasmale-
mmal CX3CLI by TACE, rather than by ADAM 10.
TP stimulation does not affect recycling of CXjCLI. Be¬
cause CX3CLI recycles between the plasma membrane and an
endocytic compartment, we questioned whether TP stimulation
might redistribute the chemokine from the superficial to the
intracellular pool (25). To prevent inadvertent shedding of
CX3CLI from the cell surface, cells were preincubated with
GM6001 and endocytosis was examined by FRAP, irreversibly
photobleaching the entire CXrCLl-containing intracellular
compartment, as previously described (25, 43). Recovery of
fluorescence, an index of internalization of CX3CLI from the
plasma membrane, was recorded over time (25). Fluorescence
of the plasma membrane pool remained largely unaffected by
the bleaching procedure and was also monitored. Figure 3
depicts a cell before, immediately after, and 5 min after
bleaching. Note that the plasmalemmal fluorescence decreased
as the juxtanuclear fluorescence recovered, consistent with
delivery of unbleached CX3CLI-GFP from the former to the
latter compartment. The juxtanuclear CX3CLI-GFP compart¬
ment recovered to 21.5 ± 3.1% of its original fluorescence by
170 s and was unchanged by TP stimulation (Fig. 3D).
To test whether TP stimulation affects delivery of internal¬
ized CX3CLI back to the plasma membrane, shedding of the
chemokine was inhibited using GM6001, and the endomem-
brane pool was loaded by incubation with CX3CLI Ab at
37°C. Ab bound to the surface was stripped by a short exposure
to an acidic solution. Cells were allowed to recover, and
reinsertion of CX3CLI in the plasma membrane was deter¬
mined by quantifying the reappearance of Ab (25). Fluores¬
cence at the cell surface increased progressively after acid
stripping, confirming that CX3CLI within the endomembrane
compartment traffics back to the plasma membrane (Fig. 4,
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Fig. 3. TP stimulation does not alter endocytosis of CX3CLI. ECV-CX3CLI-
GFP cells were grown on glass coverslips and incubated for 4 h with the
metalloprotease inhibitor GM6001 (20 jxM) to prevent inadvertent shedding of
CX3CLI from the cell surface. Cells were incubated with U46619 (20 p-M) for
30 min, and with an argon laser and scanning confocal microscope, the entire
juxtanuclear CX3CLI-containing compartment was irreversibly photo-
bleached, and recovery of fluorescence was determined at 5- to 200-s intervals.
To control for inadvertent photobleaching associated with serial image acqui¬
sition, nonbleached areas in the plasma membrane were serially observed in
parallel. The same cell is shown before bleaching 04), immediately after
photobleaching (B), and 5 min later (C). D: at each time point, the ratio of the
fluorescence intensity of the internal compartment to the mean control mem¬
brane fluorescence intensity was calculated. Each point represents the mean ±
SE for at least 6 separate experiments. Scale bar, 14 p,m.
A-E, P < 0.02). TP stimulation did not affect this traffic
(compare Fig. 4, C and D; Fig. 4£j.
TP stimulation enhances, not inhibits, CXjCLI-dependent
leukocyte adhesion. We predicted that TP stimulation, which
induces rapid loss of CX3CLI from the cell surface, would
impair adhesion of CX3CRI-expressing leukocytes. Minimal
binding of K562 cells, which do not express CXjCRl, to either
ECV-304 or ECV-CX3CL1 -GFP cells was seen (data not
shown). Likewise, there was very little adhesion of K562-
CX3CRI cells to ECV-304 cells, which do not express
CX3CLI (Fig. 54) (10). K562-CX3CRI leukocytes effectively
adhered to ECV-CX3CLI-GFP cells (Fig. 54). The presence of
plasmalemmal CX3CLI increased leukocyte adhesion fourfold
(Fig. 54, P < 0.0000001). Unexpectedly, TP stimulation
increased rather than decreased adhesion of K562-CX3CRI
leukocytes to ECV-CX3CLI-GFP cells (Fig. 54, P < 0.05). TP
stimulation did not increase adhesion of K562-CX3CRI cells
to untransfected ECV-304 cells, ruling out upregulated levels
of other adhesion molecules as the cause of the enhanced
leukocyte binding observed (Fig. 54) (10).
To verify that the observed responses were not an idiosyn¬
cratic feature of the transformed cell lines, we performed
experiments performed using primary human vascular endo¬
thelial cells. Upon TNF-a stimulation, endogenous expression
of CX3CLI increased fivefold (Fig. 5B, P < 0.01). TP stimu¬
lation caused a rapid fall in total levels of CX3CLI (Fig. 5B,
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Fig. 4. TP stimulation does not affect traffic of
internalized CX3CLI to the plasma mem¬
brane. ECV-CX3CLI cells were incubated
with anti-CX/CLl Ab (2.5 pg/ml) at 37°C for
1 h, and then membrane-associated Ab was
removed by acid wash (pH 2.5) at 4°C for 2
min. Cells were allowed to recover for 30 min
in the presence or absence of IBOP (0.1
pg/ml) and were then washed, fixed, and
stained with Cy3-conjugated secondary Ab.
In all experiments, cells were preincubated
with the metalloprotease inhibitor GM6001
(20 p.M for 4 h) to prevent cleavage of
CX3CLI from the cell surface. Immunofluo-
rescent images show cells before acid strip¬
ping (A), immediately afterward (B), and 30
min after recovering from acid shock in the
presence (O or absence (D). E: cell surface
immunofluorescence was quantified using
Volocity software. Values are means ± SE of
at least 30 fields per condition from 3 separate
experiments. *P < 0.001. tP < 0.03. IP <
0.02.
Control 0 min 30 min 30 min
IBOP
P < 0.05). In keeping with these results, TP stimulation
significantly enhanced proteolytic release of soluble CX3CLI
(P < 0.005, Fig. 5C). The enhanced shedding of CX3CLI was
prevented when activation of TACE was blocked (P < 0.005,
Fig. 5C). When F1UVEC were incubated with TNF-a, adhesion
of K562-CXsCRl cells increased by 30% (Fig. 5D; P <
0.005). In this instance, preincubation of endothelial cells with
specific function-blocking anti-CXsCLl Ab significantly de¬
creased the number of bound leukocytes (Fig. 5D, P < 0.05).
Similarly, TNF-a activation increased binding of primary
PBMC 10-fold (Fig. 5E, P < 0.001). Although TP stimulation
resulted in loss of cell-associated CX3CLI, K562-CX3CRI cell
adhesion increased by 70% (Fig. 5D, P < 0.005) and PBMC
adhesion increased by 50% (Fig. 5E, P < 0.001). Preincuba¬
tion of endothelial cells with anti-CX^CLl Ab prevented TP-
induced leukocyte adhesion, confirming the observed increase
in binding was CX3CLI dependent (Fig. 5D, P < 0.01; Fig.
5E, P < 0.001). Using a specific antagonist of TP, SQ29548,
we verified that the observed increase in leukocyte adhesion
was directly related to TP stimulation (Fig. 5F, P < 0.005).
Blocking activation of TACE using the Erk inhibitor U0I26
also prevented TP-induced increase in leukocyte adhesion (Fig.
5 F, P < 0.001). Together, these data demonstrate that TP
stimulation increases leukocyte adhesion to cell surface
CX3CLI despite reducing the overall amount of the chemokine
present on the plasma membrane.
TP stimulation mobilizes plasmalemmal CXjCLI and in¬
duces clustering of CXiCLI at sites of contact with adherent
leukocytes. In principle, increased leukocyte binding to
CX3CLI could occur despite reduced CX3CLI levels if
TP stimulation mobilized and redistributed plasmalemmal
CX3CLI, allowing the chemokine to move to sites of contact
with CX3CRI on leukocytes. TP stimulation could thereby
increase the overall avidity of ligand-receptor interactions,
strengthening adhesion between CX3CRI -expressing leuko¬
cytes and CX3CLI-expressing adherent cells.
To test this notion, an area of CX3CLI-GFP in the plasma
membrane was irreversibly photobleached and recovery of
fluorescence was serially observed (Fig. 6/4, prebleaching; Fig. 6B.
immediately after bleaching; Fig. 6C, 5 min after bleaching).
As a control, CX3CLI-expressing cells were transfected with
cDNA encoding freely mobile GPI-GFP, and recovery of
fluorescence was similarly observed (Fig. 6, D-F). CX3CLI-
GFP fluorescence recovered poorly compared with GPI-GFP
(Fig. 6, G and H). For CX3CLI-GFP, only 25.8 ± 2.6% of
fluorescence of the bleached area recovered after 60 s, com¬
pared with 85.0 ± 2.9% of GPI-GFP (Fig. 6H). As another
control, ECV-CX3CLI cells were transfected with DNA en¬
coding the single transmcmbrane-spanning protein, FcyRIIA,
conjugated to GFP (Fc-yRIIA-GFP). FcyRIIA receptors were
highiy mobiie, as indicated by the rapid and near complete
recovery of fluorescence after photobleaching (Fig. 6H). These
data demonstrate that lateral diffusion of transmembrane CX3CL1
within the membrane is highly impeded, rendering the chemokine
largely immobile.
IBOP treatment significantly enhanced mobility of plasmale¬
mmal CX3CLI. resulting in fluorescence recovery of 48.2 ± 6.2% at
55 s postbleaching, compared with 26.3 ± 2.5% recovery in
the absence of IBOP (Fig. 6G. P < 0.05). After TP-induced
ectodomain shedding of CX3CLI, we reasoned that it might
not be possible to distinguish between reappearance of GFP
fluorescence due to movement of full-length CX3CLI or to
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movement of any COOH-terminal cleavage fragments retained
within the plasma membrane. To prevent potential shedding of
CX3CLI, cells were pretreated with the metalloprotease inhib¬
itor GM6001. Accordingly, GM6001 did not affect basal mo¬
bility of CX3CLI (Fig. 6H). In the presence of GM6001, TP
similarly mobilized CX3CLI. The bleached area recovered to
55.5 ± 3.5% by 1 min, significantly greater than the 27.7 ±
2.5% recovery observed in the absence of TP stimulation (Fig.
67/, P < 0.001). At all time points after 20 s, TP facilitated
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P < 0.03 at each point). Thus TP stimulation enhances lateral
mobility of CX3CLI, which is normally tethered within the
plasma membrane.
We directly examined whether TP stimulation promotes
clustering of CX3CLI at sites of contact with CX3CRI on
adherent leukocytes, by comparing the fluorescent signal of
CX3CLI at these contact points to that of CX3CLI at adjacent
sites where no leukocyte was tethered. We reasoned that TP
stimulation could conceivably affect mobility of CX3CRI
receptor present on the surface of leukocytes, resulting in
enhanced adhesion between these cells and CX3CLI-express¬
ing cells. To selectively study the effects of TP stimulation on
clustering of plasmalemmal CX3CLI, leukocytes were pre¬
fixed, effectively converting them to "beads" coated with
CX3CRI (4). After TP stimulation, the ratio of contact site
CX3CLI to non-contact site CX3CLI was greater than in
unstimulated cells (Fig. 6, / and 7; control: 1.1 ±0.1 vs. TP
stimulated: 1.7 ± 0.2; Fig. 6K, P < 0.005). A ratio greater than
one was seen in approximately one-half (46%) of unstimulated
cells. After TP stimulation, 83% had a ratio greater than one,
indicating clustering of CX3CLI. Collectively, these results
demonstrate that TP stimulation promotes rapid shedding of
plasmalemmal CX3CLI but that despite decreased cell surface
levels of the chemokine, CX3CLI-dependent adhesion of leu¬
kocytes is enhanced due to mobilization and clustering of the
chemokine at contact sites with adherent leukocytes. In this
manner, although net cell surface exposure of CX3CLI is
decreased, the overall avidity of interactions between leuko¬
cytes and CX3CLI on the surface of adherent cells is actually
strengthened.
DISCUSSION
The principal aim of this study was to examine regulation of
CX3CLI by TP. For these studies, we used CX3CLI-express¬
ing ECV-304 cells and primary human vascular endothelial
cells. Although derived from bladder epithelial carcinoma
cells, ECV-304 cells have many endothelial features, including
the propensity to grow in monolayers of flattened cells, forma¬
tion of moderately tight intercellular junctions, and expression
of the endothelial markers Fit-1 and von Willebrand factor (14,
16, 39). Since the identification of CX3CLI, ECV-304 cells
have been used extensively to study distribution, cleavage, and
function of the chemokine, because the surface levels of
CX3CLI mirror those seen in cytokine-activated primary vas¬
cular endothelial cells and because expression of other cellular
adhesion molecules is minimal (10, 17, 25, 43). We previously
showed that addition of a GFP tag alters neither distribution
nor subcellular traffic of CX3CLI (25). To confirm the key
findings of the current study, assays were performed using
primary human vascular endothelial cells.
Overall exposure of CX3CLI at the cell surface reflects the
balance between shedding and recycling. Thus, in principle, the
TP-induced decrease in CX3CLI could result from /) in¬
creased endocytosis, 2) decreased traffic of internalized
CX3CLI back to the plasma membrane, and/or 3) increased
shedding from the cell surface. TP stimulation did not acutely
alter recycling of the chemokine. Sustained TP stimulation
(4-24 h) has been shown to augment expression of the vascular
adhesion molecules, intercellular adhesion molecule-1 (ICAM-
1), vascular adhesion molecule-1 (VCAM-1), and E-selectin
(19, 31). The resultant increase reflected enhanced nuclear
factor (NF)-KB-dependent transcription and translation (19,
31). ICAM-1 expression is significantly reduced in genetically
targeted mice lacking TP, again illustrating the ability of TP to
increase adhesion molecule expression over time (22). Like¬
wise, prolonged TP stimulation enhances expression of the
chemokine CCL2 (monocyte chemoattractant protein-1, MCP-
1), also through protein kinase C and NF-kB (20). To our
knowledge, ours is the first study to examine how TP activation
posttranslationally regulates cell surface exposure of an endo¬
thelial adhesion molecule or chemokine.
Blocking TACE. but not ADAM10. attenuated TP-induced
shedding of CX3CLI from the cell surface. Erk inhibition
similarly blocked CX3CLI shedding, consistent with studies
demonstrating that TP engagement promotes protein kinase C
activation and Erk phosphorylation (11, 30). Erk, in turn,
phosphorylates the cytoplasmic domain of TACE at Thr775 and
SerX19, thereby activating the protease (7, 9). Blocking this
phosphorylation prevents activation of TACE and ectodomain
shedding of its biological substrates (7. 9). Overall, our results
demonstrate that TP stimulation causes rapid loss of CX3CLI
from the cell surface by promoting TACE-induced, but not
Fig. 5. TP stimulation enhances CX3CLI-dependent leukocyte adhesion. A: K562 cells that express the CXiCRl receptor (K562-CXjCRl) were labeled with
Alexa555-conjugated cholera toxin B (0.5 p-g/ml) for 30 min to visualize them. ECV-304 and ECV-CX3CLI-GFP cells were grown to confluence on 25-mm
coverslips and treated with IBOP (0.1 p.g/ml) for 30 min. K562-CX?CR1 cells (5 x 105/well) were incubated with ECV-304 or ECV-CX3CLI-GFP monolayers
under gentle rocking conditions (10 cycles/min) at 37°C for the times indicated. Nonadherent cells were removed by washing, and the remaining cells were fixed.
Serial fields (X63) were examined using a Leica deconvolution microscope, and the numbers of adherent cells were counted. Values are the mean (±SE) number
of adherent K562-CX3CR1 cells from at least 3 experiments. *P < 0.01. IP < 0.02. B. top: confluent monolayers of human umbilical vein endothelial cells
(HUVEC) were incubated with TNF-a (100 U/ml) for 4 h and then with IBOP for 30 min. Cell lysates were harvested, and immunoblotting was performed using
anti-CXiCLl and anti-actin Ab. Bottom, CX3CLI band intensities were normalized to actin. Values are means ± SE from 3 separate experiments. *P < 0.03.
**P < 0.01. C: HUVEC were grown to confluence and stimulated with TNF-a as describe in B, followed by IBOP (0.1 p.g/ml for 30 min). In some instances,
cells were incubated with U0126 (5 p.M) for 30 min before incubation with IBOP. Conditioned medium was collected and cell lysates were harvested. Protease
inhibitor cocktail was added to conditioned medium and to cell lysis buffer to prevent protein degradation. Supernatants and cell lysates were cleared by
centrifugation. With fresh samples, CX3CLI was measured using a CXjCLl ELISA kit. Values are means ± SE of the fraction of soluble CX;CLI released into
the conditioned medium relative to the total amount of CXjCLl (soluble and cell associated) from 3 separate experiments. *P < 0.002. **P < 0.0001.
D: HUVEC were stimulated with TNF-a, and adhesion assays were performed as described in A using K562 or K562-CX,CR 1 cells. In some experiments. HUVEC
were preincubated with blocking anti-CX.iCLl Ab (1 p.g/ml) for 30 min. The number of adherent leukocytes was normalized to the number of cells adherent to
TNF-a-stimulated HUVEC. Values are means ± SE from 4 independent experiments. *P < 0.005. **P < 0.01. ***p < 0.05. E: adhesion assays were performed as
described in C using freshly isolated human peripheral blood mononuclear cells (PBMC). Values are means ± SE from 4 independent experiments. *P < 0.001.
F: adhesion assays were performed as described in D using K562-CXtCR 1 cells and TNF-a-stimulated HUVEC. In some experiments, HUVEC were preincubated with
U0126 (5 jj.M for 30 min) or SQ29548 (10 p.M for 15 min) before incubation with IBOP. The number of adherent leukocytes was normalized to the number of cells
adherent to TNF-a-stimulated HUVEC. values are means ± SE from 3 independent experiments. *P < 0.005. **P < 0.001.
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Fig. 6. TP stimulation mobilizes plasmalemmal CXjCLl and induces clustering of CX3CLI at sites of contact with adherent leukocytes. With the use of
ECV-CX3CLI-GFP cells, fluorescence recovery after photobleaching (FRAP) was performed as described in materials and methods. A: confocal image of
single cell (X100). B: a region within the plasma membrane was irreversibly photobleached (see arrow). C: same cell 5 min after photobleaching. D-F: as a
control, the membrane mobility of glycosylphosphatidylinositol (GPI)-linked GFP in transfected ECV-CX3CLI cells was determined in the same manner. G: cells
were incubated with IBOP (0.1 p-g/ml) for 30 min, and fluorescence recovery of the photobleached area was monitored over time. Values are means ± SE from
9 separate experiments per condition. P < 0.05, untreated vs. IBOP at all time points after 11 s. H. recovery of fluorescence of the photobleached area was
measured over time. In some experiments, ECV-CX3CLI-GFP cells were preincubated with GM6001 (20 pM for 2 h), to inhibit cleavage of CX3CLI from the
cell surface, and then incubated with IBOP (0.1 pg/ml) for 30 min. In some experiments, ECV-CX3CLI cells were transfected with cDNA encoding
GFP-conjugated FcyRIlA. Recovery of fluorescence after photobleaching of untreated ECV-CX3CL1-GFP, GM6001 -treated ECV-CX3CLI-GFP, and GM6001-
treated ECV-CX3CLI-GFP stimulated with IBOP, GPI-GFP, or FcyRIIA-GFP was measured. At each time point, fluorescence intensity in the bleached region
was normalized to the mean control unbleached membrane fluorescence intensity. Values are means ± SE from 5-9 separate experiments per condition. I and
J: ECV-304 cells were transfected with CXsCLl-mCherry cDNA. Adhesion assays were performed by incubating ECV-CX3CLl-mCherry cells for 30 min with
K562-CX3CR1 cells (5 X lOVwell) in the presence (/) or absence (/) of IBOP. To prevent unwanted shedding of CX3CLI, in some wells ECV-CXsCLl-mCherry
cells were preincubated with GM6001. To rule out potential effects of TP stimulation on cell surface clustering of CX3CRI, K562-CX3CRI cells were first fixed
using 4% paraformaldehyde and then washed with 100 mM glycine. At the end of the adhesion assay, cells were fixed and permeabilized, and K562-CX3CRI
cells were visualized by labeling with anti-BCR Ab and Alexa488-conjugated secondary Ab. Z-stack images are from spinning disk confocal microscopy (X63).
K: experiments were performed as described in / and J. XY or YZ dimensions of the Z-stack images were used to compare the localized fluorescence intensity
of CXsCLl-mCherry at sites of interface with adherent K.562-CX3CRI cells with the signal in an adjacent, similar-size region in the plasma membrane, where
no leukocyte was attached. With the use of ImageJ software, the ratio of fluorescent signal intensities between the site of contact and site of no contact was
measured for 24 randomly chosen cells for each treatment condition. Values are means ± SE from 3 separate experiments. *P < 0.005 vs. control.
ADAMlO-induced, shedding of CXjCLl, rather than by inter¬
fering with recycling of the chemokine.
Despite inducing proteolysis of approximately one-half the
CX3CLI present, TP augmented CX3CLI-dependent leuko¬
cyte adhesion. Although unexpected, this is not inconceivable,
since the overall binding of CX3CRI receptor on the leukocyte
is determined by two distinct factors, namely, the density of
CX3CLI ligand present and the mobility of CX3CLI within the
plasma membrane. We hypothesized that TP stimulation must
increase the avidity of remaining CX3CLI for its receptor. In
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principle, this could occur through mobilization of plasmale-
mmal CX3CLI and subsequent clustering of the chemokine at
points of contact with adherent leukocytes. Accordingly, plas-
malemmal CX3CLI was relatively immobile under basal con¬
ditions but became highly mobile following TP stimulation.
We previously reported that plasmalemmal CX3CLI is also
immobile in other cell types under basal conditions (8). TP
stimulation promoted clustering of CX3CLI at contact inter¬
faces with bound leukocytes. Similarly, Kobayashi et al. (22)
reported less leukocyte rolling and adherence in mice lacking
TP, perhaps due to the absence of TP-induced clustering of
CX3CLI on the surface of the vascular wall. Our results are
reminiscent of a study demonstrating that isoprostane iPF2a-
III, a known agonist of TP, enhances neutrophil adhesion to
endothelial cells despite no increase in expression of endothe¬
lial adhesion molecules (1, 46). Although the authors postu¬
lated that release of an unknown endothelial activating factor
was responsible, isoprostane activation might also increase
mobility of plasmalemmal adhesion molecules, thereby
strengthening the avidity of interactions between neutrophils
and endothelial cells.
Our results differ somewhat from those of Hundhausen et al.
(17), who reported that the synthetic phorbol ester PMA
inhibited adhesion of THP-1 monocytic cells to CX3CLI-
expressing adherent cells. Several possible explanations for
this apparent discrepancy exist. First, THP-1 cells express
other adhesion receptors whose levels and function may be
modulated by PMA stimulation. In our study, we purposely
used CX3CRI-expressing K562 cells, which do not express
adhesion molecules such as L-selectin (10). Thus any adhesion
observed was presumably attributable to interactions between
leukocyte CX3CRI and CX3CLI on the surface of adherent
cells. Stimulation by PMA and TP may have differential
effects on the cell. TP receptors couple to Gt|/Gn, with most
functioning attributed to signaling via the a- rather than P7-
subunits (21). Thus stimulation by PMA or TP can activate
phospholipase C, generating inositol triphosphate (IP3) and
diacylglycerol (DAG), increasing intracellular calcium concen¬
tration, and activating protein kinase C (21). In primary human
cells, TP also couples to Gj and to G12/13 and is linked to cAMP
(15, 21). Thus the TP receptor has the potential to utilize at
least four distinct intracellular signaling pathways. Mobiliza¬
tion of CX3CLI by TP may reflect activation of these path¬
ways. In our study, TP activation consistently increased
CX3CLI-dependent leukocyte adhesion, even to primary hu¬
man vascular endothelial cells expressing endogenous
CX3CLI, highlighting the physiologic relevance of these ob¬
servations. This is the first description of regulation of
CX3CLI exposure and mobility by a G protein-coupled recep¬
tor.
An intriguing question is how CX3CLI is anchored to the
plasma membrane in the first place. Previously, we reported
that CX3CLI does not directly interact with the actin cytoskel-
eton (8). Recent work has demonstrated an integral role for
dendritic cell (DC) CX3CLI in the accumulation of lipid rafts
at DC-NK cell synapses (34). However, we found that in
adherent cells, plasmalemmal CX3CIJ does not associate with
lipid rafts and. accordingly, that cholesterol depletion does not
alter the mobility of the chemokine (8). Future studies are
needed to investigate I) whether CX3CLI indirectly associates
with the actin cytoskeleton by one or more Triton-soluble
adaptor proteins, 2) whether CX3CLI is "fenced" into discrete
regions of the membrane, and 5) precisely how TP uncouples
CX3CLI from its membrane anchor (33, 38).
TP plays a complex role in vascular inflammation. Given the
timeframe of events that we investigated, it appears that early
in the inflammatory cascade, TP stimulation induces shedding
of endothelial CX3CLI to release the soluble chemoattractant
species, thereby recruiting circulating leukocytes. Slightly
later, the balance is subtly altered to facilitate adhesion of
leukocytes thus recruited to the area of vascular injury. Regu¬
lation of CX3CLI by TP in this manner may represent a link,
heretofore unexplored, between the events accompanying the
platelet aggregation and activation and those accompanying the
vascular inflammation that, collectively, contribute to athero-
genesis. The dynamic interplay among these individual events
in vivo remains to be elucidated.
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